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In the beginning of this century Anitschkow and De Langen started pioneering 
work concerning the relation between cholesterol and coronary heart disease.' ·2 
Both showed that there was a possible relation between cholesterol in the diet, blood 
cholesterol levels and atherosclerosis. It took until the second half of the twentieth 
century before large-scale population based studies, like the Framingham Study and 
the Seven Countries Study, were started to investigate the relation between serum 
cholesterol levels and coronary heart disease. These studies showed positive 
associations between serum cholesterol and incidence of and mortality from 
coronary heart disease in middle-aged men.3-6 Since then, other large 
epidemiological studies have shown that serum total cholesterol is positively 
associated and HDL cholesterol inversely associated with coronary heart disease 
mortality in middle-aged men.7-9 
Quantifying the effect of chOlesterol lowering interventions on for example 
incidence of coronary heart disease in The Netherlands is an important public health 
issue. Total cholesterol levels in the Dutch population are relatively high and did not 
substantially decrease until the beginning of the nineteen nineties.,o,11 To quantify 
the amount of health gain that can be achieved through cholesterol lowering, 
additional information has to be gathered. First, recent levels of and trends in total 
and HDL cholesterol and prevalences of hypercholesterolemia and low HDL 
cholesterol levels in the Dutch population have to be described. Second, more 
evidence on the impact of total and HDL cholesterol on coronary heart disease in 
elderly men and women has to be collected. It is well known that serum total and 
HDL cholesterol are associated with coronary heart disease in middle-aged men and 
women, but it is still unclear whether this relation holds in the elderly.12-18 Third, risk 
functions to predict absolute risk of coronary heart disease in middle-aged men and 
women are well developed.19 However, in the elderly it is not clear whether these risk 
functions are a valid tool for risk prediction. This is important to know because 
cholesterol lowering treatment is nowadays based on the absolute level of risk, 
taking the total risk profile of an individual into account. 
Coronary heart disease 
Despite the declining trend in age-adjusted coronary heart disease mortality since 
1972, it is still the most important cause of death in The Netherlands and other 
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developed countries.20022 Almost 20,000 persons died from coronary heart disease in 
1997 in The Netherlands, of which more than 14,000 died from myocardial 
infarction20 The declining trend in coronary heart disease mortality may, at least in 
part, be attributed to changes in the classical risk factors and to improvements in 
medical care. In a descriptive study based on literature data it was tried to explain 
the declining trend in coronary heart disease mortality in The Netherlands between 
1974 and 199223 The largest part of the decline in coronary heart disease mortality 
seems to be explained by changes in mainly smoking in the 1970's and 
improvements in therapy in the 1980'S.23 Hunink et al.24 estimated that in the United 
States 25% of the decline in coronary heart disease mortality between 1980 and 
1990 was explained by changes in risk factors like serum cholesterol, blood pressure 
and smoking and 71 % of the decline by improvements in the treatment of patients 
with coronary heart disease. 
The declining trend in coronary heart disease mortality in The Netherlands 
contrasts with the increasing trend in number of hospital admissions for coronary 
heart disease. In the Dutch elderly (aged 65 years and over) the hospitalisation rate 
for coronary heart disease almost doubled between 1972 and 1997.20 This is due to 
a strong increase in the number of hospital admissions for the more chronic fonms of 
coronary heart disease, because the hospitalisation rate for acute myocardial 
infarction has declined since 1972. Healthier life-styles (less smoking and better 
nutrition) and better treatment of hypercholesterolemia and hypertension cause this 
decline.20.21 The rising number of hospital admissions for the more chronic forms of 
coronary heart disease can be explained by an improvement in technology and 
treatment leading to a better prognosis after an acute myocardial infarction.21 Due to 
better treatment and the increasing number of elderly in the Dutch population in the 
future, the prevalence of coronary heart disease will increase. The expectation is that 
the prevalence of coronary heart disease will increase with 35-45% between 1994 
and 2015.21 This means that coronary heart disease remains one of the biggest 
public health problems in The Netherlands, as is the case in other affluent countries. 
Cholesterol metabolism and atherosclerosis 
Cholesterol is an essential component of cell membranes and serum lipoproteins 
and it is a precursor of bile acids, adrenal steroids and sex hormones.25 Cholesterol 
enters the body through the diet or is produced in the liver. The transport of 
cholesterol from the intestine to the liver occurs through triglyceride-rich lipoproteins 
called chylomicrons. The liver secretes triglyceride-rich lipoproteins called very low-
density lipoproteins (VLDLs), which are degraded by lipoprotein lipase to VLDL 
remnants. These remnants can be taken up by the liver or transformed into low-
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density lipoproteins (LDLs). Most cholesterol (70%) is carried in the plasma in LDL 
particles. The majority of circulating LDL is removed from plasma via LDL receptors 
on the liver cells and the remainder part is cleared by the extrahepatic tissues, like 
the endothelium. High-density lipoproteins (HDLs) are synthesised in the liver and 
small intestine. HDLs transport cholesterol from peripheral tissues back to the liver 
were it can be degraded and excreted into bile acids or incorporated again in LDL 
and VLDL particles. About 20% of cholesterol is transported in HDL particles.25,26 
Atherosclerosis is the most common pathophysiological condition that underlies 
coronary heart disease. It is a progressive disease characterised by the 
accumulation of lipids and fibrous elements in the large arteries.27,28 Cholesterol, in 
particular LDL, plays an important role in the process of atherosclerosis. A primary 
initiating event in the atherosclerotic process is the accumulation of LDL in the 
subendothelial matrix. When the levels of LDL in the circulation are raised, 
accumulation and retention of LDL increased in the intima of the vessel wa1L27.29 The 
infiltration of LDL may be accelerated by endothelial injury, which removes a natural 
barrier to the entrance of LDL into the vessel walL25 LDL can be modified in the 
vessel wall through oxidation, lipolysis, proteolysis and aggregation. Especially 
oxidised LDL plays an important role in the process of atherosclerosis29 The 
oxidised LDL particles can be taken up by macrophages to form foam_cells.27.29 
These foam cells together with platelet thrombi release growth factors that cause 
prOliferation of smooth muscle cells and deposition of monocytes. The plaques can 
be divided in several types. The unstable lesions characterised by a high 
concentration of extracellular lipids are most prone to rupture"8 HDL cholesterol can 
have a positive influence on the process of atherosclerosis through removing 
cholesterol from macrophages, thus preventing the formation of foam cells and 
through increasing plaque stability. HDL can possibly also prevent the oxidation of 
LDL, the adhesion of monocytes to the endothelium and HDL prolongs the half-life of 
prostacycline and preserves its vasodilatory effect.26 
Dietary and lifestyle determinants of serum cholesterol 
From results of the Seven Counties Study it became clear that at the population 
level a large part of the variation in serum cholesterol levels is related to diet' 
Controlled dietary experiments have shown that saturated fat is one of the most 
important dietary factors that increase serum total cholesteroL"o.31 Increasing the 
intake of saturated fatty acids by 1 percent of energy causes an increase in the total 
cholesterol level by 0.07 mmol/L, largely due to changes in LDL cholesterol. 
Saturated fatty acids suppress the activity of the LDL receptor, which increases the 
serum LDL cholesterol level. Trans fatty acids increase serum total and LDL 
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cholesterol and decrease HDL choiesteroL32 An increase in the intake of trans fatty 
acids by 1 percent of energy results in an increase in total cholesterol by 0.026 
mmol/L, an increase in LDL cholesterol by 0.037 mmoliL and a decrease in HDL 
cholesterol by 0.017 mmol/L. If the intake of polyunsaturated fatty acids is increased 
with 1 percent of energy, serum total cholesterol decreases by 0.06 mmol/L, of which 
most is due to a decline in LDL choiesteroL30 The intake of dietary cholesterol 
doesn't have a large impact on the serum cholesterol level. An increase in dietary 
cholesterol of 5 mg/day results in an increase in total cholesterol of 0.0065 mmol/L.3o 
Lifestyle factors can also affect serum total and HDL cholesterol levels. Obesity 
increases total cholesterol and decreases HDL cholesterol levels. Every kilogram 
decrease in body weight is associated with a 0.05 mmol/L decrease in total 
cholesterol and a 0.009 mmol/L increase in HDL cholesterol33 Smoking has also an 
unfavourable effect on serum cholesterol. Smokers have on average 3% higher 
serum total cholesterol levels, 2% higher LDL cholesterol levels and 6% lower HDL 
cholesterol levels compared to non-smokers.34 Physical activity increases HDL 
cholesterol and decreases total and LDL cholesterol. Aerobic exercise training is 
associated with a 0.05 mmoliL higher HDL cholesterol level, a 0.10 mmol/L lower 
total cholesterol level and a 0.10 mmol/L lower LDL cholesterol level.35 Moderate 
alcohol consumption increases HDL cholesterol. Increasing alcohol intake by 1 gram 
of alcohol per day was associated with an increase in HDL cholesterol of 0.003 
mmol/L.36 
Cholesterol lowering in a public health context 
In the mid nineteen nineties the first results of the randomised controlled trials with 
the new generation cholesterol lowering drugs (HMG-CoA reductase inhibitors, the 
so-called 'statins') were presented. I n a recently published meta-analysis of the most 
important trials it was estimated that treatment with statins was associated with a 
20% reduction in total cholesterol, 28% reduction in LDL cholesterol and 5% 
increase in HDL cholesterol. This results in a 29% reduction in coronary heart 
disease mortality and a 21 % reduction in all-cause mortality.3? The risk reduction 
calculated in this meta-analysis was comparable for men and women, for elderly 
(aged 65 years and over) and middle-aged persons and for primary and secondary 
prevention trials. The conclusion is therefore that treatment with statins is sensible, 
but the question arises who must be treated with these cholesterol lowering drugs. 
In the nineteen eighties guidelines for identification of high risk groups according 
to their cholesterol level were developed.38.39 In these guidelines treatment with 
cholesterol lowering therapy was based primarily on the cholesterol level. Nowadays 
treatment decisions are based on the total risk profile of a patient:0,41 as described 
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in the revised version of the Dutch consensus guidelines for cholesterol lowering 
therapy published in 1998:2 According to this consensus, treatment with cholesterol 
lowering medication in primary prevention is recommended in persons with a 
combination of risk factors for coronary heart disease leading to a high absolute risk 
for developing coronary heart disease. The risk factors taken into account are 
gender, age, serum total and HDL cholesterol, hypertension, diabetes mellitus, 
smoking and family history of premature coronary heart disease « 60 years). 
Cholesterol lowering medication in primary prevention is indicated if the absolute risk 
for developing coronary heart disease is above a given age- and gender specific cut-
off point. In addition, information about a healthy diet and lifestyle should be given: 
stop smoking, weight reduction if overweight, remain physically active and eat 
healthy ($ 10 percent of energy from saturated and trans fatty acids, 400 g fruits and 
vegetables each day and once or twice a week fish) in order to reduce the incidence 
of coronary heart disease at the population level. 
Outline of the thesis 
The aim of the research described in this thesis is to quantifY the impact of serum 
total and HDL cholesterol on public health in The Netherlands. In chapter 2 the 
prevalence of and trends in total and HDL cholesterol levels in The Netherlands 
between 1993 and 1997 are described. Furthermore, the extent to which these 
trends in cholesterol could be explained by changes in lifestyle factors, like body 
mass index, smoking, alcohol intake, intake of saturated and trans fatty acids is 
studied. The effect of low, medium and high serum cholesterol levels in combination 
with elevated blood pressure and smoking on 20-year cause-specific and all-cause 
mortality in adult men and women is described in chapter 3. In chapter 4 and 5 is 
reported whether the relations between total and HDL cholesterol and coronary heart 
disease mortality observed in middle-aged persons still hold in the elderly. In chapter 
4 the relation between total and HDL cholesterol and myocardial infarction in men 
and women aged 55 years and over is analysed. In chapter 5 the relation between 
total and HDL cholesterol and coronary heart disease mortality in men aged 65-84 
years in different European countries is investigated. In chapter 6 risk functions are 
described for coronary heart disease and cardiovascular diseases mortality for 
elderly men in different European countries. The impact of different population 
prevention strategies and a high-risk strategy on the primary prevention of coronary 
heart disease through cholesterol lowering is presented in chapter 7. A general 
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Trends in total and HDl cholesterol and their determinants 
in The Netherlands between 1993 and 1997 
Abstract 
Objective. The aim of this study is to describe trends in plasma total and HDL 
cholesterol in The Netherlands between 1993 and 1997 and to examine whether 
these trends in cholesterol could be explained by changes in body mass index, 
smoking, alcohol intake, use of cholesterol lowering medication, intake of saturated 
fat, trans fatty acids and dietary cholesterol. 
Methods. Each year a random sample of men and women aged 20-59 years living in 
three towns in The Netherlands was invited to participate in the study. In total more 
than 21 000 persons were examined. 
Results. Between 1993 and 1997 plasma total cholesterol decreased significantly by 
0.19 mmol/L in men and by 0.27 mmol/L in women. HDL cholesterol remained stable 
during this period in both men and women. Small decreases were observed in the 
intake of saturated fat. trans fatty acids and dietary cholesterol in both men and 
women. The use of cholesterol lowering medication and for women oral 
contraceptives and prescribed estrogens increased significantly. After adjustment for 
these determinants in multivariate analyses the trend in total cholesterol remained 
highly significant. 
Conclusion. Between 1993 and 1997 the mean total cholesterol level decreased 
significantly while the mean HDL cholesterol remained stable in both men and 
women in The Netherlands. The observed trend in total cholesterol could only for a 




Since 1972, age-adjusted coronary heart disease mortality has declined in The 
Netherlands by about 40%, but is still a major public health problem.' Further decline 
of coronary heart disease mortality is therefore warranted. A decline in plasma total 
cholesterol could have a significant impact on mortality. It is known from longitudinal 
studies that a plasma total cholesterol reduction of 1 % results in a decrease of 
coronary heart disease mortality of 2_3%.2 Eariier results of monitoring projects in 
The Netherlands between 1974 and 1992 showed that plasma total and HDL 
cholesterol levels were relatively stable, except for a decline in total cholesterol of 0.2 
mmol/L in men aged 33-37 years in the early eighties and a decline of 0.1 mmol/L in 
1991-1992 in men aged 20-59 years.3.' 
Nutritional and lifestyle factors affect plasma total and HDL cholesterol levels. 
Obesity, smoking and a high intake of saturated and trans fatty acids and dietary 
cholesterol increase plasma total cholesterol. Obesity, smoking and trans fatty acids 
decrease HDL cholesterol while physical activity, saturated fat and alcohol 
consumption increase HDL cholesterol.5-11 
The first aim of the present study is to describe trends in plasma total and HDL 
cholesterol in The Netherlands between 1993 and 1997. The second aim is to 
examine if the observed trend in total cholesterol could be explained by changes in 
body mass index, smoking, use of cholesterol lowering medication, intake of 
saturated fat, cholesterol and trans fatty acids. 
Methods 
Study population 
The Monitoring Project on Risk Factors for Chronic Diseases (MORGEN-project) 
has been carried out in The Netherlands from 1993 to 1997. The general purpose of 
this project was to determine both the prevalence of risk factors for chronic diseases 
(e.g. plasma cholesterol, blood pressure and smoking habits) and the prevalence of 
some specific chronic conditions in a sample of the general population. The project 
was carried out at the municipal health services in three towns in The Netherlands: 
Amsterdam, Doetinchem, and Maastricht. Each year a new random sample of men 
and women aged 20-59 years was selected from the municipal registry of 
Amsterdam and Maastricht, stratified by age and sex. In Doetinchem, the study 
population consisted of individuals aged 26-59 years who had participated in the 
previous Monitoring Project on Cardiovascular Disease Risk Factors (1987-1991) 
and a new random sample of men and women aged 20-25 years from the municipal 
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registry of Doetinchem to cover the whole age range of 20-59 years4 The overall 
response rate for the three towns was 48% in 1993, 51% in 1994,44% in 1995 and 
1996, and 40% in 1997. Each year the number of respondents from each town was 
about equal. In the analyses, respondents were excluded if they were pregnant 
(n=137) or if they had no measurements for the potential confounders (n=452). Data 
of in total 9773 men and 11 678 women were used for the analysis. 
Measurements 
The subjects who agreed to participate, received a general questionnaire and a 
semi-quantitative food frequency questionnaire, to fill in at home. 
The general questionnaire asked for demographic variables, lifestyle factors, 
psycho-social factors, (family) history of diseases, medication use and (for women) 
reproductive history. Alcohol intake was measured with a standardised questionnaire 
as number of drinks per day and subsequently converted to grams of alcohol by 
multiplying each glass of beer, wine, or spirit with its alcohol content. Educational 
level, measured with a standardised questionnaire, was classified into three 
categories: low (intermediate secondary education or less), medium (intermediate 
vocational or higher secondary education) and high (higher vocational or university 
education). Information on cigarette smoking (current, former or never) was obtained 
by a standardised questionnaire. Physical activity was measured between 1994 and 
1997 with an extended version of a validated physical activity questionnaire. '2 For 
the analyses, we classified physical activity in three categories: 1) less than 3.5 
hours per week physical activity 2) more than 3.5 hours per week physical activity, of 
which less than 2 hours strenuous and 3) more than 3.5 hours per week physical 
activity, of which more than 2 hours strenuous. 
The semi-quantitative food frequency questionnaire was designed to assess the 
habitual consumption of 178 food items during the previous year. In addition, this 
questionnaire provided information on the use of a prescribed diet. In 1991 and 
1992, the reproducibility and relative validity of the nutrients were assessed in a 
validation study.13 Nutrient and energy intake were quantified for each individual 
using an extended version of the 1996 computerised Dutch food composition table.14 
Because of the recent interest in trans fatty acids a food table was constructed with 
data on the amount of trans fatty acids in products. 's Chemical analyses were 
available for edible fats in 1990'6, 199517.18 and 199617 In addition, cookies and 
pastries as well as dairy products and meats were analysed contributing to 95% of 
the total mean fat intake of the Dutch national survey of 1992. '8 Trans fatty acid 
contents of fruit, vegetables, legumes, nuts, and game and offal were derived from 
the UK food table '9 or based on some other analyses.2o.21 The trans fatty acids 
content of the remaining foods was derived from recipes or deduced from other 
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foods. Trans fatty acid concentrations were corrected for measurement error due to 
the use of different methods of chemical analysis. To estimate the trans fatty acid 
concentration in 1993 and 1994, interpolation was done, assuming that the decline in 
trans fatty acid concentration was linear between 1990 and 1995. For 1997 the same 
food table was used as for 1996, because the assumption was made that there was 
no further decline in trans fatty acid concentration in this period. 
During a physical examination weight and height were measured. Body mass 
index was calculated by dividing weight (kg) by the square of height (m2). 
Total and HDL cholesterol determination 
Non-fasting blood samples were obtained in all three towns using a standardised 
protocol. Venous blood samples were collected in vacutainers containing 7.5% tri 
potassium (K3) ethylenediaminetetraacetic acid (Safety-Monovette® tubes, Sarstedt, 
Tilburg, The Netherlands). More than 30 minutes after the blood collection, the 
samples were centrifuged at room temperature for 10 minutes at 3000 x g. After 
centrifugation the plasma was separated from blood cells, and stored at -20°C. 
Once a week the blood samples were transported from the three towns to the 
laboratory in Rotterdam. 
Total and HDL cholesterol determinations were performed in the lipid Reference 
Laboratory (LRL) of the UniverSity Hospital Dijkzigt in Rotterdam using standardised 
enzymatic methods. Total cholesterol was measured using a CHOD-PAP method 
(Boehringer).22 HDL cholesterol was determined in the supernatant after precipitation 
of apoB-containing lipoproteins with phosphotungstic acid/MgCI2 (Boehringer).23 
Although the specimen type was EDTA-plasma, results are standardised to a serum 
matrix. For lipid standardization, there is international consensus that CDC 
Reference Methods are solely used in combination with a serum matrix. Field 
methods may use an alternative matrix but standardization should be performed by 
means of a split sample comparison, against serum reference values. Accordingly, 
lipid levels in EDTA-plasma as measured in the present study, are traceable to 
serum values. 
The LRL Rotterdam is a permanent member of the international Cholesterol 
Reference Method Laboratory Network24, performing the Abell-Kendall cholesterol 
reference method exactly as it is performed at the Centres for Disease Control 
(CDC), Atlanta, Georgia, USA and being standardised to CDC through participation 
in the CDC-National Heart Lung and Blood Institute (NHLBI) Lipid Standardization 
Program. For HDL cholesterol the accuracy base at the LRL Rotterdam is the HDL 
cholesterol Designated Comparison Method.24.25 Performance for enzymatic total 
and HDL cholesterol measurements fulfilled National Cholesterol Education Program 
(NCEP) recommendations throughout the entire study period24.26,27 Furthermore, the 
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internal quality control data of the LRL were analysed to detect whether, within the 
recommendations made by NCEP, there had been any laboratory drift over time that 
would influence the observed trend in plasma total cholesterol. For HDL cholesterol, 
adjustment was necessary for the period January 1993 to November 1994. During 
this period HDL cholesterol was determined manually and from November 1994 to 
December 1997 automatically. In total 40 samples were analysed with both methods. 
This crossover experiment was performed according to the NCCLS guideline EP9-A. 
HDL cholesterol levels ranged between 0.65 and 3.1 mmollL -i.e. encompassing the 
NCEP cutpoints of 0.91 and 1.55 mmol/L- and the distribution was Gaussian. 
Consequently, slope and intercept of the calculated regression line of the method 
comparison are reliable and accurate. The following orthogonal regression equation 
was found: Y (automatic method, mmol/l) = 1.055 (manual method, mmol/l) + 
0.029. Due to this change, HDl cholesterol was adjusted by +6.5% in the period 
January 1993 to November 1994. 
Hypercholesterolemia was defined as a plasma total cholesterol concentration of 
6.5 mmolll or higher. For low HDl cholesterol the cut-off point of 0.9 mmolll was 
used.2B 
Statistical analyses 
All data were age-standardised to the age distribution of the Dutch population 
aged 20-59 years in 1995. Univariate regression analysis was used to analyse trends 
over time with time (day) as independent variable and plasma total or HDl 
cholesterol as dependent variable. The multivariate regression analysis concerning 
total cholesterol was adjusted for age, town, body mass index, intake of saturated 
fat, intake of trans fatty acids, dietary cholesterol, education, smoking, cholesterol 
lowering medication, cholesterol or fat lowering diet, and (for women) use of oral 
contraceptives and estrogens. Intake of saturated fat and trans fatty acids was 
expressed as a percentage of total energy. Whether trends in total and HDl 
cholesterol differed between the three towns, the 10-year age categories, and the 
different educational levels was studied by including interaction terms in the 
regression models between town and day, age group and day, and educational level 
and day. All analyses were carried out for men and women separately. The SAS 
computer package (version 6.12) was used for all statistical analyses (SAS Institute 




Age-standardised yearly means and prevalence of high-risk levels of plasma total 
and HDL cholesterol for both men and women are given in table 1. The changes 
over time in plasma total and HDL cholesterol in both men and women are shown in 
figure 1. Between 1993 and 1997 there was a decrease in total cholesterol in both 
men and women, with the largest decline between 1994 and 1995. Consequently, 
the prevalence of hypercholesterolemia also decreased in men and women during 
this period. The concentration of HDL cholesterol remained almost stable from 1993 
to 1997 in men and women and the prevalence of a low HDL cholesterol level « 0.9 
mmol/L) declined somewhat. 
No significant differences were found in trends over time between the three towns, 
between 1 O-year age categories or between the different educational levels. Only for 
women aged 50-59 years the decline in plasma total cholesterol was significantly 
larger than in the other age categories. 
In table 2 the changes in determinants of total and HDL cholesterol are shown. 
Between 1993 and 1997 the intake of trans fatty acids decreased significantly by 0.4 
percent of energy in both men and women. The intake of saturated fat decreased 
significantly by 0.4 percent of energy in men and 0.5 percent of energy in women. 
The intake of cholesterol decreased Significantly by 0.6 mgfMJ in men and 1.9 
mg/MJ in women. The use of cholesterol lowering medication increased significantly 
by 1.5% in men and 0.4% in women. The use of oral contraceptives increased 
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Figure 1 Mean plasma total and HDL cholesterol level per quarter in men and women, 
standardised for the age distribution of the Dutch population aged 20-59 years in 1995. 
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Table 1 Mean, slandard devialion (sd) and prevalence of high-risk levels of plasma lolal and HDL choleslerol per year in men and women aged 
20-59 years (slandardised for Ihe age dislribution of Ihe Dulch population aged 20-59 years in 1995). 
1993 1994 1995 1996 1997 p-Irend 
Men 
N 2,155 1,816 2,106 2,015 1,681 
lolal choleslerol (mmoIlL) 5.27 (1.10) 5.25 (1.05) 5.06 (1.09) 4.99 (1.08) 5.08 (1.05) < 0.001 
lolal choleslerol ~ 6.5 mmoliL (%) 12.3 12.2 10.4 8.2 9.8 < 0.001 
HDL choleslerol (mmoIlL) 1.17 (0.29) 1.20 (0.30) 1.17 (0.29) 1.19 (0.29) 1.19(0.30) 0.1 
HDL < 0.9 mmoliL (%) 16.7 14.6 16.0 14.0 12.6 < 0.001 
Women 
N 2,639 2,031 2,446 2,417 2,145 
lolal choleslerol (mmoIlL) 5.26 (1.03) 5.27 (1.02) 5.04 (1.01) 4.96 (0.93) 4.99 (0.99) < 0.001 
lolal choleslerol ~ 6.5 mmol/L (%) 12.4 11.8 8.1 6.2 7.6 < 0.001 
HDL choleslerol (mmoI/L) 1.48 (0.36) 1.54 (0.37) 1.50 (0.38) 1.49 (0.35) 1.52 (0.36) 0.2 
HDL < 0.9 mmol/L (%) 3.4 2.0 2.7 2.3 2.3 <0.05 
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Table 2a Mean, standard deviation (sd) and prevalence of determinants per year in men 
aged 20-59 years (standardised for the age distribution of the Dutch population aged 20-59 
years in 1995). 
1993 1994 1995 1996 1997 p-trend 
N 2,155 1,816 2,106 2,015 1,681 
Classical CHD 
determinants: 
current smoker (%) 37.0 39.6 37.1 36.3 40.1 0.7 
ex smoker (%) 28.0 27.0 28.2 27.6 26.1 
never smoker (%) 35.0 33.4 34.7 36.1 33.8 
BMI (kgfm') 25.0 (3.4) 25.1 (3.4) 25.0 (3.7) 25.0 (3.6) 25.1 (3.6) 0.6 
alcohol intake (gfday)* 17.2 (20.0) 17.0 (20.7) 17.7 (22.6) 16.3 (18.8) 17.1 (18.8) 0.5 
low activity (%) 43.7 43.0 42.4 43.6 0.9 
medium activity (%) 35.8 34.9 36.2 36.6 
high actvity (%) 20.5 22.1 21.4 19.9 
Diet: 
saturated fat 15.5 (2.4) 15.3 (2.5) 15.2 (2.5) 15.1 (2.4) 15.1 (2.4) < 0.001 
(percent of energy) 
trans fatty acids 2.2 (0.7) 2.2 (0.7) 2.0 (0.6) 1.8 (0.5) 1.8 (0.5) < 0.001 
(percent of energy) 
PUFA's 7.3 (1.8) 7.2 (1.8) 7.3 (1.8) 7.2 (1.8) 7.3(1.8) 0.4 
(percent of energy) 
cholesterol (mgfMJ) 25.2 (6.7) 25.4 (7.1) 25.1 (7.0) 24.8 (7.1) 24.6 (7.0) < 0.001 
cholesterol/fat lowering 1.9 1.5 2.2 1.2 2.1 0.9 
diet(%) 
Other factors: 
low education (%) 43.9 41.8 38.6 38.3 35.1 < 0.001 
medium education (%) 31.3 34.4 34.2 35.0 33.3 
high education (%) 24.8 23.8 27.2 26.7 31.7 
cholesterol medication (%) 0.7 1.0 1.0 1.3 2.2 < 0.001 
* among the total population 
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Table 2b Mean, standard deviation (sd) and prevalence of determinants per year in women 
aged 20-59 years (standardised for the age distribution of the Dutch population aged 20-59 
years in 1995). 
1993 1994 1995 1996 1997 p-trend 
N 2,639 2,031 2,446 2,417 2,145 
Classical CHO 
detenninants: 
current smoker (%) 36.4 39.0 37.9 37.9 35.8 0.3 
ex smoker (%) 24.9 25.3 23.6 24.2 24.3 
never smoker (%) 38.7 35.7 38.5 37.9 39.9 
BMI (kg/m') 24.4 (4.1) 24.3 (4.2) 24.1 (4.0) 24.4 (4.2) 24.4 (4.3) 0.9 
alcohol intake (g/dayj> 7.1 (11.2) 7.3 (10.8) 7.6 (11.3) 7.3 (10.7) 7.8 (11.0) < 0.1 
low activity (%) 48.1 46.1 44.5 45.0 0.07 
medium activity (%) 39.1 40.8 42.5 41.7 
high activity (%) 12.8 13.1 12.9 13.3 
Diet: 
satu rated fat 15.5 (2.5) 15.3 (2.7) 15.1 (2.6) 15.0 (2.6) 15.0 (2.6) < 0.001 
(percent of energy) 
trans fatty acids 2.2 (0.7) 2.2 (0.7) 2.0 (0.6) 1.8 (0.5) 1.8 (0.5) < 0.001 
(percent of energy) 
PUFA's 7.1 (1.7) 7.2 (1.7) 7.2(1.7) 7.2 (1.8) 7.3 (1.8) < 0.01 
(percent of energy) 
cholesterol (mg/MJ) 26.3 (6.8) 25.9 (7.2) 25.5 (7.1) 25.1 (6.7) 24.4 (7.0) < 0.001 
cholesterol/fat lowering 2.8 3.3 3.2 3.1 3.4 0.3 
diet (%) 
Other factors: 
low education (%) 53.4 50.6 44.6 44.8 42.1 < 0.001 
medium education (%) 27.9 30.7 30.2 31.2 31.7 
high education (%) 18.7 18.7 25.2 24.0 26.3 
cholesterol medication (%) 0.4 0.5 0.5 0.8 0.8 0.02 
use of oral contraceptives 32.8 35.3 37.0 37.2 35.8 < 0.Q1 
(%) 
use of estrogens (%) 2.6 3.7 3.0 3.4 3.9 0.04 
. among the total population 
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Table 3 Regression ccefficients (11) and 95% confidence intervals for changes in plasma 
total cholesterol over time, based on age-standardised data, from univariate and 
multivariatea regression models. 
men women 
univariate multivariate'" univariate multivariate'" 
11 (95% GI) 11 (95% GI) 11 (95% GI) 11 (95% GI) 
(mmoI/Uyear) (mmoVUyear) (mmoI/Uyear) (mmoI/Uyear) 
total -0.062t -0.060t -O.084t -0.075t 
cholesterol (-0.077;-0.047) (-0.074;-0.046) (-0.097;-0.072) (-0.087;-0.063) 
adjusted for age, town, body mass index, intake of saturated fat, intake of trans fatty acids, dietary 
cholesterol, education, smoking, cholesterol lowering medication, cholesterol or fat lowering diet 
and (for women) use of oral contraceptives and estrogens 
t p<O.001 
Multivariate regression models were used to examine if the changes in the 
determinants mentioned above could explain the trend in plasma total cholesterol 
(table 3). In men, the univariate and multivariate regression coefficient for the change 
in total cholesterol was comparable. The multivariate regression coefficient in women 
was somewhat lower than the univariate coefficient for the change in total 
cholesterol, but still significant. This means that the observed trend in total 
cholesterol could only for a small part be explained by changes in the determinants 
studied. The multivariate regression coefficients for the most important determinants 
of total cholesterol are given in table 4. 
Discussion 
The plasma total cholesterol level and the prevalence of hypercholesterolemia 
decreased significantly between 1993 and 1997 in men and women. The HDL 
cholesterol level remained stable during this period. The observed trend in total 
cholesterol in men and women could only for a small part be explained by changes in 
the determinants studied, like intake of saturated fat, trans fatty acids, dietary 
cholesterol, use of cholesterol lowering medication and for women use of oral 
contraceptives and prescribed estrogens. 
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Table 4 Multivariate' regression coefficients (11) and 95% confidence intervals for 
determinants oftotal cholesterol. 
men women 
11 95%CI 11 95%CI 
age (year) 0.036 0.034;0.038 0.041 0.039;0.043 
ex smoking (yes/no) -0.00076 -0.00026;-0.0013 -0.0010 -0.00059;-0.0015 
never smoking (yes/no) -0.0012 -0.00074;-0.0017 -0.00051 -0.00090;-0.00013 
BMI (kg/m') 0.059 0.053;0.065 0.023 0.018;0.027 
saturated fat 0.020 0.0097;0.030 0.019 0.010;0.027 
(percent of energy) 
trans fatty acids 0.012 -0.025;0.049 -0.010 -0.044;0.023 
(percent of energy) 
cholesterol (mg/MJ) 0.0015 -0.0016;0.0046 -0.00073 -0.0034;0.0020 
adjusted for the other variables in the table and town, body mass index, education, cholesterol 
lowering medication, cholesterol or fat lowering diet and (for women) use of oral contraceptives 
and estrogens 
The response rate ranged from 48% in 1993 to 40% in 1997. Each year, a small 
non-response survey was carried out. Plasma cholesterol levels could not be 
measured in non-responders, so educational level, an important determinant of non-
response and associated with biological determinants like cholesterol level and blood 
pressure, was used to asses possible selection bias.>9.3o From the non-response 
surveys it can be concluded that people with a lower level of education are possibly 
under-represented in the MORGEN-project. Furthermore, the number of 
respondents with a high level of education increased while the number of 
respondents with a low level of education decreased during the study period in both 
men and women. This change in level of education can be due to the declining 
response rate between 1993 and 1997 but can also be the result of the known 
increase in the level of education of the general Dutch population. However, we 
included level of education in our multivariate model so educational level cannot 
explain the trend in total cholesterol. 
Previous monitoring projects carried out in The Netherlands between 1974 and 
1992 showed almost no changes in plasma total and HDL cholesterol, except a 
decline in total cholesterol of 0.2 mmol/L in men aged 33-37 years in the early 
eighties and a decline of 0.1 mmol/L in 1991-1992 in men aged 20-59 years.3A ln the 
present study however, plasma total cholesterol decreased significantly by 0.19 
mmol/L in men and by 0.27 mmollL in women in the relatively short period between 
28 
Trends in cholesterol, 1993-1997 
1993 and 1997. HDL cholesterol remained stable in both men and women. Results 
from the Zutphen Elderly Study showed a decline in serum total cholesterol of similar 
magnitude in Dutch men aged 70 years and older in the early nineties as observed in 
our study.31 Therefore, a decline in total cholesterol levels seems to be generalizable 
to the total Dutch population. 
Saturated fat is one of the most important dietary factors that influence plasma 
total cholesterol. 8.9 Between 1993 and 1997 a small, but significant, decline was 
observed in the intake of saturated fat in both men and women. The intake of 
polyunsaturated fat remained stable in men and increased in women whereas 
dietary cholesterol declined in both men and women. Using the equation of Keys et 
al.32, a decline in mean plasma total cholesterol of 0.03 mmol/L in men and 0.06 
mmolfL in women from 1993 to 1997 was predicted based on the change in the 
intake of saturated fat, polyunsaturated fat and dietary cholesterol during this period. 
Trans fatty acids from the diet also increase plasma total cholesteroI9 .11 Since 
1985, the trans fatty acid content of margarines and spreads has substantially 
declined in The Netherlands.,s,33 In the present study a significant decline was 
observed in the intake of trans fatty acids in men and women between 1993 and 
1997. Mensink and Katan" estimated that each additional percent of dietary energy 
as trans fatty acids results in an increase in total cholesterol of 0.026 mmol/L. 
Extrapolated to this study, the observed change in trans fatty acid intake would lead 
to a decline in mean total cholesterol of 0.01 mmol/L in both men and women 
between 1993 and 1997. This means that the change in the intake of the dietary 
determinants would result in a decline in total cholesterol of 0.04 mmol/L (20%) in 
men and 0.07 mmol/L (29%) in women. 
The reproducibility and relative validity of the nutrients, like total fat intake, was 
assessed in a validation study and seemed to be adequate.'3 This was not 
investigated for saturated fat and trans fatty acids. Random misclassification of 
dietary exposure, due to error in the quantification of saturated fat and trans fatty 
acids, cannot be excluded. However, using the equation of Keys, it can be calculated 
that a decline in the intake of saturated fat of almost 3 percent of energy in men and 
4 percent of energy in women would be needed for a reduction of total cholesterol by 
0.19 mmol/L in men and 0.27 mmol/L in women. This calculated decline in saturated 
fat is about ten times higher than the real decline observed in this study. It is 
therefore unlikely that misclassification of saturated fat explains the findings of this 
study. 
In our study the use of cholesterol lowering medication, mostly statins, increased 
significantly by 1.5% in men and 0.4% in women. In a meta-analysis of randomised 
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clinical trials it was estimated that persons who used statins had a 20% lower total 
cholesterol level compared with persons not using such cholesterol lowering 
medication after a mean follow-up period of 5 years.34 This observed change in the 
use of cholesterol lowering medication would in our population lead to a decline in 
total cholesterol of 0.02 mmol/L in men and 0.004 mmol/L in women. 
The observed trend in plasma total cholesterol could only for a small part be 
explained by changes in the determinants studied, like trans fatty acids, saturated 
fat, dietary cholesterol, use of cholesterol lowering medication and for women use of 
oral contraceptives and estrogens. Including these determinants and the variables 
age, town, body mass index, education, smoking and diet in the regression models 
only slightly changed the coefficients for change in total cholesterol over time. It is 
unclear which (other) factors are responsible for the trend . 
. In many other countries cholesterol levels have also declined during the last 
decades. In the WHO MONICA Project, carried out in 38 populations in 21 countries, 
the mean total cholesterol level declined by 0.008 mmol/L per year in men and 0.015 
mmol/L per year in women between 1985 and 1995.35 In the WHO MONICA Project 
dietary data were only collected in subsamples of some of the populations studied. 
The most important determinants of population changes in total cholesterol could 
therefore not be studied. In Finland a declining trend in serum total cholesterol is 
observed since 1972. Serum total cholesterol decreased by 0.9 mmoliL in men and 
by 1.2 mmol/L in women aged 30 to 59 years between 1972 and 199236, which 
seemed to be explained by dietary changes. The intake of polyunsaturated fatty 
acids increased by 2 percent of energy, saturated fat decreased by 5 percent of 
energy and dietary cholesterol decreased by about 25 mg/1000 kcal in both men and 
women. The expected decline in total cholesterol based on these dietary changes 
would be 0.6 mmol/L. A change from boiled to filtered coffee could have declined the 
cholesterol levels by another 0.3 mmoliL. This means that dietary changes fully 
explained the decline in total cholesterol in men. In women the decrease in weight 
was also an important determinant in addition to the dietary changes.37 
In the United States the mean serum total cholesterol level declined by 0.2 
mmol/L and HDL cholesterol slightly increased by 0.03 mmol/L between 1976 and 
1991 in men and women aged 20-74 years?B This change was fully explained by 
changes in the intake of polyunsaturated fatty acids, saturated fat and dietary 
cholesterol. 39 
The decline in plasma total cholesterol by 4% in men and 5% in women between 
1993 and 1997 in The Netherlands could only for a small part be explained by 
changes in trans fatty acids, saturated fat, dietary cholesterol and use of cholesterol 
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lowering medication. A decline in total cholesterol of this magnitude is of great public 
health importance because it could lead to a decline in mortality of coronary heart 
disease of about 8-15% in the future.2 
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Smoking and elevated blood pressure at low, medium and 
high serum cholesterol levels and 20-year mortality in men 
and women aged 30-54 
Abstract 
Objective. Few studies have examined the effect of smoking andlor blood pressure 
conditional on cholesterol levels. We investigated the additional effect of smoking 
and elevated blood pressure at different total cholesterol levels on mortality risk in 
middle-aged men and women. 
Methods. Men and women aged 30-54 were examined and followed for on average 
20 years. Several risk factor profiles were defined according to levels of total 
cholesterol, systolic blood pressure and smoking. Age-adjusted relative risks for 
mortality from coronary heart disease (CHD), cardiovascular diseases (CVD) and all-
causes were estimated for these risk factor profiles. 
Results. Given a low cholesterol level « 5.2 mmol/L) the impact of smoking on 
CHD, CVD and all-cause mortality was larger than that of elevated blood pressure 
(systolic" 140 mmHg). A low cholesterol level in combination with both elevated 
blood pressure and smoking was associated with relative risks for CHD, CVD and 
all-cause mortality of 3.0 (95% CI 1.1-8.8), 6.0 (2.4-14.9) and 4.1 (2.7-6.3) 
respectively in men and 2.3 (0.6-8.6), 3.6 (1.8-7.1) and 2.6 (2.0-3.5) respectively in 
women. An elevated cholesterol level (" 6.50 mmol/L) in combination with elevated 
blood pressure and smoking was associated with relative risks for CHD, CVD and 
all-cause mortality of respectively 9.7 (3.6-26.7), 13.9 (5.7-34.0) and 5.7 (3.7-8.6) 
respectively in men and 15.9 (5.6-44.8), 9.3 (4.8-17.8) and 4.3 (3.1-5.8) respectively 
in women. 
Conclusion. Even at low cholesterol level smoking in combination with elevated 
blood pressure is associated with an increased risk of CHD, CVD and all-cause 





It is well known from prospective studies that total cholesterol, blood pressure, 
and smoking are independent risk factors for mortality from coronary heart disease 
(CHD) and cardiovascular diseases (CVD) in middle-aged men and women. ' ·5 
Several studies have examined the effect of combinations of these risk factors on 
cause-specific and all-cause mortality and showed that risk increased with each 
additional risk factor.5•7 Few studies have examined the effect of smoking andlor 
blood pressure conditional on cholesterol levels. Stamler et al. 8 examined the effect 
on long-term cause-specific and all-cause mortality of elevated risk factor levels 
compared to a low risk factor profile (defined as serum cholesterol < 5.17 mmollL, 
blood pressure S 120/80 mmHg, no smoking and no history of diabetes or MI). CHD 
death rates were 77% to 92% lower in persons with a low risk factor profile 
compared to all others combined. 
Since it is not realistic to expect a population in which everyone has a low risk 
factor profile, for public health implications it is interesting to know for example the 
additional effect of smoking andlor elevated blood pressure at different cholesterol 
levels. A prospective cohort study carried out in Korean men aged 35-59 years 
showed that having a low cholesterol level was not protective against the harmful 
effects of smoking on CHD." It has not yet been studied whether elevated blood 
pressure alone or in combination with smoking increases mortality risk of CHD and 
CVD at low cholesterol levels. 
A large population-based study with a mean follow-up of 20 years carried out in 
about 50,000 persons aged 30 to 54 provided us with the opportunity to examine the 
effect of smoking andlor elevated blood pressure at different total cholesterol levels 
on CHD, CVD and all-cause mortality in both men and women. 
Methods 
Study population 
The Consultation Bureau Project on Cardiovascular Diseases was carried out 
from 1974 to 1980 in five towns in The Netherlands: Amsterdam, Doetinchem, 
Maastricht, Leiden, and Tilburg. Different birth cohorts were selected in different 
towns. Names and addresses of the partiCipants were obtained from the municipal 
registries. About 50,000 men and women were examined. The response rate ranged 
from 70 to 80%,'0 The project was aimed primarily at the age group of around 40 
years, but in some towns a wider age range was taken. The age range of the 
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population examined was 30 to 54 years, with about 75% aged between 35 and 44 
years. 
Measurements 
The participants filled out a questionnaire in which information was obtained about 
smoking habits, use of anti-hypertensive medication, cardiovascular complaints and 
history of myocardial infarction, stroke, hypertension, and diabetes mellitus. Weight 
and height were measured and body mass index was calculated as weight in 
kilograms divided by height in meters squared. Blood pressure was measured once 
while subjects were seated with a random-zero sphygmomanometer placed on the 
right upper arm." A non-fasting blood sample was taken in which total cholesterol 
was measured (with an accuracy of 0.1 mmollL) at the Central Clinical Chemistry 
Laboratory of the University Hospital Dijkzigt in Rotterdam. This laboratory 
participated in the standardisation programme of the World Health Organisation 
(WHO). Total cholesterol was determined according to a direct Liebermann-Burchard 
method.12,13 These cholesterol values were converted to enzymatic values as 
described before.13 
Mortality follow-up 
The mortality follow-up lasted until January 1, 2000. Information about the vital 
status was obtained from the municipal population registry in the town of residence. 
If a person had moved with unknown destination, the date on which the person's 
name was removed from the municipal population register was used as censor date. 
For 49,153 persons mortality follow-up was successfully completed, resulting in a 
loss to follow-up of 3.4%. The total number of person years was almost 480,000 in 
men and almost 535,000 in women. The mean (sd) duration of follow-up was 20.4 
(3.8) years for men and 20.8 (3.3) years for women. A total of 4,186 persons had 
died. For 4,065 persons, the primary cause of death was obtained from the Central 
Bureau of Statistics, while for 121 persons such information could not be obtained. 
Causes of death were coded according to the ninth revision of the International 
Classification of Diseases (ICD-9) for deaths that occurred before January 1, 1996 
(65%) and according to the tenth revision (ICD-10) for deaths that occurred from 
January 1, 1996 onwards (35%). Coronary heart disease was defined as ICD-9 
codes 410-414 or ICD-10 codes 120-125. Cardiovascular diseases were defined as 
ICD-9 codes 390-459 or ICD-10 codes 100-199. 
Statistical analysis 
Several risk factor profiles were defined based on levels of total cholesterol, 
systolic blood pressure and smoking. Cholesterol levels were divided into three 
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categories: < 5.20 mmol/L, 5.20-6.49 mmol/L and " 6.50 mmol/L. Systolic blood 
pressure was also divided into three categories: < 120 mmHg, 120-139 mmHg and" 
140 mmHg. Smoking was dichotomised (yes/no). Absence of all major risk factors, 
defined as total cholesterol < 5.2 mmoliL, systolic blood pressure < 120 mmHg and 
no smoking, was the reference category for all analyses and will be referred to as the 
'low risk factor profile'. Age-adjusted relative risks (RRs) were estimated using the 
Cox proportional hazards model. Subjects with diabetes (n=661) and prevalent 
cases of angina, stroke, and/or myocardial infarction (n=1 ,304) were excluded. The 
scope of this article was to investigate the additional effect of smoking and elevated 
blood pressure at different cholesterol levels. Results on six risk factor profiles are 
presented (see table 1). These risk factor profiles are: 1) no elevated risk factors (low 
risk factor profile; total cholesterol < 5.20 mmol/L, systolic blood pressure < 120 
mmHg and no smoking), 2) one risk factor at low cholesterol level « 5.20 mmoI/L): 
elevated blood pressure (" 140 mmHg), 3) one risk factor at low cholesterol level: 
smoking, 4) two risk factors at low cholesterol level: elevated blood pressure and 
smoking, 5) two risk factors at medium cholesterol level (5.20-6.49 mmoI/L): elevated 
blood pressure and smoking, 6) three risk factors (high risk factor profile; total 
cholesterol" 6.50 mmol/L, elevated blood pressure and smoking). No significant 
interactions were observed between the different risk factor profiles, age and use of 
anti-hypertensive medication. 
The SAS computer package (version 6.12) was used for all statistical analyses 
(SAS Institute Inc., Cary, North Carolina, USA, 1989). 
Results 
In total 3% of the men and 12% of the women had a low risk factor profile and 5% 
of the men and 1 % of the women had a high risk factor profile (table 1). About 3% of 
the men and women with a low risk factor profile died during 20 years of follow-up, 
compared to 23% of the men and 19% of the women with a high risk factor profile. 
The difference between men and women with a low risk factor profile versus men 
and women with a high risk factor profile was for total cholesterol almost 3.0 mmol/L, 
for systolic blood pressure more than 40 mmHg, for diastolic blood pressure about 
20 mmHg and for body mass index more than 3 kg/m2• 
For the low risk factor category and the category 'low cholesterol level, elevated 
blood pressure and no smoking', mortality rates were comparable in men and 
women (table 2a and table 2b). For the other four risk factor categories CHD, CVD 
and all-cause mortality rates were higher in men compared to women. The mortality 
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Table 1 Mean, standard deviation and prevalences of risk factors in men and women aged 30-54 years according to the different risk factor 
profiles. 
chol < 5.2 chol < 5.2 chol < 5.2 chol < 5.2 chol 5.2·6.5 ehal ~ 6,5 
SBP < 120 SBP> 140 SBP < 120 SBP> 140 SBP> 140 SBP> 140 
no smoking no smoking smoking smoking smoking smoking 
Men 
N (% of the total study population) 728 (3%) 757 (3%) 1,333 (6%) 1,134(5%) 1,793 (8%) 1,107(5%) 
number of CHD events 3 4 12 23 75 73 
number of CVD events 4 8 22 57 115 133 
number of events total 23 35 125 182 308 250 
age (years) 37.3 (4.1) 38.7 (4.3) 38.1 (4.1) 39.4 (4.7) 40.1 (4.5) 40.4 (4.2) 
total cholesterol (mmoI/L) 4.43 (0.51) 4.58 (0.44) 4.45 (0.51) 4.60 (0.45) 5.80 (0.36) 7.29 (0.74) 
systolic blood pressure (mmHg) 111.8 (5.8) 152.3 (10.9) 111.2(6.0) 152.0 (11.0) 153.4 (11.7) 154.6 (12.0) 
diastolic blood pressure (mmHg) 72.1 (8.3) 90.0 (10.8) 70.3 (8.0) 88.5 (11.3) 90.3 (11.1) 92.1 (10.5) 
BMI (k9/m') 22.9 (2.5) 25.0 (3.1) 22.4 (2.5) 24.5 (3.2) 25.4 (3.2) 26.1 (3.3) 
Women 
N (% of the total study population) 2,867 (12%) 1,148(5%) 2,560 (10%) 794 (3%) 855 (4%) 355 (1%) 
number of CHD events 5 6 10 4 10 14 
number of CVD events 15 12 23 19 34 25 
number of events total 96 72 131 86 101 68 
age (years) 37.5 (3.9) 41.2 (4.6) 37.5 (3.7) 40.0 (4.0) 40.8 (4.1) 41.7 (4.5) 
total cholesterol (mmoIlL) 4.40 (0.51) 4.53 (0.46) 4.42 (0.51) 4.52 (0.48) 5.77 (0.36) 7.32 (0.94) 
systolic blood pressure (mmHg) 109.6 (6.9) 153.1 (12.7) 109.0 (7.0) 152.6 (12.0) 152.9 (11.5) 153.7 (11.2) 
diastolic blood pressure (mmHg) 70.3 (7.6) 88.9 (10.3) 68.7 (7.6) 89.4 (10.4) 90.3 (9.8) 91.8 (11.2) 
BMI (kg/m') 22.3 (2.8) 25.6 (4.5) 22.1 (2.8) 24.6 (4.4) 25.3 (4.3) 25.9 (4.0) 
Table 2 Mortality rates per 10,000 person years and relative risks' (95% confidence intervals) for mortality from coronary heart disease (CHD), 
cardiovascular disease (CVD) and all causes according to the different risk factor profiles in men and women aged 30-54 years. 
GHD mortality GVD mortality All-cause mortality 
Mortality rate per RR (95% GI) Mortality rate per RR (95% GI) Mortality rate per RR (95% GI) 
10,000 py 10,000 py 10,000 py 
Men 
chol < 5.21 SSP < 120 I no smoking 2.0 1.00 2.7 1.00 15.3 1.00 
chol < 5.21 SSP:?: 140 I no smoking 2.5 0.83 (0.21-3.31) 5.1 1.32 (0.43·4.03) 22.3 1.23 (0.73-2.06) 
chol < 5.21 SSP < 120 I smoking 4.4 1.57 (0.51-4.85) 8.1 2.28 (0.87-6.03) 45.9 2.75 (1.78·4.25) 
chol < 5.21 SSP:?: 140 I smoking 10.0 3.04 (1.05·8.80) 24.8 5.96 (2.39-14.9) 79.1 4.09 (2.67-6.26) 
chol 5.2-6.5/ SBP > 140/ smoking 20.8 5.98 (2.18-16.4) 31.9 7.22 (2.95-17.7) 85.3 4.17 (2.75·6.33) 
chol:?: 6.5! ssp 2:: 140 I smoking 33.5 9.73 (3.55·26.7) 61.0 13.9 (5.69-34.0) 114.7 5.65 (3.71-8.59) 
Women 
chol < 5.21 SSP < 120 I no smoking 0.8 1.00 2.5 1.00 16.2 1.00 
chol < 5.21 SSP 2:: 140 I no smoking 2.5 2.05 (0.62-6.80) 5.0 1.35 (0.63-2.90) 29.8 1.35 (0.99-1.84) 
chol < 5.2/ SSP < 120 I smoking 1.9 2.31 (0.79·6.77) 4.4 1.77 (0.92-3.39) 24.8 1.54 (1.18·2.00) 
chol < 5.2/ SSP> 140/ smoking 2.4 2.30 (0.62·8.59) 11.4 3.61 (1.83-7.12) 51.8 2.64 (1.97-3.53) 
choJS.2-6.S/ SSP;:: 140 I smoking 5.7 5.12 (1.74·15.1) 19.3 5.73 (3.10-10.6) 57.3 2.78 (2.10-3.69) 
chol ;:: 6.5! SSP ~ 140 I smoking 19.3 15.9 (5.62·44.8) 34.5 9.28 (4.84-17.8) 93.9 4.25 (3.10·5.81) 
adjusted for age and use of anU-hypertensive medication and excluding prevalent CVD cases and diabetes 
Smoking and elevated blood pressure at different cholesterol levels 
rates in persons with the low risk factor profile were very low, i.e. 3 per 10,000 
person-years for CVD mortality in men and women. These were in sharp contrast to 
the CVD mortality rates in persons with the high risk factor profile, i.e. 61 per 10,000 
person-years in men and 35 per 10,000 person-years in women. 
Relative risks for the relation between the different risk factor profiles and CHD, 
CVD and all-cause mortality are shown in table 2a for men and in table 2b for 
women. At low cholesterol levels, in the absence of smoking, elevated blood 
pressure increased the relative risk of CVD and all-cause mortality by about 30% 
compared to the low risk factor profile. At low cholesterol levels, in the absence of 
elevated blood pressure, smoking increased the relative risks for CHD, CVD and all-
cause mortality by approximately 100%. Men with a low cholesterol level, who 
smoked and had elevated blood pressure had a significantly higher risk of CHD 
mortality (RR=3.0), CVD mortality (RR=6.0) and all-cause mortality (RR=4.1) 
compared to men with a low risk factor profile. For women these relative risks were 
somewhat lower, 2.3 for CHD mortality, 3.6 for CVD mortality and 2.6 for all-cause 
mortality. 
Men with intermediate cholesterol levels (total cholesterol 5.2-6.5 mmoI/L), 
elevated blood pressure and who smoked had a six times higher risk of CHD 
mortality, a seven times higher risk of CVD mortality and a four times higher risk of 
all-cause mortality compared to men with a low risk factor profile. In women, these 
relative risks were also somewhat lower, i.e. 5.1 for CHD mortality, 5.7 for CVD 
mortality and 2.8 for all-cause mortality. The highest relative risks were found for 
men and women with elevated levels for ali three risk factors. In men with high 
cholesterol levels, elevated blood pressure and who smoked the relative risk was 9.7 
for CHD mortality, 13.9 for CVD mortality and 5.7 for all-cause mortality. In women, 
these relative risks were 15.9, 9.3 and 4.3 respectively. 
Discussion 
The results of the present study show that a low risk factor profile leads to very 
low mortality rates and, surprisingly, to similar rates in men and women. Given a low 
cholesterol level, the additional effect of smoking on CHD, CVD and all-cause 
mortality was larger compared to the additional effect of elevated blood pressure. 
Despite low cholesterol levels, a significantly higher risk of CHD, CVD and all-cause 
mortality was found in smoking men and women with elevated blood pressure. When 
elevated blood pressure and smoking were accompanied by intermediate cholesterol 
levels, these mortality risks increased further. The highest relative risks were 
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observed in smoking men and women with high cholesterol levels and elevated 
blood pressure. 
We found similar mortality rates in men and women with a low risk factor profile 
and in non-smoking men and women with a low cholesterol level and elevated blood 
pressure. This is a surprising finding compared to other studies that examined the 
effect of different risk factor profiles on mortality6.8 In these American studies, higher 
CHD, CVD and all-cause mortality rates were observed when men and women with 
a low risk factor profile were compared. 6.8 In all those studies the number of deaths 
in the low risk category was small. A definite statement about differences in mortality 
rates between men and women with a low risk factor profile can therefore not be 
made. 
We are not aware of other studies that focused on the additional effect of elevated 
blood pressure given a low cholesterol level. The present study showed that the 
relative risks for CHD, CVD and all-cause mortality were not significantly different 
from 1.00 in non-smoking men and women with a low cholesterol level and elevated 
blood pressure. Although not statistically significant, the risk of CVD and all-cause 
mortality was about 20-30% higher in both men and women compared to those with 
a low risk factor profile. The blood pressure values used in the present study were 
based on a single measurement and not on the average of two readings at one visit. 
This has lead to an underestimation of the relative risks in the present study. 
The effect of smoking was stronger than the effect of elevated blood pressure in 
men and women with a low cholesterol level, as shown by the differences in relative 
risks. The relative risks for CVD and all-cause mortality in smokers with low 
cholesterol and blood pressure levels were larger in men compared to women. A 
prospective study carried out in Korean men aged 35 to 59 years investigated 
smoking as an independent risk factor for cardiovascular diseases in a population 
with low cholesterol levels9 They found that smoking men with a serum cholesterol 
level < 4.42 mmoliL had a relative risk of 3.3 (95% CI 1.7-6.2) for CHD and 1.6 (95% 
CI 1.2-2.3) for CVD. This indicates that having a low cholesterol level did not protect 
against the harmful effects of smoking in Korean men. The results of the present 
study are in line with those of the Korean study. The relative risks found in the 
present study were 1.8 (95% CI 0.8-4.0) for CHD mortality and 1.8 (95% CI 1.1-3.1) 
for CVD mortality in men and women combined. The relative risk for CHD in our 
study was somewhat lower than that found in the Korean study, but the relative risks 
for CVD were similar in both studies. These results suggest that smokers are at 
elevated risk for CHD and CVD, even at low cholesterol levels. 
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Several studies have investigated the effect of combinations of risk factors on 
mortality, but most studies examined the effect of the number of risk factors 
regardless of the combination of risk factors. Lowe et al6 studied the effect on CHD 
and all-cause mortality of a high risk profile (consisting of total cholesterol " 6.20 
mmol/L; SBP " 140 mmHg or DBP " 90 mmHg or use of anti-hypertensive 
medication; and current smoking) compared to a low risk factor profile. The relative 
risk for CHD mortality was 6.73 (95% CI 3.70-12.25) for men compared to 9.73 (95% 
CI 3.55-26.7) in the present study. For women, the relative risk was 8.92 (95% CI 
3.58-22.26) compared to 15.9 (95% CI 5.62-44.8) in the present study. The most 
likely explanation for the higher relative risks observed in the present study is that 
the men and women in our study were about 10 years younger at the time of 
examination. It is known from several studies that the relative risk is higher the 
younger the age at examination4 .14 Besides this, the cut-off point for total cholesterol 
in the present study was 6.5 mmol/L compared to a cut-off point of 6.2 mmol/L in the 
study of Lowe et al.6 It is therefore not surprising that higher relative risks were found 
in our study, because the higher the cholesterol level, the higher the risk of coronary 
heart disease death 
Because only a single measurement of total cholesterol and blood pressure was 
taken, the relative risks in the present study will be underestimated. A single baseline 
measurement is subject to random fluctuations, due to both measurement error and 
biological variation of cholesterol or blood pressure levels in individuals over time.'6 
Clarke et al.17 found that studies with a follow-up of about 20 years underestimate 
the relative risks of elevated cholesterol and systolic blood pressure separately with 
about 50%. If this regression dilution ratio would also apply to a combination of risk 
factors (in which cholesterol, systolic blood pressure and also smoking is included), 
correcting the regression coefficients obtained in the present study for regression 
dilution bias would lead to a relative risk of CHD mortality for men with a high risk 
factor profile of 30.4 (9.73"\ For women with a high risk factor profile, the corrected 
relative risk of CHD mortality would be 63.4 (15.9,·5). This emphasises the impact 
that a favourable risk profile can have on mortality. 
We can conclude that for a low cholesterol level with one additional risk factor, the 
effect of smoking is more harmful than the effect of elevated blood pressure. A low or 
intermediate cholesterol level in combination with both elevated blood pressure and 
smoking is associated with significantly elevated risks for CHD, CVD and all-cause 
mortality. When high cholesterol levels accompanied by both smoking and elevated 
blood pressure were adjusted for regression dilution bias, the risk of CHD mortality 
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was 30 times higher in men and 63 times higher in women compared to those having 
neither of these three risk factors. This highlights the importance of combinations of 
the classical risk factors in CHD and CVD mortality prevention. 
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Serum cholesterol is a risk factor for myocardial infarction 
in elderly men and women: the Rotterdam Study 
Abstract 
Objective. To investigate the associations of serum total and HDL cholesterol with 
the risk of myocardial infarction in men and women of 55 years and over. 
Methods. The Rotterdam Study is a population-based prospective cohort study. In 
total 2,453 men and 3,553 women of 55 years and older were included in this study. 
The mean duration of follow-up was 4 years. Relative risks were estimated with 
Cox's proportional-hazard analysis. Cholesterol was analysed as a continuous 
variable and in sex-specific quartiles. 
Results. In subjects aged 55 years and older the relative risk of myocardial infarction 
was 1.9 in men (95% confidence interval 1.1-3.3) and 3.2 in women (1.5-6.4) in the 
highest compared to the lowest serum total cholesterol quartile (Q4 vs. Q1). In men 
and women of 70 years and older, total cholesterol remained an important risk factor 
for myocardial infarction (Q4 vs. Q1 relative risk 3.2; 1.3-7.7 and 2.9; 1.3-6.6, 
respectively). For HDL cholesterol, the relative risk in the highest compared to the 
lowest quartile (Q4 vs. Q1) was 0.5 in men (0.3-0.9) and 0.4 in women (0.2-0.9). 
HDL cholesterol was a weaker predictor in men after age 70 (Q4 vs. Q1 0.8; 0.3-
2.1). In women of 70 years and older the relative risk was also not significant (Q4 vs. 
Q1 0.6; 0.3-1.3), although the trend over the quartiles was still significant. 
Conclusion. Serum total cholesterol remains an important risk factor for myocardial 
infarction in men and women aged 70 years and older, while HDL cholesterol at 




Several prospective studies have shown that serum total cholesterol and HDL 
cholesterol are important independent risk factors for coronary heart disease in 
middle-aged men and women. ' -5 However, the relation between cholesterol and 
coronary heart disease in elderly subjects is less well established. Some studies 
have found that serum total and HDL cholesterol are important risk factors for 





, or even disappears.13 For the discussion about treatment of 
elevated cholesterol levels in the elderly it is important to know whether the 
relationship between cholesterol and coronary heart disease still holds in this age 
group. 
In the Rotterdam Study we have investigated serum total cholesterol, HDL 
cholesterol and the ratio of non-HDL to HDL cholesterol as risk factors for myocardial 
infarction in men and women of 55 years and over. In addition, separate analyses 
were performed in men and women of 70 years and older. 
Methods 
Study population 
The Rotterdam Study is a population-based prospective cohort study among 
7,983 men and women aged 55 years and over, living in an urban district of 
Rotterdam, The Netherlands. The rationale and design of the study have been 
described previously." In short, the Rotterdam Study investigates the prevalence, 
inCidence, and determinants of cardiovascular, neurological, locomotor, and 
ophthalmological diseases at older age. Baseline measurements were carried out 
from July 1989 to July 1993. The overall response rate was 78%. The study has 
been approved by the Medical Ethics Committee of the Erasmus University and 
written informed consent was obtained from all participants. 
A total of 7,129 subjects visited the research centre. Cholesterol measurements 
were available for 2,554 men and 3,789 women. Subjects with incomplete data for 
the potential confounders, Le. systolic blood pressure, body mass index and smoking 
(101 men and 236 women), were excluded. For 728 men and 1,307 women dietary 
data were not available. For alcohol, these missing values were substituted by the 
sex-specific median of the alcohol intake for each 5-year age group. The data of 
2,453 men and 3,553 women were used in the present analyses. 
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Measurements 
The participants were interviewed in their homes by trained research assistants. 
Information on current health status, medical history (including myocardial infarction), 
medication use, and smoking behaviour was obtained by a computerised 
questionnaire. A history of myocardial infarction was considered positive if the 
subject reported to have been hospitalised for this condition. 
The home interview was followed by two visits at the research centre. During 
those visits several cardiovascular risk indicators were determined. Height and 
weight were measured, and body mass index was calculated (kg/m2). Blood 
pressure was measured on the right upper arm with the participant in sitting position 
using a random zero sphygmomanometer. The first and fifth Korotkoff phases were 
recorded as systolic and diastolic blood pressure. The average of two consecutive 
measurements was used to calculate the diastolic and systolic blood pressure. The 
mean alcohol consumption (g/day) was calculated from a semi-quantitative food 
frequency questionnaire. Serum total cholesterol was determined by an automated 
enzymatic procedure in a non-fasting blood sample. 15 HDL was measured after 
precipitation of the non-HDL fraction with phosphotungstate-magnesium. All 
cholesterol measurements were carried out in the laboratory of the Department of 
Epidemiology & Biostatistics (Erasmus University Medical School), which 
participates in the Dutch National Cholesterol Standardisation Program, initiated in 
analogy to the program of the CDC Lipid Standardisation Laboratory in Atlanta. The 
cholesterol ratio was defined as the concentration of non-HDL cholesterol divided by 
HDL cholesterol. Hypercholesterolemia was defined as a serum total cholesterol 
concentration of 6.5 mmoliL or higher. 
Follow-up 
The follow-up started at the baseline examination and lasted until April 1, 1996. 
The mean follow-up was 4.2 years, ranging from 3.0 to 6.5 years. With respect to the 
vital status of participants, information was obtained at regular intervals from the 
municipal registry in Rotterdam. Information on fatal and non-fatal endpOints was 
obtained weekly from the general practitioners working in the study district and 
yearly from the general practitioners working outside the study district. All the 
reported events were verified by research physicians from the Rotterdam Study by 
examining patient records of the participating general practitioners. All general 
practitioners working outside the study district, who had patients who participated in 
the Rotterdam Study, were visited to obtain information on the occurrence of non-
fatal and fatal events. Cause and circumstances of death were established, shortly 
after deaths were reported by the municipal registry or the general practitioner. A 
questionnaire was sent to the general practitioner concerning the cause of death. 
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Overall, complete follow-up information was available for 7,054 subjects (88.4%) in 
the present study. Participants for whom no follow-up information was available were 
on average 3 years older, had a 0.1 mmollL lower total cholesterol concentration and 
a 0.04 mmollL higher HDL cholesterol concentration. 
Classification of fatal and non-fatal events was based on the 10th revision of the 
International Classification of Diseases. '6 Myocardial infarction, fatal and non-fatal, 
was defined as ICD-1O: 121-24. All events were classified independently by two 
research physicians. If there was disagreement, a consensus was reached in a 
special session. Finally, all these events were verified by a medical expert in the field 
of cardiovascular diseases. In case of discrepancies, the judgment by this expert 
was considered definite. 
Statistical analyses 
Differences in risk factor levels at baseline between men and women were tested 
using Student's t-test. The Mann-Whitney test was used in case the risk factor 
distributions were skewed. For differences in levels of categorical variables 
(smoking) the x'-test statistic was calculated. 
Cox's proportional-hazard (survival) analysis was used to estimate relative risks 
(RRs) and their 95% confidence limits with myocardial infarction, fatal and non-fatal, 
as the dependent variable. Fatal and non-fatal myocardial infarction were not 
analysed separately because of the small number of cases in this study. Separate 
analyses were carried out using total cholesterol, HDL cholesterol and the non-
HDUHDL cholesterol ratio as the independent variables. Cholesterol was analysed 
both as a continuous variable, for 1.0 mmol/L increase in total cholesterol, 0.1 
mmol/L increase in HDL cholesterol and 1 unit increase in the cholesterol ratio, and 
as a categorical variable calculated for each sex-specific quartile, with the lowest 
quartile as the reference category. Because total and HDL cholesterol were 
measured in one decimal, the total number of respondents in each cholesterol 
quartile was not completely equal. In all analyses, adjustments were made for age 
(years), cigarette smoking (never, former and current), systolic blood pressure 
(mmHg) and body mass index (kg/rif). For HDL cholesterol and the cholesterol ratio, 
adjustment was also made for alcohol consumption (g/day). All the analyses were 
carried out separately for men and women. The analyses were repeated in men and 
women of 70 years and over. The cutpoint of 70 years was used to ensure enough 
subjects in this age group. Possible interactions between either total cholesterol, 
HDL cholesterol or the cholesterol ratio and age, cigarette smoking, systolic blood 
pressure, body mass index and alcohol consumption were tested by adding 
interaction terms to the model. Analyses were carried out with and without 
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respondents with a history of myocardial infarction (12% men and 4% women) and 
with and without users of cholesterol lowering medication andlor diet (3% men and 
2% women). Because these results did not differ and because of the small numbers 
using cholesterol lowering medication andlor diet, the results reported in this article 
are based on all subjects. 
The number of myocardial infarctions that could be prevented if the cholesterol 
levels of all subjects had been in the lowest, and for HDL cholesterol in the highest, 
cholesterol quartile were calculated as population-attributable risks (PARs). PARs 
were calculated using the following formula 17: 
PAR = L;CF;(RRr1)/RR; 
where CF is the proportion of cases with myocardial infarction, RR is the relative risk 
and i is the quartile number. The summation ranged over all the cholesterol quartiles 
with the lowest quartile as the reference category. 
The deviance (i.e. log likelihood) from the different survival models was compared 
to test whether total cholesterol, HDL cholesterol or the cholesterol ratio was the best 
predictor of myocardial infarction in our study. The smaller the deviance the better 
the prediction of the model. 
Results 
During 4 years of fOllOW-Up, 117 men and 76 women experienced a first or 
recurrent myocardial infarction of which 20 were fatal in men and 19 were fatal in 
women. 
Baseline characteristics of the total study population are shown in table 1. The 
mean serum total and HDL cholesterol levels at baseline were significantly lower in 
men than in women. The non-HDUHDL cholesterol ratio was significantly higher in 
men compared to women. The prevalence of hypercholesterolemia (total cholesterol 
;;, 6.5 mmol/L) was 43% in men and 62% in women. In men aged 70 years and older 
the mean age was 76.7 years (range: 70.0-97.8 years) and in women aged 70 years 
and older the mean age was 78.0 years (range: 70.0-98.6 years). 
In both men and women the relative risk of myocardial infarction increased with 
increasing total cholesterol concentration in both age categories (table 2). The age-
adjusted relative risk of myocardial infarction in the highest compared to the lowest 
total cholesterol quartile was almost two times higher in men and more than three 
times higher in women aged 55 years and over. In men and women aged 70 years 
and over, the age-adjusted relative risk of myocardial infarction was about three 
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Table 1 Baseline characteristics (mean (SO)) of men and women aged 55 years and over in 
the Rotterdam Study. 
age (years) 
total cholesterol (mmoI/L) 
HOL cholesterol (mmoI/L) 
non-HOUHOL cholesterol ratio 
systolic blood pressure (mm Hg) 
BMI (kg/m') 
alcohol drinking (% > 0 g/day) 
alcohol consumption (g/day)* 
smoking (%) - current 
former 
hypercholesterolemia (%)' 
history of myocardial infarction (%) 
cholesterol lowering medicaflon (%j' 
among alcohol drinkers 
















:j: information available for 2,379 men and 2,463 women 
















times higher in the highest compared to the lowest total cholesterol quartile. Further 
adjustment for systolic blood pressure, body mass index and smoking did not 
change the risk estimates. 
The relative risk of myocardial infarction decreased with increasing HDL 
cholesterol concentration in both age categories in women and in men aged 55 
years and over (table 3). The age-adjusted relative risk of myocardial infarction in the 
highest quartile was less than half that of the lowest quartile in both men and women 
aged 55 years and over. In subjects aged 70 years and older the age-adjusted 
relative risk of myocardial infarction was more than 15% lower in men and almost 
40% in women in the highest compared to the lowest HDL cholesterol quartile. The 
risk estimates did not change after further adjustment for systolic blood pressure, 
body mass index, smoking and alcohol consumption. 
There was a positive trend in relative risk of myocardial infarction with increase of 
the non-HDUHDL cholesterol ratio in both age categories (table 4). The age-
adjusted relative risk in the highest compared to the lowest quartile, was more than 
three times higher in both men and women of 55 years and older and in men and 
women aged 70 years and over. 
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Table 2 Adjusled' relative risks (RR) (95% confidence intervals (GI)) of fatal and non·fatal myocardial infarction associated wilh lotal 
choleslerol in Ihe lolal population men and women (~ 55 years) and in Ihe population aged ~ 70 years in the Rotterdam Study. 
tolal group 
~ 55 years ~ 70 years 
quartile total number of total number of 
(mmoI/L) mean number events RR (95% GI) number events RR (95% GI) 
Men 
<;5.4 4.9 565 19 1.00 290 8 1.00 
5.5 - 6.2 5.9 659 30 1.45 (0.81-2.59) 263 14 2.09 (0.87-5.01) 
6.3 - 7.0 6.6 620 33 1.75 (0.98-3.10) 219 16 2.89 (1.22-6.82) 
> 7.0 7.8 609 35 1.88 (1.06-3.33) 176 14 3.17 (1.31-7.67) 
per 1.0 mmol/L 2.453 117 1.20 (1.03-1.41) 948 52 1.42 (1.13-1.79) 
increase 
Women 
<; 5.9 5.3 803 10 1.00 421 8 1.00 
6.0 - 6.7 6.4 937 13 1.14 (0.50-2.61) 428 11 1.26 (0.50-3.17) 
6.8 - 7.5 7.1 895 18 1.68 (0.76-3.68) 375 11 1.37 (0.54-3.50) 
> 7.5 8.4 918 35 3.15 (1.54-6.42) 408 24 2.93 (1.29-6.62) 
per 1.0 mmol/L 3,553 76 1.40 (1.20-1.65) 1,632 54 1.36 (1.12-1.65) 
increase 
. adjusted for age, systolic blood pressure, body mass index and smoking 
Table 3 Adjusted' relative risks (RR) (95% confidence intervals (el)) of fatal and non-fatal myocardial infarction associated with HDL 
cholesterol in the total population men and women (2 55 years) and in the population aged 2 70 years in the Rotterdam Study. 
total group 
;> 55 years ;> 70 years 
quartile total number of total number of 
(mmoIlL) mean number events RR (95% el) number events RR (95% el) 
Men 
"' 0.9 0.84 496 26 1.00 202 9 1.00 
1.0-1.1 1.05 664 39 1.09 (0.66-1.79) 258 16 1.29 (0.56-2.93) 
1.2-1.3 1.24 615 35 1.09 (0.65-1.83) 224 17 1.70 (0.75-3.88) 
> 1.3 1.61 678 17 0.47 (0.25-0.89) 264 10 0.82 (0.32-2.09) 
per 0.1 mmoliL 2,453 117 0.91 (0.86·0.98) 948 52 0.96 (0.87·1.05) 
increase 
Women 
"' 1.2 1.06 1,152 36 1.00 587 26 1.00 
1.3-1.4 1.35 859 19 0.70 (0.40·1.24) 395 11 0.54 (0.26-1.13) 
1,5-1.6 1.55 694 11 0.57 (0.29-1.13) 292 7 0.51 (0.22-1.19) 
> 1.6 1.93 848 10 0.44 (0.22-0.91) 358 10 0.62 (0.29·1.32) 
per 0.1 mmoliL 3,553 76 0.89 (0.83·0.96) 1,632 54 0.90 (0.83·0.98) 
increase 
. adjusted for age, systolic blood pressure, body mass index, smoking and alcohol consumption 
Table 4 Adjusted' relative risks (RR) (95% confidence intervals (GI)) of fatal and non-fatal myocardial infarction associated with the non-
HDUHDL cholesterol ratio in the total population men and women (~ 55 years) and in the population aged ~ 70 years in the Rotterdam Study. 
total group 
~ 55 years ~ 70 years 
total number of total number of 
quartile mean number events RR (95% GI) number events RR (95% GI) 
Men 
~ 3.3 2.7 600 13 1.00 272 7 1.00 
3.4 - 4.3 3.9 666 33 2.34 (1.22-4.47) 279 16 2.25 (0.92-5.52) 
4.4 - 5.3 4.8 532 30 2.80 (1.44-5.44) 188 15 3.27 (1.31-8.15) 
> 5.3 6.6 655 41 3.24 (1.69-6.19) 209 14 3.06 (1.18-7.91) 
per unit 2,453 117 1.16 (1.05-1.28) 948 52 1.16 (1.01-1.33) 
increase 
Women 
~ 2.8 2.3 811 8 1.00 359 7 1.00 
2.9 - 3.8 3.4 1,021 15 1.45 (0.61-3.43) 474 12 1.29 (0.51-3.29) 
3.9 - 4.8 4.3 844 14 1.43 (0.59-3.48) 376 8 0.90 (0.31-2.57) 
> 4.8 6.3 877 39 4.00 (1.85-8.65) 423 27 3.24 (1.40-7.53) 
per unit 3,553 76 1.25 (1.16-1.36) 1,632 54 1.37 (1.20-1.56) 
increase 
, 
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Figure 1 Mortality rates (%) of myocardial infarction in men and women aged 55 years and 
over per sex-specific total cholesterol quartile in the Rotterdam Study. 
The mortality rates of myocardial infarction in men and women aged 55 years and 
over per quartile of total cholesterol are given in figure 1. In both sexes, the mortality 
rate increased with higher cholesterol concentrations. The mortality rates were about 
two times higher in men compared to women at all levels of total cholesterol, 
whereby the mortality rate of the highest total cholesterol concentration in women is 
comparable to the mortality rate of the lowest total cholesterol concentration in men. 
Population-attributable risks (PARs) indicate that there would have been 34% fewer 
cases with myocardial infarction in men and 43% in women of 55 years and older if 
total cholesterol levels in the whole population were 5,4 mmol/L or lower in men and 
5.9 mmol/L or lower in women (lowest quartiles) (table 5). If HDL cholesterol levels in 
the whole population would be 1,4 mmol/L or higher in men or 1.7 mmol/L or higher 
in women (highest quartiles) there would have been 48% fewer cases with 
myocardial infarction in men and 39% in women. The PAR for total cholesterol in 
subjects aged 70 years and older was higher in men (53%) and almost similar in 
women (39%) compared to subjects aged 55 years and over. The PAR for HDL 
cholesterol was lower in both men and women aged 70 years and older (31 % and 
12%, respectively). 
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Table 5 Population-attributable risk (PAR)' of myocardial infarction in the total population 
men and women (~ 55 years) and in the population aged ~ 70 years for the cholesterol 
parameters in the Rotterdam Study. 
men women 
cholesterol parameters ~ 55 years ~ 70 years ~ 55 years ~ 70 years 
total cholesterol 34 53 43 39 
H DL cholesterol 48 31 39 12 
non-HDUHDL cholesterol ratio 57 56 50 38 
assuming that the whole population had levels similar to those of the lowest quartile for total 
cholesterol and the non~HDUHDL cholesterol ratio or the highest quartile for HDL cholesterol 
The deviances for the models with total cholesterol, HDL cholesterol or the non-
HDUHDL cholesterol ratio were not significantly different, meaning that no one 
parameter was significantly more predictive than the other in men and women aged 
55 years and older. 
Discussion 
The results of the present study suggest that serum total cholesterol, HDL 
cholesterol and the ratio of non-HDL to HDL cholesterol are important risk factors for 
myocardial infarction in men and women aged 55 years and over. These risk factors 
remain important after age 70, except for HDL cholesterol in men. 
Before interpreting the results of our study some methodological issues will be 
discussed. First, the population of the Rotterdam Study was recruited from an urban 
district of Rotterdam and had a somewhat higher social economic status than the 
general population. Our results may therefore not be completely generalizable to the 
general Dutch population of 55 years and over. Second, the strength of the 
association between the cholesterol parameters and the risk of myocardial infarction 
is likely to be underestimated in our study, because the cholesterol levels were 
measured only once. A single baseline cholesterol measurement is subject to 
random fluctuations, due to both laboratory measurement error and biological 
variation of cholesterol levels in individuals over time. '8 Third, we had a relative short 
follow-up in this study. Because of this short follow-up period, we could not exclude 
events occurring during the first years of fOllow-up. Underlying diseases at baseline 
could have lowered the cholesterol levels. However, if this was the case it would 
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have decreased the relative risks and the true relative risks would have been even 
larger. Fourth, there was incomplete follow-up information in this study for 12 % of 
the subjects. This group mainly consisted of subjects who had a general practitioner 
without an automated patient registry, changed their general practitioner or moved 
outside the study district. These factors all contribute to a retardation in the data 
collection process. Based on these main reasons for incomplete follow-up 
information, we expect that the observed differences in baseline characteristics 
(subjects lost to follow-up were on average older and had a more favorable 
cholesterol profile) have not influenced the relation between cholesterol and 
myocardial infarction in this study. 
Results of epidemiological studies on cholesterol and coronary heart disease in 
the elderly are inconsistent. Some studies that examined the relation between total 
cholesterol and coronary heart disease in men aged 65 years and older found a 
positive relation?·'·1O·" However, other studies reported no association in elderly 
men6.9.12.13 In women aged 65 years and older, two studies found a positive 
relationship between total cholesterol and coronary heart disease6•9 and two studies 
did not find an association."·13 For HDL cholesterol, few studies observed an 
association with coronary heart disease in men aged 71 years and 0Ider.6.12 Most 
studies found no association in men aged 65 years and 0Ider?-11.13 A relation 
between HDL cholesterol and coronary heart disease in women with a cut-off age 
ranging from 65 to 71 years was seen in three studies6.9." Two other studies did not 
find an association in elderly women. '2.'3 Three out of four studies that have 
measured the cholesterol ratio observed a positive relation with coronary heart 
disease in elderly men and women with cut-off ages ranging from 65 to 71 years6.9.10 
The other study reported no relation in subjects older than 70 years.'3 
In our study we found a positive relation between total cholesterol and myocardial 
infarction in men and women aged 70 years and over. The relative risks for total 
cholesterol in our study are higher than those found in most studies mentioned 
above when comparable cut-offs were chosen. Only the Zutphen Elderly Study 
showed a relative risk of comparable magnitude for men aged 64 years and over.'0 
We found an inverse relation between HDL cholesterol as a continuous parameter 
and myocardial infarction in women aged 70 years and older. The relative risk in the 
highest HDL cholesterol quartile compared to the lowest lacked significance, 
probably due to small number of cases. In men aged 70 years and older the relation 
was not present. HDL cholesterol is apparently not as good a predictor of myocardial 
infarction in elderly men as total cholesterol. This is consistent with other studies 
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which also observed that HDL is not a strong predictor in older men9-11 ,13, although 
two other studies found a clear relationship in men aged 65 years and 01der.6,12 For 
women, only the Framingham Study9 found a relative risk for HDL cholesterol in 
women aged 65 years and older comparable in strength to that one observed in our 
study. The non-HDUHDL cholesterol ratio in our study was a good predictor of 
myocardial infarction in men and women aged 70 years and older. The relative risks 
for the cholesterol ratio observed in our study are comparable to those found in the 
EPESE study6, other studies found weaker associations. 
The results of this study showed pronounced relationships for total cholesterol in 
men and total and HDL cholesterol in women at older age. In our study, we used 
fatal and non-fatal myocardial infarction as endpOint rather than coronary heart 
disease mortality as used in most other studies in the elderly. Possibly, the 
relationship between cholesterol and incidence of myocardial infarction is stronger 
than the relationship between cholesterol and coronary heart diseases mortality. 
Another explanation could be that most other studies have excluded cases with 
coronary heart disease at baseline. However, we have done analyses with and 
without respondents with myocardial infarction at baseline and these results did not 
differ. 
We found that total cholesterol, HDL cholesterol and the cholesterol ratio were all 
important risk factors for myocardial infarction in men and women aged 55 years and 
older. In this study, the non-HDUHDL cholesterol ratio was a slightly better predictor 
of myocardial infarction for both men and women compared with total cholesterol 
and HDL cholesterol. However, no one parameter was significantly more predictive 
than the others. 
Population-attributable risks (PARs) are determined by relative risks and 
prevalences. Usually, relative risks for coronary heart disease decrease with 
advancing age and prevalences of coronary heart disease increase with age. A 
decrease in relative risk does not mean a decline in PAR. The differences in PARs in 
this study, in both age groups and between men and women, depended largely upon 
the differences in relative risks found. The PAR in women aged 55 years and older 
for total cholesterol is somewhat higher compared to men. However, the absolute 
number of myocardial infarctions that could be prevented in women would be smaller 
than that in men, because of the lower mortality rates in women (figure 1). 
Observational studies alone are insufficient to decide whether elderly have to be 
treated for elevated cholesterol levels or not. An evaluation of 28 randomised clinical 
trials showed that a lowering of the plasma cholesterol concentrations is associated 
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with a reduction in incidence of coronary heart disease.'9 There is little experimental 
data on cholesterol-lowering strategies in elderly. The Scandinavian Simvastatin 
Survival Study showed that also in elderly patients with coronary heart disease (aged 
60-70 years) there was a significant treatment effect (RR 0.7; 95% CI 0.6_0.9).20 
Whether reduction of cholesterol levels in the elderly would have a beneficial effect 
on primary prevention should be further investigated in clinical trials. The results of 
our study indicate that the public health gain to be achieved in elderly men and 
women is potentially large. 
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Total but not HDL cholesterol is consistently associated 
with coronary heart disease mortality in elderly men in 
Finland, Italy and The Netherlands 
Abstract 
Objective. To study the relation between serum total and high-density- lipoprotein 
(HDL) cholesterol and 10-year coronary heart disease mortality in elderly men in 
different European countries. 
Methods. The Finland, Italy and The Netherlands Elderly (FINE) Study is a 
prospective follow-up study in 2132 elderly men aged 65 to 84 years in Finland, The 
Netherlands and Italy. Relative risks using Cox's proportional-hazard analysis with 
time-dependent covariates. 
Results. Total cholesterol was positively related to coronary heart disease mortality 
in all three countries. The combined relative risk for the total population of the FINE 
Study was 1.17 (95% CI = 1.06-1.29) for each 1.00 mmollL increase in total 
cholesterol. HDL cholesterol was inversely related to coronary heart disease 
mortality in Finland, but not in The Netherlands and Italy. In Italy we noted an 
interaction between HDL cholesterol, body mass index and alcohol intake, with an 
inverse association for HDL cholesterol in lean men who drank < 40 g of alcohol 
daily and a positive association for HDL cholesterol among overweight men who 
drank ~ 40 g of alcohol per day. 
Conclusion. Serum total cholesterol remains an important predictor of coronary 
heart disease mortality in elderly men in different European countries. The effect of 




It is well established that serum total and high-density-lipoprotein (HDL) 
cholesterol are important predictors of coronary heart disease mortality in middle-
aged men.' "" Whether this relation holds in the elderly is not clear.S.11 It is also 
important to know whether the relation between serum cholesterol and coronary 
heart disease mortality in elderly men differs between countries. After 25-years of 
follow-up, the Seven Countries Study showed that the strength of the relation 
between serum total cholesterol and coronary heart disease mortality is similar in 
middle-aged men across cultures.4 The absolute risks, however, were markedly 
different. Similar information on HDL cholesterol is lacking because at the beginning 
of the Seven Countries Study HDL cholesterol was not measured. Information on 
both total and HDL cholesterol was collected in the Finland, Italy and The 
Netherlands Elderly (FINE) Study. This study is an extension of the Seven Countries 
Study and carried out since 1984 in Finland, The Netherlands and Italy. The FINE 
Study provided the possibility to investigate the relations between serum total and 




The FINE Study is an extension of the Seven Countries Study." The survivors of 
the cohorts in Finland, The Netherlands and Italy were re-examined after 25 years. 
This examination was the baseline of the FINE Study, a prospective study in elderly 
men 65 to 84 years of age. The FINE Study includes the two Finnish cohorts (both 
rural) known as East Finland and West Finland, the Dutch cohort from the small town 
of Zutphen, and the two rural cohorts in Italy from the villages of Crevalcore and 
Montegiorgio (in northern and central Italy, respectively). 
In Finland, 716 men were re-examined in 1984 and in rural Italy, 682 men in 1985. 
In The Netherlands, 380 survivors were re-examined in 1985, together with a new 
random sample conSisting of 507 men aged 65 to 84 years in Zutphen who did not 
participate earlier in the Zutphen Study. The response rate was 94% in Finland, 74% 
in The Netherlands and 76% in Italy. 
Subjects with incomplete data for the main cardiovascular risk factors were 
excluded. The data of 668 Finnish men, 824 Dutch men and 640 Italian men were 
used in the present analyses. 
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Measurements 
All men were examined according to the international protocol used in previous 
surveys of the Seven Countries Study.'2 Survivors were re-examined after 5 and 10 
years of fOllOW-Up. 
In Finland, fasting blood samples were taken and non-fasting blood samples in 
The Netherlands and Italy. In each country, total and HDL cholesterol determinations 
were carried out in lipid laboratories standardized according to the criteria of the 
WHO Lipid Reference Laboratories in Prague or Atlanta, Georgia. '3 In all three 
laboratories, serum total cholesterol was detenmined enzymatically with the CHOD-
PAP mono-testkit of Boehringer Mannheim (Mannheim, West Genmany)M,15 HDL 
cholesterol was determined after precipitation of the apo-B containing lipoproteins 
with dextran-magnesium chloride in Finland, dextran-magnesium sulfate in The 
Netherlands, and magnesium phosphotungstate in Italy.'6.17 Hypercholesterolemia 
was defined as a serum total cholesterol concentration of 6.5 mmol/L (251 mg/dl) or 
more. A low HDL cholesterol level was defined as HDL cholesterol less than 0.9 
mmol/L (35 mg/dl).'8 
Height and weight were measured in light clothing without shoes and body mass 
index was calculated (kg/m2). Blood pressure was measured twice on the right arm 
with the. men in supine position using a standard sphygmomanometer in Finland and 
Italy and a random zero sphygmomanometer in The Netherlands. Systolic and 
diastolic blood pressure were recorded at the onset of the first and fifth Korotkoff 
phase, respectively. 
Smoking was measured as never, ex, or current. Alcohol intake was measured as 
number of drinks per day and subsequently converted to grams of alcohol by 
multiplying each glass of beer, wine, or spirit with its alcohol content. '3 
Follow-up 
The history of coronary heart disease was defined by the Rose questionnaire'9, 
combined with information from reported clinical records and additional questions 
from the examining physician. Coronary heart disease was considered to be present 
when either myocardial infarction (definite) or angina pectoris (definite) was 
diagnosed. 
Complete follow-up infonmation after 10 years, obtained through official death 
certificates was available for 99.7% of the population of the FINE Study. In Finland, 
only information on causes of death was available. In The Netherlands and Italy, 
causes of death were validated through review of clinical records. Final causes of 
death were adjudicated by a single reviewer using the 9th revision of the WHO-ICD20 
adopting a hierarchical order when multiple causes were given, as follows: violent 
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causes, cancer, coronary heart disease, stroke and other. Coronary heart disease 
mortality was defined as ICD-9: 410-414 as the primary cause of death. 
Statistical analyses 
We computed age-standardized 10-year mortality rates of coronary heart disease 
by weighting the mortality rates for 5-year age categories to the age distribution of 
the total study population. We used Cox's proportional-hazard (survival) analysis, 
pooled after stratification by cohort, to investigate the relation between serum total 
and HDL cholesterol and coronary heart disease mortality during 10 years of follow-
up. We included serum total and HDL cholesterol and all the covariables as time-
dependent covariates. The baseline measurement and the measurement after 5 
years of follow-up were both used. For those who died during the first 5 years of 
follow-up only the baseline measurement was used. For those who died during the 
second 5 years of follow-up the baseline measurement was used for the first 5-year 
period and the measurement after 5 years of follow-up was used for the second 5-
year period. Relative risks (RR) are presented for each 1.00 mmol/L increase in total 
cholesterol and 0.10 mmol/L increase in HDL cholesterol, and for tertiles, the lowest 
tertile being the reference category. In all analyses adjustment was made for age 
(years), body mass index (kg/m2 ), systolic blood pressure (mmHg), cigarette 
smoking (ex and never or current) and history of coronary heart disease. For HDL 
cholesterol, adjustment was also made for alcohol intake (D, 1-19, 20-39, ;, 4D 
g/day). Analyses were carried out with and without respondents with a history of 
coronary heart disease, but because these results did not differ by much the results 
reported in this article are based on all respondents. We evaluated interaction by 
comparing the risk in the group with both an unfavorable cholesterol and covariate 
level with the risk expected from the additive effects of cholesterol and the covariate 
alone.21 
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Table 1 Baseline characteristics (mean (SD)) according to coronary heart disease (CHD) mortality in men aged 65 to 84 years in Finland, 
The Netherlands and Italy. 
CHD mortality 
Finland (N=668) The Netherlands (N=824) Italy (N=640) 
no (N=528) yes (N=140) no (N=736) yes (N=88) no (N=592) yes (N=48) 
age (years) 71.2 (5.0) 72.6 (5.4) 71.2 (5.2) 72.4 (5.8) 71.7 (4.4) 73.3 (4.2) 
history of CHD (%) 18.6 49.3 13.0 37.5 13.2 18.8 
total cholesterol (mmoI/L) 6.09 (1.21) 6.39 (1.39) 6.08(1.11) 6.36 (1.10) 5.88 (1.13) 6.09 (1.13) 
HDL cholesterol (mmoI/L) 1.24 (0.33) 1.15 (0.32) 1.13 (0.29) 1.11 (0.29) 1.30 (0.34) 1.35 (0.32) 
% total cholesterol ~ 6.5 mmol/L 36.2 40.0 35.6 35.2 26.4 27.1 
% HDL cholesterol < 0.9 mmol/L 12.3 19.3 22.8 19.3 8.3 6.3 
systolic blood pressure (mmHg) 153.3 (21.9) 156.9 (25.3) 150.7 (21.3) 150.3 (20.7) 166.7 (22.0) 167.1 (25.9) 
hypertension' (%) 57.1 70.0 41.6 39.8 75.1 87.0 
BMI (kg/m') 25.7 (4.1) 25.8 (4.0) 25.5 (3.2) 25.4 (3.1) 25.9 (3.6) 26.2 (3.9) 
overweight' (%) 58.5 56.4 54.2 63.6 59.3 66.7 
current smoking (%) 18.2 20.0 29.6 33.0 27.0 20.8 
ex-smoking (%) 55.3 57.5 51.8 51.1 42.9 43.8 
alcohol drinking (% > 0 g/day) 62.4 61.4 73.6 71.6 89.0 87.5 
alcohol intake§ (g/day) 5.3 (9.6) 4.6 (8.2) 18.3 (23.5) 16.2 (23.4) 43.3 (42.0) 47.3 (50.8) 
systolic blood pressure ~ 160 mmHg andlor diastolic blood pressure L 95 mmHg andlor on anti-hypertensive medication 
t body mass index L 25 kg/m2 
l among alcohol drinkers 
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Results 
Mean total cholesterol levels were similar in Finland and The Netherlands, but 
lower in Italy in both men with and without coronary heart disease mortality (table 1). 
The mean prevalence of hypercholesterolemia (total cholesterol ;;, 6.5 mmol/L) was 
37% in Finland, 36% in The Netherlands and 26% in Italy. Mean HDL cholesterol 
levels were different between the three countries, with the lowest level in The 
Netherlands and the highest level in Italy in both men with and without coronary 
heart disease mortality. The mean prevalence of a HDL cholesterol level less than 
0.9 mmol/L was 14% in Finland, 23% in The Netherlands and 8% in Italy. 
The age-adjusted coronary heart disease mortality rates of coronary heart disease 
were much higher in Finland than in The Netherlands and Italy (figure 1). The 
number of men who died from coronary heart disease after 10 years of follow-up was 
140 in Finland (21%), 88 in The Netherlands (11%) and 48 in Italy (8%). For total 
cholesterol, the age-adjusted coronary heart disease mortality rate in the lowest 
tertile in Finland was more than 1.5 times higher than that in the highest tertile in The 
Netherlands and Italy. For HDL cholesterol, the age-adjusted coronary heart disease 
mortality rate in Finland and The Netherlands decreased with respectively 12 and 3 
percentage points from the lowest to the highest tertile in contrast to an increase in 
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Figure 1 Age-adjusted mortality rates (%) from coronary heart disease in men aged 65 to 84 
years per tertile of baseline total cholesterol and HDL cholesterol. 
The risk of mortality from coronary heart disease increased with each 1.00 mmol/L 
increase of total cholesterol, with the highest relative risks in The Netherlands and 
the total population of the FINE Study (table 2). In The Netherlands, the relative risk 
in the highest total cholesterol terti Ie was about two times that in the lowest tertile 
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and there was a trend across the total cholesterol tertiles. In Finland and Italy there 
was no trend across the tertiles. 
Table 2 Adjusted' relative risks (95% Cis) of coronary heart disease mortality in men aged 
65 to 84 years in Finland, The Netherlands and Italy associated with total cholesterol as 
time..cfependent covariate. 
mean total number of 
country tertile (mmoI/L) (mmoI/L) number deaths RR (95% Cl) 
Finland < 5.51 4.85 216 41 1.00 
5.51 - 6.49 6.00 205 43 1.13 (0.74,1.72) 
> 6.49 7.33 247 56 1.07 (0.70,1.62) 
slope of trend line 0.03 (-0.18,0.24) 
1.00 mmol/L 668 140 1.10 (0.96,1.26) 
increase 
The < 5.51 4.85 246 15 1.00 
Netherlands 5.51 - 6.49 6.00 285 42 1.71 (0.91,3.21) 
>6.49 7.33 293 31 2.10 (1.12,3.92) 
slope of trend line 0.34 (0.04,0.63) 
1.00 mmol/L 824 88 1.29 (1.07,1.56) 
increase 
Italy < 5.51 4.85 247 11 1.00 
5.51 - 6.49 6.00 221 23 1.40 (0.69,2.83) 
> 6.49 7.33 172 14 1.92 (0.93,3.96) 
slope of trend line 0.33(-0.04, O. 69) 
1.00 mmol/L 640 48 1.20 (0.94,1.52) 
increase 
FINE 1.00 mmol/L 2132 276 1.17 (1.06,1.29) 
increase 
adjusted for age, body mass index. systolic blood pressure, smoking and history of CHO and 
stratified by cohort 
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Table 3 Adjusted' relative risks (95% Cis) of coronary heart disease mortality in men aged 
65 to 84 years in Finland, The Netherlands and Italy associated with HDL cholesterol as 
time-dependent variable. 
mean total number of 
country terti Ie (mmoIlL) (mmoI/L) number deaths RR (95% CI) 
Finland < 1.04 0.89 204 57 1.00 
1.04-1.31 1.17 224 45 0.96 (0.93,1.00) 
> 1.31 1.57 240 38 0.95 (0.91,0.99) 
slope of trend line -0.04(-0.05, -0.005) 
0.10 mmol/L 668 140 0.93 (0.88,0.99) 
increase 
The < 1.04 0.89 367 42 1.00 
Netherlands 1.04-1.31 1.17 265 31 0.99 (0.95,1.04) 
> 1.31 1.57 192 15 0.96 (0.90,1.02) 
slope of trend line -0.02(-0. OS, O. 01) 
0.10 mmol/L 824 88 0.99 (0.92,1.08) 
increase 
Italy < 1.04 0.89 142 8 1.00 
1.04-1.31 1.17 210 12 0.97 (0.89,1.06) 
> 1.31 . 1.57 288 28 1.01 (0.94,1.09) 
slope of trend line 0.01(-0.03, O. OS) 
0.10 mmol/L 640 48 1.01 (0.92,1.11) 
increase 
... adjusted for age, body mass index, systolic blood pressure, smoking, alcohol 'Intake and history of 
CHD and stratified by cohort. 
In Finland, the risk of mortality from coronary heart disease decreased with an 
increase in HDL cholesterol and there was a trend (table 3). In The Netherlands and 
Italy, HDL cholesterol was not associated with mortality from coronary heart disease. 
In Italy, the risk for coronary heart disease mortality in men with both a low HDL 
cholesterol level and a high 8MI was lower than expected from the additive effects, 
which turned out to be dependent on the level of alcohol intake: there was an inverse 
association between HDL cholesterol and coronary heart disease mortality in lean 
men (body mass index < 25 kg/m2) with no or moderate alcohol intake « 40 g/day) 
(RR 0.76; 95% CI = 0.59-0.97) and a positive association in overweight men (body 
mass index;;' 25 kg/m2) with a high alcohol intake (;;' 40 g1day) (RR 1.25; 95% CI = 
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1,07-1A6),The HDL concentration was 1,29 mmol/L in both subgroups, The total 
cholesterol concentrations were 5,88 mmol/L in lean men with no or moderate 
alcohol intake and 6,01 mmol/L in overweight men with a high alcohol intake. In the 
other two subgroups, lean men with a high alcohol intake and overweight men with 
no or moderate alcohol intake, a weak association was found with coronary heart 
disease mortality (RR 0.90; 95% CI = 0.72-1.13 and RR 0.96; 95% CI = 0.81-1.14, 
respectively). Also in Finland and The Netherlands there was an inverse, but less 
strong, relation between HDL cholesterol and coronary heart disease mortality (RR 
0.93; 95% CI = 0.85-1.02 and RR 0.99; 95% CI = 0.85-1.15, respectively) in lean 
men with no or moderate alcohol intake. In the total population of the FINE Study the 
relative risk in lean men with no or moderate alcohol intake was 0.92 (95% CI = 0.86-
0.99). 
Discussion 
The results of the present study show that serum total cholesterol is positively 
associated with 10-year coronary heart disease mortality in elderly men in Finland, 
The Netherlands and Italy. HDL cholesterol is inversely associated with 10-year 
coronary heart disease mortality in Finnish men only. 
Non-response could have influenced the results of our study, especially in The 
Netherlands and Italy. In Zutphen (The Netherlands), however, there was no 
difference in average serum total cholesterol level in 1960 between respondents of 
the 25-year follow-up survey and non-respondents, men who did not participate in 
the 25-year follow-up survey. Similar results were found in Montegiorgio (Italy). In 
Crevalcore (Italy), the respondents had in 1960 a lower total cholesterol level (0.16 
mmol/l) compared with the non-respondents. The difference in average serum total 
cholesterol level in 1960 between the respondents in the three countries together 
and the non-respondents was 0.08 mmol/L. It is therefore unlikely that our results are 
strongly influenced by non-response. 
Estimation of absolute risks is important, because decisions to treat high risk 
persons are based on absolute risks, which increase with age. For total cholesterol, 
the mortality rates for coronary heart disease showed large differences between the 
countries, with the highest rates in Finland, intermediate rates in The Netherlands 
and the lowest rates in Italy. In the middle total cholesterol terti Ie for example, the 
absolute risk in Finland is almost 1.5 times higher than that in The Netherlands and 
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2.5 times that in Italy. This finding is in accordance with previous reports from the 
same countries in middle-aged men 4 .22 
We found a positive association in this study between serum total cholesterol and 
coronary heart disease mortality. The results using time-dependent covariates did 
not differ much from those using only the baseline cholesterol measurement for each 
respondent (results not shown). Usually the relation found using time-dependent 
covariates is stronger than that using the baseline measurement only, because with 
longer follow-up a risk factor loses its predictive value.23 The more or less similar 
relative risks found in the present study for the two methods could be explained by 
the relatively short follow-up period of 10 years. 
Other epidemiologic studies among elderly men have so far given ,equivocal 
results concerning the relation between serum total cholesterol and coronary heart 
disease mortality.5-11 A possible explanation for this result could be the age at which 
the cholesterol level of the respondents was measured. Our hypothesis is that in the 
studies that did not find a relation between total cholesterol and coronary heart 
disease mortality the respondents were older at the time of the measurements (> 70 
years) compared with the studies that did find a positive relation (> 60 or 65 years). 
Also the present study provides some evidence for this hypotheSiS. Our data showed 
that the association between total cholesterol and coronary heart disease mortality in 
the total FINE population in the first 5 years of follow-up (men aged 65-84 years) was 
stronger (RR 1.21; 95% CI = 1.06-1.38, per 1.00 mmolfL increase) than in the 
second 5 years of follow-up (men aged 70-89 years) (RR 1.13; 95% CI = 0.94-1.36, 
per 1.00 mmolfL increase). The Whitehall study also observed a weaker association 
between total cholesterol and coronary heart disease mortality for men whose 
cholesterol concentration was measured at older age24 In the Seven Countries 
Study, the overall estimate of the predictive power of serum total cholesterol 
decreased from 1.25 (95% CI = 1.19-1.35, per 1.00 mmolfL increase) in middle-aged 
men to 1.17 (95% CI = 1.06-1.29) in the elderly in the present analyses4 The results 
of the present study, however, indicate that serum total cholesterol remains a 
predictor of coronary heart disease mortality in men aged 65 to 84 years in different 
countries. 
For HDL cholesterol, we found a different relation with coronary heart disease 
mortality between the three countries. In Finland we found an inverse association 
and in The Netherlands and Italy no association. For HDL cholesterol we found 
somewhat lower relative risks using time-dependent covariates compared with using 
only the baseline measurement (results not shown). Also in other studies 
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inconsistent results were noted for the association between HDL cholesterol and 
coronary heart disease mortality.?·9.11 
Overall, we found little relation between HDL cholesterol and coronary heart 
disease mortality in Italy. Exploring these differences we found that there was an 
inverse association in Italy in lean men (body mass index < 25 kg/m2) with no or 
moderate alcohol intake « 40 g/day), but a positive association in overweight men (~ 
25 kg/m2) with a high alcohol intake (20 40 g/day). These findings could be a chance 
result owing to the small numbers in the subgroups. 
A biological explanation for the interaction between HDL cholesterol, body mass 
index and alcohol might be that a potentially favorable effect of high HDL cholesterol 
on coronary heart disease mortality may be counterbalanced by a high body mass 
index in combination with a high alcohol intake. Being overweight reduces HDL 
cholesterol through a high concentration of triglycerides and an increased catabolism 
of HDL by an excess of adipose tissue.25 This effect could counterbalance the HDL 
cholesterol increasing effect of alcohol. This hypothesis is supported by our data. 
The HDL cholesterol concentration in overweight men with a high alcohol intake 
(1.29 mmol/L) was comparable with that in lean men with no or moderate alcohol 
intake (1.29 mmoI/L). Nevertheless, the total cholesterol concentrations were 
different between both groups. This finding indicates a disturbance of the lipid 
metabolism in overweight men with a high alcohol intake. 
Using the combined data of Finland, The Netherlands and Italy we observed an 
inverse relation between HDL cholesterol and coronary heart disease mortality in 
lean men with no or moderate alcohol intake. Thus, in a particular subgroup of the 
elderly population there may be an inverse association between HDL cholesterol and 
coronary heart disease mortality. We could not investigate this association in 
overweight men with a high alcohol intake in Finland and The Netherlands, because 
in both Finland and The Netherlands high alcohol intake (~ 40 g/day) is rare. We 
know of no other study that has reported on this interaction. A prospective follow-up 
study in middle-aged Russian men also found no relation between HDL cholesterol 
and coronary heart disease mortality, a result that could be due to the high intake of 
alcohol in these men26 
In conclusion, this study indicates that serum total cholesterol remains an 
important predictor of coronary heart disease mortality in men aged 65 to 84 years in 
the countries studied. The effect of HDL cholesterol on coronary heart disease 




We are indebted to the many people involved in this longitudinal study, including all 
participants and the fieldwork teams in Finland, Italy and The Netherlands. 
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Predicting cardiovascular risk in the elderly in different 
European countries 
Abstract 
Objective. The objective of this study was to develop risk functions for coronary 
heart disease (CHD) and cardiovascular diseases (CVD) mortality for elderly men in 
different European countries. 
Methods. The FINE Study is a prospective follow-up study in 2,170 elderly men aged 
65-84 years in Finland, The Netherlands and Italy. During 10-years of follow-up 289 
men died from CHD and 545 men from CVD. Risk functions were estimated using 
logistic regression analysis, in order to take competing causes of death into account. 
Results. Total cholesterol and smoking were the most important predictors for CHD 
mortality and HDL cholesterol, systolic blood pressure and smoking for CVD 
mortality. Left ventricular hypertrophy, being a prevalent case of CHD or CVD in 
Finland and The Netherlands and use of anti-hypertensive medication in Italy were 
also important risk factors. For estimating the absolute risk of CHD and CVD mortality 
in these elderly it was necessary to take country into account. 
Conclusion. Total and HDL cholesterol, systolic blood pressure and smoking remain 
important predictors of CHD and/or CVD mortality in elderly men but also left 
ventricular hypertrophy, being a prevalent case, use of anti-hypertensive medication 




Guidelines for prevention of coronary heart disease (CHD) or cardiovascular 
diseases (CVD) are nowadays based on the absolute level of risk of CHD or CVD, 
taking the total risk profile of an individual into account. Absolute risks for CHD and 
CVD in the elderly are high and the number of elderly people in Europe will increase 
in the years to come. Therefore even a small decrease in risk causes a substantial 
reduction in the number of CHD and CVD events. Estimation of absolute risk of CHD 
and CVD in the elderly is needed for targeted preventive activities. 
In middle-aged men and women, the Framingham risk function 1 is widely used to 
estimate absolute risks of CHD and CVD and has proven to be reasonably valid also 
for northern European populations'> Menotti et al3 showed that in middle-aged men 
the Framingham risk function overestimates absolute coronary risk in Italy due to a 
lower incidence of coronary events. In the elderly it is not known whether the 
Framingham risk function is a valid tool for risk prediction. Due to weaker 
associations between risk factors and CHD and CVD mortality in the elderly 
compared with middle-aged men4-6 it is necessary to develop separate risk functions 
for CHD and CVD mortality in the elderly. 
The aim of the present study is to develop risk functions for CHD and CVD 




The FINE Study is an extension of the Seven Countries Study. Between 1958 and 
1964, 16 cohorts of middle-aged men were examined according to a standardized 
protocol in seven countries.7 The survivors of the cohorts in Finland, The Netherlands 
and Italy were re-examined after 25 years. This examination was the baseline of the 
FINE Study, a prospective study in elderly men aged 65 to 84 years. The FINE Study 
includes the two Finnish cohorts (both rural) known as East Finland and West 
Finland, the Dutch cohort from the small town of Zutphen, and the two rural cohorts 
in Italy from the villages of Crevalcore and Montegiorgio 0n northern and central Italy, 
respectively). 
In Finland, 716 men were re-examined in 1984 and in rural Italy, 682 men in 1985. 
In The Netherlands, 380 survivors were re-examined in 1985, together with a new 
random sample consisting of 507 men aged 65 to 84 years in Zutphen who did not 
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participate earlier in the Zutphen Study. The response rate was 94% in Finland, 74% 
in The Netherlands and 76% in Italy. 
Subjects with incomplete data for the risk factors included in the risk function (age, 
total and HDl cholesterol, systolic blood pressure, smoking, diabetes, ECG-Ieft 
ventricular hypertrophy, use of anti-hypertensive medication and being a prevalent 
case of CHD or CVD) were excluded (n=115). 
Measurements 
All men were examined according to the intemational protocol used in previous 
surveys of the Seven Countries Study.7 In Finland, fasting blood samples were taken 
and non-fasting blood samples in The Netherlands and Italy. In each country, total 
and HDl cholesterol determinations were carried out enzymatically in lipid 
laboratories standardized according to the criteria of the WHO lipid Reference 
laboratories in Prague, Czech Republic, or Atlanta, Georgia, USA.s Blood pressure 
was measured twice on the right arm with the men in supine position using a 
standard sphygmomanometer in Finland and Italy and a random zero 
sphygmomanometer in The Netherlands. Systolic blood pressure was recorded at 
the first Korotkoff phase. Smoking was measured as current or non-smoking. Clinical 
diabetes mellitus was established by means of a standardised questionnaire. A 12-
lead resting ECG was recorded. ECG-Ieft ventricular hypertrophy was defined 
according to the Minnesota Code (codes 3.1 or 3.3, plus any code 4.1 to 4.3 or 5.1 to 
5.3)" Use of anti-hypertensive medication was assessed with a standardised 
questionnaire. 
Information on the history of CHD and CVD was obtained from the Rose 
questionnaire', combined with information from reported clinical records and 
additional questions from the examining physician. CHD was considered to be 
present when either myocardial infarction (definite) or angina pectoris (definite) was 
diagnosed. CVD was considered to be present when either myocardial infarction 
(definite), angina pectoris (definite), intermittent claudication (definite), stroke 
(definite), TIA (definite) or heart failure (definite) was diagnosed. 
Follow-up 
Complete follow-up information after 10 years, obtained through official death 
certificates, was available for 99.7% of the population of the FINE Study. In Finland, 
only information on causes of death was available. In The Netherlands and Italy, 
causes of death were in part validated through review of clinical records. Final 
causes of death were adjudicated by a Single reviewer using the 9th revision of the 
WHO_ICD 'o adopting a hierarchical order when multiple causes were given, as 
79 
Chapter 6 
follows: violent causes, cancer, CHD, stroke and other. CHD mortality was defined as 
ICD-9: 410-414 and CVD mortality as ICD-9: 390-459. 
Statistical analyses 
Logistic regression analysis was used to calculate the 10-year probability of CHD 
and CVD mortality. We did not use the Cox proportional hazards regression model or 
an accelerated failure time model like the Framingham Study did'·11 because these 
models calculate the risk of CHD or CVD mortality in the absence of competing 
causes of death. As death by other causes becomes more important with increasing 
age, calculating the risk of CHD or CVD mortality in the presence of competing 
causes of death, as is done by logistic regression, yields different results. As these 
equations are meant to be used by clinicians in order to predict the risk of individual 
patients, and such patients are subject to competing causes of death, equations 
should give risk in the presence of competing causes of death, and thus logistic 
regression is better suited for the elderly. A disadvantage of logistic regression is that 
results apply only to the fixed follow-up time chosen for the analysis. 
Risk factors included in the risk functions were: age, total and HDL cholesterol, 
systolic blood pressure, smoking, diabetes mellitus, ECG-Ieft ventricular hypertrophy, 
use of anti-hypertensive medication and being a prevalent case of CHD or CVD. 
Dummy variables for country were added to the logistic regression models to take 
into account the differences in absolute risk between the countries. The maximum 
likelihood method was used to test if quadratic terms, log transformations of the 
continuous variables or interaction terms had to be added to the risk functions. A 
statistically significant interaction between the use of anti-hypertensive medication 
and Italy was included in the risk function for CHD and CVD mortality and a 
statistically significant interaction between being a prevalent case of CHD or CVD 
and Italy was also included in the risk functions. 
The SAS computer package (version 6.12) was used for all statistical analyses 
(SAS Institute Inc., Cary, North Carolina, USA, 1989). 
Results 
The mean levels of the risk factors included in the risk functions for CHD and CVD 
mortality are given in table 1. Total cholesterol ranged from 5.9 mmollL in Italy to 6.2 
mmol/L in Finland. HDL cholesterol ranged from 1.1 mmol/L in The Netherlands to 
1.3 mmollL in Italy. Systolic blood pressure was lowest in The Netherlands (151 
mmHg) and highest in Italy (167 mmHg). The percentage of smokers was 19% in 
Finland, 26% in Italy and 30% in The Netherlands. The prevalence of diabetes was 
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highest in Italy and Finland (9%) and lowest in The Netherlands (6%). The 
prevalence of left ventricular hypertrophy was highest in Finland (10%) and lowest in 
Italy (3%). The use of anti-hypertensive medication varied from 13% in The 
Netherlands to 34% in Italy. A history of CHD (25%) and a history of CVD (39%) were 
both most prevalent in Finland. During the 10 years of follow-up, 289 CHD events 
(13%) and 545 CVD events (25%) occurred in 2,170 men. 
Table 1 Mean, standard deviation and prevalence of risk factors included in the risk functions 
for CHD and CVD mortality in men aged 65-84 years in the total population of the FINE 
Study, Finland, The Netherlands and Italy. 
The 
FINE Finland Netherlands Italy 
total number 2,170 679 879 612 
number of CHD events 289 142 100 47 
number of CVD events 545 204 198 143 
age (years) 71.6(5.1) 71.5 (5.2) 71.5 (5.3) 72.0 (4.5) 
total cholesterol (mmoI/L} 6.05 (1.18) 6.17(1.26) 6.10 (1.11) 5.85 (1.15) 
HDL cholesterol (mmoI/L) 1.20 (0.33) 1.23 (0.33) 1.12 (0.29) 1.29 (0.34) 
systolic blood pressure (mmHg) 156.5 (23.1) 153.9 (22.6) 151.1 (21.5) 167.1 (22.4) 
smoking (%) 25.5 18.6 30.4 26.3 
diabetes (%) 7.6 8.8 5.7 9.0 
left ventricular hypertrophy (%) 6.7 9.9 6.7 3.1 
anti-hypertensive medication (%) 21.2 20.8 12.9 33.5 
history of CHD (%) 18.0 24.6 15.9 13.6 
history of CVD (%) 31.0 39.3 24.9 30.4 
Table 2 shows the risk functions for CHD and CVD mortality fitted on the FINE 
data. The table presents the regression coefficients and the corresponding odds 
ratios (with 95% CI) for the risk factors. In appendix A the calculation of absolute risks 
for those coefficients is described. In the risk function for CHD mortality, total 
cholesterol was a statistically significant predictor (OR=1.24; 95% Confidence 
Interval 1.11-1.38), but this was not the case in the risk function for CVD mortality 
(OR=1.06; 95% CI 0.97-1.16). HDL cholesterol was statistically significantly 
associated with CVD mortality (OR=0.69; 95% CI 0.49-0.96), but not with CHD 
mortality. Systolic blood pressure was only statistically significantly associated with 
CVD mortality (OR=1.05; 95% CI 1.01-1.11). The effect of smoking on CHD and CVD 
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mortality was comparable, but was only statistically significant for CVD mortality 
(OR=1.28; 95% CI1.01-1.63). 
In these elderly men, diabetes was not statistically significantly associated with 
CHD and CVD mortality. Elderly men with left ventricular hypertrophy had a two times 
higher risk of CHD and CVD mortality compared to men without left ventricular 
hypertrophy. In Finland and The Netherlands, use of anti-hypertensive medication 
was not associated with CHD mortality. However, in Italy the odds ratio for the use of 
anti-hypertensive medication in the risk function for CHD mortality was 3.4 
(0.95*3.58). Use of anti-hypertensive medication was not statistically significantly 
associated with CVD mortality. Being a prevalent case of CHD or CVD was 
associated with both CHD and CVD mortality, especially in Finland. and The 
Netherlands. In Italy, the effect of being a prevalent case on CHD and CVD mortality 
was much lower, as shown by the lower ORs (OR=1.34 (0.32*4.18) for CHD mortality 
and 1.30 (0.51*2.55) for CVD mortality). 
Table 2 Regression coefficients and odds ratios (95% Confidence IntelVals) for the risk 
factors and 1 O-year CHD and CVD mortality in men aged 65-84 years. 
CHD mortality eVD mortality 
coefficient OR (95% el) coefficient OR (95% el) 
intercept -7.9578 -9.0941 
age (years) 0.0682 1.07 (1.04-1.10) 0.0963 1.10 (1.08-1.12) 
total cholesterol (1 mmol/L) 0.2146 1.24 (1.11-1.38) 0.0584 1.06 (0.97-1.16) 
HDL cholesterol (1 mmollL) -0.1842 0.83 (0.54-1.27) -0.3773 0.69 (0.49-0.96) 
systolic blood pressure (10 mmHg) 0.0014 1.01 (0.94-1.07) 0.0523 1.05 (1.01-1.11) 
smoking (no/yes) 0.2140 1.24 (0.91-1.69) 0.2471 1.28 (1.01-1.63) 
diabetes (no/yes) 0.0765 1.08(0.67-1.74) 0.2230 1.25 (0.87-1.80) 
left ventricular hypertrophy (no/yes) 0.6842 1.98 (1.30-3.02) 0.7042 2.02 (1.40-2.93) 
anti-hypertensive medication -0.0515 0.95 (0.63-1.42) 0.2306 1.26 (0.91-1.75) 
anti-hypertensive medication" Italy 1.2741 3.58 (1.72-7.43) 0.4605 1.59 (0.96-2.62) 
prevalent case 1.4291 4.18 (3.05-5.71) 0.9378 2.55 (1.98-3.29) 
prevalent case" Italy -1.1495 0.32 (0.13-0.77) -0.6775 0.51 (0.31-0.82) 
dummy The Netherlands (no/yes) -0.6264 0.53 (0.40-0.72) -0.2858 0.75 (0.59-0.97) 
dummy Italy (nolyes) -1.2469 0.29 (0.16-0.50) -0.2846 0.75 (0.52-1.09) 
The coefficients in the estimated risk functions for the dummy variables of country 
showed that the risk of CHD mortality was significantly lower in both The Netherlands 
and Italy, with the lowest risk in Italy. The risk of CVD mortality was highest in 
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Finland. The Netherlands and Italy had comparable absolute risks of CVD mortality, 
as shown by the comparable coefficients for the dummy variables of these countries. 
Discussion 
The results of the present study show that most classical risk factors for CHD and 
CVD mortality remain predictive in the elderly, of which total cholesterol and smoking 
were the most important ones for CHD mortality and HDL cholesterol, systolic blood 
pressure and smoking for CVD mortality. Left ventricular hypertrophy was also an 
important risk factor for CHD and CVD mortality in these elderly men. Being a 
prevalent case of CHD or CVD was an important risk factor in Finland and The 
Netherlands, while in Italy the use of anti-hypertensive medication was a risk factor 
for CHD mortality. For estimating the absolute risk of CHD and CVD mortality in the 
elderly it is necessary to take into account the European country in which they live. 
In this study separate risk functions for CHD and CVD mortality in the elderly were 
developed. Several reasons could be given for the fact that it is important to have 
separate risk functions for the elderly to predict absolute risks instead of using the 
Framingham risk function in this age group. First, the Framingham risk function is 
developed to estimate absolute risks in persons aged 30-74 years.' The number of 
elderly (> 70 years) used to calculate the risk function in the Framingham Study is 
only 111 (4%) men and 163 (5%) women leading to unreliable estimates for the 
elderly. 
Second, the Framingham risk function is calculated with an accelerated time 
failure model in which the presence of competing causes of death is not taken into 
account. Especially in the elderly in whom dying of causes other than CHD and CVD 
is frequent, it is important that absolute risks are calculated in the presence of 
competing causes of death. This is so because overall health in a population does 
not benefit from preventive action against CVD in persons who will die from other 
causes. Therefore in the present study, logistiC regression analysis was used in 
which absolute risks of CHD or CVD mortality are calculated in the presence of 
competing causes of death. 
Third, the relation between cardiovascular disease risk factors and CHD or CVD 
mortality is weaker in elderly men compared to middle-aged men.4-6 In general, 
relative risks decrease with increasing age, but absolute risks increase. The relative 
risk found in the Seven Countries Study for the relation between total cholesterol and 
CHD mortality in middle-aged men using Cox proportional hazards regression was 
1.25 (95% CI 1.19-1.35, per 1.00 mmol/L increase).12 In a recent analysis carried out 
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in the elderly men in the FINE Study, we found a relative risk of 1.17 (95% CI1.06-
1.29) using Cox proportional hazard analysis 13 showing that also in this study 
population the predictive power of total cholesterol was lower in the elderly compared 
to that in middle-aged men. 
In the present study, a non-significant odds ratio was found for the relation 
between total cholesterol and CVD mortality. This could be due to the assumption 
that serum total cholesterol is not associated with stroke. '4 Therefore, the effect of 
total cholesterol on CVD mortality is diluted compared to the effect on CHD mortality. 
HDL cholesterol was not significantly associated with CHD mortality in the present 
study. It is unclear whether HDL cholesterol is an important risk factor for CHD 
mortality in the elderly.13 However, there was a statistically significant inverse 
association between HDL cholesterol and CVD mortality in the present study. This 
could be explained by the fact that several studies have found that a low HDL 
cholesterol level is a risk factor for stroke, even in the elderly.'5-'7 
SystoliC blood pressure was statistically significantly associated with CVD mortality 
but not with CHD mortality in these elderly men. Van den Hoogen et al. '8 found a 
significant relation between systolic blood pressure. and CHD mortality in middle-
aged men in the Seven Countries Study (RR=1.17; 95% CI 1.14-1.20 per 10 mmHg 
increase). It was not estimated what the effect was of systolic blood pressure on CVD 
mortality in these middle-aged men. Systolic blood pressure is a risk factor for both 
CHD and CVD in Norwegian men until age 80, although the relative risks decrease 
with age6 However, a relation between systoliC blood pressure and CHD mortality in 
the elderly was not supported by our results. 
There was an effect of smoking in both CHD and CVD risk functions, but only for 
CVD mortality the odds ratio was statistically significant. The effect of smoking in the 
elderly is attenuated compared to the effect in middle-aged men. Shopland et al.5 
reported a relative risk for the relation between smoking and CHD mortality in men 
aged < 65 years of 2.8 and a relative risk in men aged;;, 65 years of 1.6. 
There was a positive, non-significant, effect of diabetes on both CHD and CVD 
mortality in this elderly population. The reason for the somewhat lower odds ratios for 
diabetes found in the present study compared with those found in other studies 19,20 
could be that we have adjusted for several variables associated with diabetes. If we 
calculate the crude odds ratio for diabetes in this study, it is indeed higher for both 
CHD and CVD mortality (OR=1,30; 95% CI 0.85-2,01 and OR=1.59; 95% CI 1.13-
2.23, respectively). 
Left ventricular hypertrophy was positively associated with CHD and CVD 
mortality, From the literature it is known that left ventricular hypertrophy is an 
independent risk factor for CHD and CVD mortality in the elderly.21,22 The odds ratio 
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found in the present study was comparable with that found in the Framingham Study 
in men aged 65 years and older (OR=2.1 ; 95% CI 1.3-3.5). 
In Italy, men using anti-hypertensive medication had a higher risk of CHD mortality 
compared to those not using this type of medication. In Finland and The Netherlands, 
prevalent cases had a statistically significant higher risk of dying of CHD and CVD. 
These findings are difficult to explain with the data available. An explanation could be 
that using anti-hypertensive medication in Italy and being a prevalent case in Finland 
and The Netherlands are both proxies for being at a high risk for dying of CHD or 
CVD in the future. To examine this hypothesis a combined 'disease variable' was 
included in the risk functions for men using anti-hypertensive medication andlor being 
a prevalent case. The odds ratio for this 'disease variable' in the risk function for CHD 
mortality was 2.83 (95% CI 2.16-3.72) and in the risk function for CVD mortality 2.25 
(1.82-2.78). These odds ratios were not significantly different between the countries. 
This means that elderly men using anti-hypertensive medication andlor being a 
prevalent case have a higher risk of dying of CHD and CVD, irrespective of the 
country in which they live. 
The present study showed that, except for the intercept, the same risk functions 
for CHD and CVD mortality could be used in Finland, The Netherlands and Italy. 
Earlier results of the FINE Study showed indeed comparable relative risks for the 
relation between cholesterol levels and CHD mortality in the different European 
countries, but different absolute risks at the same the same cholesterol level in the 
elderly.'" Different absolute risks between the countries for men with the same risk 
factor profile were also found in the present study (see Appendix A). Therefore, 
dummy variables for country were added to the risk functionsto take into account the 
differences in absolute risk between the countries. This means that a person in Italy 
with the same risk profile as a person in Finland would have a lower absolute risk 
due to a negative coefficient in the risk function for the dummy variable in Italy. 
Appendix A gives two examples demonstrating the effect of this difference between 
the countries. This may be due to differences in e.g. dietary patterns between the 
countries. The Mediterranean diet consumed by the Italian men is healthier than the 
Northern European diet consumed by the Finnish and Dutch men. This may explain 
the lower absolute risk for CHD at the same risk blood pressure and cholesterol 
levels in Italy.12.18 The effect of the dummy variables for country on the prediction of 
the absolute risks is larger for the risk function for CHD compared to that for CVD 
mortality. This is probably due to the fact that diet has a larger impact on the absolute 
risks of CHD compared to CVD. 
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We can conclude that there is still an association between the risk factors total and 
HDL cholesterol, systolic blood pressure and smoking and CHD andlor CVD mortality 
in elderly men although the associations are weaker than in middle-aged men. 
Therefore, specific risk functions are needed for the elderly. Left ventricular 
hypertrophy, being a prevalent case of CHD or CVD in Finland and The Netherlands 
and using anti-hypertensive medication in Italy are also important risk factors. 
Besides this, it is necessary to take the European country into account when the 
absolute risk of CHD and CVD mortality in elderly men is calculated. The results of 
the present study have important implications for prevention in the elderly. A 
reduction in the absolute risk of dying from CHD or CVD through lifestyle and dietary 
changes in combination with proper clinical treatment is necessary and will probably 
increase the quantity and quality of life of elderly men. 
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Appendix A 
In this appendix the method of calculating absolute risks is presented, using the 
regression coefficients given in table 2. The 10-year probability of dying from a 
coronary heart disease (CHD) event is computed using the following equation: 
1 O-year probability = 1 
l+exp(-L) 
,where L = -7.9578 + 0.0682"age + 0.2146"total cholesterol- 0.1842"HDL 
cholesterol + 0.0014"systolic blood pressure + 0.2140"smoking + 0.0765"diabetes + 
0.6842"left ventricular hypertrophy - 0.0515"use of anti-hypertensive medication + 
1.2741"(anti-hypertensive medication"ltaly) + 1.4291"prevalent case -
1.1495"(prevalent case"ltaly) - 0.6264"dummy The Netherlands - 1.2469"dummy 
Italy. 
Using the above mentioned equation, the 10-year probabilities of dying from a 
CHD event is estimated for four fictive persons. An Italian man aged 70 years without 
diabetes, who smokes, has no ventricular hypertrophy, no history of CHD, doesn't 
use anti-hypertensive medication, has a total cholesterol level of 6.0 mmol/L, HDL 
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cholesterol level of 1.3 mmolll, and systolic blood pressure of 145 mmHg, , has an L 
of -7.9578 + 0.0682'70 + 0.2146'6.0 - 0.1842'1.3 + 0.0014'145 + 0.2140'1 -
1.2469'1 = -2.9656 and thus a 10-year probability of dying from a CHD event of 
1 = 0.05. A Finnish man of the same age and with a similar risk profile 
1 + exp(2.9656) 
has a 10-year probability of dying from a CHD event of 0.15. 
An Italian man aged 80 years with diabetes, who smokes, has ventricular 
hypertrophy, a history of CHD, use anti-hypertensive medication, has a total 
cholesterol level of 6.5 mmolll, HDl cholesterol level of 1.2 mmol/l, and systolic 
blood pressure of 150 mmHg, has a 10-year probability of dying from a coronary 
heart disease event of 0.47. A Finnish man of the same age and with a similar risk 
profile has a 10-year probability of dying from a CHD event of 0.74. 
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CHAPTER 7 
Primary prevention of coronary heart disease through 
serum cholesterol lowering: quantifying the impact of 
different population strategies and a high-risk strategy 
Abstract 
Objective. Modeling the impact of different population prevention strategies and a 
high-risk strategy on the primary prevention of coronary heart disease (CHD). 
Methods. Recent data on prevalence of risk factors from two Dutch population-
based studies, including men and women aged 35-74 years, were used. We used 
the Framingham risk function to estimate absolute risks of CHD. Several population 
strategies were simulated: lowering the intake of saturated and trans fatty acids and 
smoking cessation. In the high-risk strategy, all persons with a high absolute risk for 
CHD were treated with cholesterol lowering medication. 
Results. In total 13% of the CHD events can be prevented through lowering the 
intake of saturated fat from on average 15 percent of energy to 12 percent of energy, 
trans fatty acids from on average 1.9 percent of energy to 0.5 percent of energy and 
reducing the number of smokers by 15% in the The Netherlands. Almost 2% of the 
CHD events can be prevented using the high-risk strategy. 
Conclusion. Of the population interventions, lowering the intake of trans fatty acids, 
attainable through advances in food technology, had the largest impact on the 




Observational studies and clinical trials have indicated that a reduction in serum 
cholesterol is associated with a reduction of coronary heart disease and total 
mortality.'-4 The serum cholesterol level can be lowered through different preventive 
strategies aimed at the total population or at high risk groups only. In the population 
strategy, focused on the reduction of risk factors in the general population, changes 
in lifestyle such as lowering the intake of saturated fat" and trans fatty aCids6, and 
smoking cessation7 could be induced. In the high-risk strategy, focused on 
individuals with a high absolute risk of coronary heart disease due to an unfavorable 
risk factor profile, serum cholesterol could be lowered by cholesterol lowering 
medication, like statins. 
In 1998, a revised version of the Dutch consensus guidelines for cholesterol 
lowering therapy was published8 According to this consensus, treatment with 
cholesterol lowering medication in primary prevention is based on the absolute level 
of risk of coronary heart disease, taking the total risk profile of an individual into 
account, including gender, age, serum total and HDL cholesterol, hypertenSion, 
diabetes mellitus, smoking and family history of premature coronary heart disease « 
60 years). Cholesterol lowering therapy is indicated in persons with an absolute risk 
for developing coronary heart disease above a given age- and gender specific cut-off 
point. 
The purpose of this article is to calculate the impact of different preventive 
population strategies and a high-risk strategy on the primary prevention of coronary 
heart disease, using the new Dutch consensus guidelines for cholesterol lowering 
therapy based on absolute risks. Outcome parameters that are modeled are 10-year 
absolute risk of coronary heart disease, the number of coronary heart disease 
events, life expectancy and the number of people needing cholesterol lowering 
medication in The Netherlands. 
Methods 
Study population 
We used data of two population-based studies carried out in The Netherlands. 
The first study, the Monitoring Project on Risk Factors for Chronic Diseases 
(MORGEN-project), is a cross-sectional study carried out from 1993 to 1997 in more 
than 21,000 men and women aged 20-64 years. The general purpose of this project 
was to determine both the level of risk factors for chronic diseases, e.g. cholesterol, 
blood pressure, smoking, and the prevalence of several chronic conditions in a 
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random sample of the general population. The project was carried out at the 
municipal health services in three towns in The Netherlands: Amsterdam, 
Doetinchem, and Maastricht. 
The second study, the Rotterdam Study, is a population-based prospective study 
carried out in almost 8,000 men and women aged 55 years and over, living in an 
urban district of Rotterdam. The Rotterdam Study investigates the prevalence, 
incidence, and detenminants of cardiovascular, neurological, locomotor, and 
ophthalmologic diseases9 Baseline measurements were carried out from 1990 to 
1993. 
In the analyses, respondents with prevalent cardiovascular disease (n=463 in 
MORGEN and n=440 in the Rotterdam Study) or miSSing values for the risk factors 
(n=355 and n=254 respectively) were excluded. Respondents with prevalent 
cardiovascular disease were excluded because we studied only primary prevention. 
In total data of 8,019 men and 9,674 women aged 35 to 74 years were used for the 
modeling approach. 
Dutch consensus guidelines for cholesterol lowering therapy 
In the new Dutch consensus guidelines for cholesterol lowering therapy, 
medication treatment in primary prevention is recommended in persons with a 
combination of risk factors for coronary heart disease leading to a high absolute risk 
for developing coronary heart disease based on the Framingham risk function.B,1O 
The factors included in the risk function are gender, age, total to HDL cholesterol 
ratio, hypertension, diabetes mellitus and smoking, 
Cholesterol lowering medication in primary prevention is indicated if the absolute 
risk of coronary heart disease over the next 10 years (based on a combination of the 
above mentioned risk factors) is > 25% at ages < 60 years and> 30% at age 60-69 
years. In persons aged 70 years and over, cholesterol lowering medication is 
indicated if the absolute risk exceeds 40% in men and 35% in women, For persons 
with a family history of premature coronary heart disease and for patients with 
diabetes mellitus the cut-off point was lowered with 5%, because of their increased 
risk of coronary heart disease due to factors that are not taken into account in the 
Framingham risk function. 
Measurements 
Nonfasting serum total cholesterol was determined in both studies using a CHOD-
PAP method (Boehringer),11,12 HDL cholesterol was determined in the supernatant 
after precipitation of apoB-containing lipoproteins with magnesium 
phosphotungstate.'3 All cholesterol measurements were performed in two 
laboratories that are permanent members of the international Cholesterol Reference 
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Method Laboratory Network. The cholesterol ratio was defined as the concentration 
of total cholesterol divided by HDL cholesterol. The levels for the cholesterol ratio 
were somewhat higher in the Rotterdam Study compared with those in the 
MORGEN-project, mostly due to time trends. Cholesterol levels in all age groups 
have declined in The Netherlands since 1993 and data from the Rotterdam Study 
were collected earlier (1990-1993) than those from the MORGEN-project (1993-
1997). To make the levels of the cholesterol ratio consistent over the entire age 
range we corrected these levels in the Rotterdam Study in both men and women 
assuming a uniform decrease of 0.05 in men and 0.09 in women over the time period 
between both studies. 
Blood pressure was measured twice on the upper arm with the participant in 
sitting position using a random zero sphygmomanometer. Systolic and diastolic blood 
pressure were recorded as the first and fifth Korotkoff phase, respectively. 
Hypertension was defined as a systolic blood pressure " 160 mmHg and/or a 
diastolic blood pressure " 95 mmHg and/or the use of anti-hypertensive 
medication.14 I nformation on smoking habits was obtained from a standardized 
questionnaire in both studies. Two categories were defined: current smokers and 
non-smokers. In the MORGEN-project, diabetes mellitus was defined as self-
reported diabetes or a random nonfasting serum glucose level" 11.1 mmol/L. In the 
Rotterdam Study, diabetes mellitus was defined as use of antidiabetic medication or 
a random or post-load serum glucose level " 11.1 mmol/L. Family history of 
premature coronary heart disease in first degree relatives was measured in the 
MORGEN-project for premature «60 years) myocardial infarction in parents only 
and in the Rotterdam Study for premature « 65 years) myocardial infarction in 
parents, siblings and children. Prevalence of cardiovascular disease was defined as 
a self-reported history of myocardial infarction, stroke or claudicatio intermittens in 
the MORGEN-project and as a self-reported history of myocardial infarction, stroke, 
claudicatio intermittens or angina pectoris in the Rotterdam Study. 
In the MORGEN-project dietary intake was measured with a 178-item semi-
quantitative food frequency questionnaire." In the Rotterdam Study dietary intake 
was assessed with a 170-item semi-quantitative food frequency questionnaire 
adapted for use in the elderly.'6 Nutrient and energy intake were quantified for each 
individ ual using the 1996 automated version of the Dutch food composition table for 
the MORGEN-project and that from 1993 for the Rotterdam Study."·1. Separate food 
tables were constructed with data on the amount of trans fatty acids in products.
" 
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Strategies of intervention 
We simulated different inteNention strategies: three population strategies and a 
high-risk strategy, and compared them with a reference scenario of no inteNention. 
In the reference scenario, the current age- and gender specific prevalence of the 
risk factors from the MORGEN-project and the Rotterdam Study were used. 
Three different population strategies were simulated: inteNention on saturated fat, 
trans fatty acids and smoking. For the inteNention on saturated fat and smoking we 
defined an optimistic and a realistic scenario, based on what is known from the 
literature. We also estimated the combined effect of the three different population 
strategies. In the optimistic inteNention scenario on saturated fat, the saturated fat 
intake of each individual was reduced to 10 percent of energy (the Dutch national 
target, the current average intake in The Netherlands is 15 percent of energy) and in 
the realistic scenario, it was reduced to 12 percent of energy. For each individual, the 
equation of Keys et al.20 was used to transform the reduction in saturated fat intake 
into a reduction in serum total cholesterol. For the inteNention on trans fatty acids 
we simulated one feasible scenario in which the intake of trans fatty acids of each 
individual was reduced to 0.5 percent of energy (the current average intake in The 
Netherlands is 1.9 percent of energy). This intake level could be achieved if all trans 
fatty acids are removed from predominantly vegetable oils, through food technology, 
leaving an intake level of 0.5 percent of energy from natural sources (meat and dairy 
products).21 In the Rotterdam Study, there were no data available about the intake of 
trans fatty acids and therefore we have assumed a mean intake of trans fatty acids 
of 1.9 percent of energy in both men and women (mean intake in the MORGEN-
project), which was reduced to 0.5 percent of energy. To transform the reduction in 
the intake of trans fatty acids into a change in serum cholesterol, we assumed a 
decline in total cholesterol by 0.026 mmollL and an increase in HDL cholesterol by 
0.017 mmol/L for each 1 percent of energy decline in trans fatty acids.s In the 
optimistic inteNention scenario on smoking, the number of smokers was reduced by 
25% (e.g. from 40% to 30%) and in the realistic scenario, it was reduced by 15% 
(e.g. from 40% to 34%). These percentages were chosen based on the results of a 
Dutch media campaign to encourage smokers to quit smoking, that found that about 
14% of the smokers had stopped smoking after one year.22 
In the high-risk strategy we assumed that all persons with an absolute risk for 
developing coronary heart disease above their age- and gender specific cut-off point 
were treated with cholesterol lowering medication according to the primary 
prevention guidelines of the Dutch cholesterol consensus. We assumed that the 
absolute risk of coronary heart disease of those using cholesterol lowering 
medication was lowered by 33%.' 
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Calculation method of outcome parameters 
To estimate the 10-year absolute risk of coronary heart disease, the number of 
coronary heart disease events in the next ten years and the number of people 
needing cholesterol lowering medication for the different strategies, we used the 
Framingham risk function,'0 the age- and gender specific prevalence of the risk 
factors from the MORGEN-project for the 35-64 year olds and from the Rotterdam 
Study for the 65-74 year olds and demographic data from Statistics Netherlands 
[http://statline.cbs.nl/statwebl]. 
To estimate the gain in life expectancy for the different strategies we used the life 
table method. Total mortality rates were derived from Statistics Netherlands for 1994. 
For each strategy, all cause mortality rates were calculated for each 5-year age 
group, USing the age and gender-specific prevalence of the risk factors and relative 
risks from literature. For the interventions on saturated fat and trans fatty acids, the 
decrease in total mortality was calculated using a relative risk of 0.94 per 1 mmol/L 
decrease in total cholesterol for men and women23 and relative risks of 0.95 and 0.98 
per 0.1 mmollL increase in HDL cholesterol in men and women, respectively.24 For 
the interventions on smoking, we used a relative risk of 2.34 for current smoking 
versus non-smoking men and a relative risk of 1.90 for current smoking versus non-
smoking women.2S For the high-risk strategy, new total mortality rates were 
calculated by subtracting the reduction in coronary heart disease mortality (33%)' , 
assuming that the mortality reduction was proportional to the reduction of event risks. 
Results 
Baseline characteristics of both populations studied are shown in table 1. The 
mean total to HDL cholesterol ratio was 5.0 in men and 3.9 in women aged 35-64 
years and 5.5 in men and 5.1 in women aged 65-74 years. Almost 95% of the men 
and women aged 35-74 years consumed more than 10 percent of energy saturated 
fat and more than 80% consumed more than 12 percent of energy saturated fat. The 
prevalence of diabetes and hypertension was higher and the prevalence of smoking 
was lower in men and women in the older age group compared with the younger age 
group. 
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Table 1 Mean, standard deviation and prevalence of risk factors in men and women aged 35-64 years in the Monitoring Project on Risk Factors 
for Chronic Diseases (MORGEN-project) and in men and women aged 65-74 years in the Rotterdam Study. 
men (N=8,019) women (N=9,674) 
MORGEN-project Rotterdam Study MORGEN-project Rotterdam Study 
(N=7,289) (N=730) (N=8,593) (N=1,081) 
age (years) 47.6 (7.4) 69.4 (2.9) 47.5 (7.4) 69.9 (2.8) 
total cholesterol (mmoIlL) 5.52 (1.02) 6.29 (1-14) 5.46 (1.05) 6.98 (1.21) 
HDL cholesterol (mmoIlL) 1.19 (0.31) 1.23 (0.33) 1.51 (0.38) 1.45 (0.39) 
totallHDL cholesterol 4.96 (1.69) 5.45 (1.67)' 3.85 (1.25) 5.11 (1.56)' 
saturated fat intake (percent of energy)" 14.8 (2.6) 14.4 (3.0) 15.0 (2.7) 14.7 (3.3) 
trans fatty acids (percent of energy)t 1.9 (0.6) 1.9 (0.6) 
current smoker (%) 34.8 23.7 35.3 18.4 
non-smoker (%) 65.2 76.3 64.7 81.6 
hypertension (%)§ 13.8 30.3 11.7 36.1 
diabetes (%)§ 2.3 10.5 1.7 10.2 
cholesterol lowering medication (%) 1.7 1.4 1.5 2.2 
information available for 7,253 men and 8,565 women from the MORGEN-project and 559 men and 774 women from the Rotterdam Study 
t information available for 7,253 men and 8,565 women from the MORGEN-project and no information about the intake of trans fatty acids 
available from the Rotterdam Study 
:I: not corrected 
§ for definition see methods 
Table 2 10-year absolule risk (%) of coronary heart disease for the reference scenario, the different population strategies and the high-risk 
slralegy and baseline values of Ihe risk faclors in men and women aged 35-74 years in 10-year age groups. 
men (N=8,019) women (N=9,674) 
35-44 yrs 45-54 yrs 55-64 yrs 65-74 yrs 35-44 yrs 45-54 yrs 55-64 yrs 65-74 yrs 
(N=2,731) (N=2,974) (N=1,584) (N=730) (N=3,331) (N=3,415) (N=1,847) (N=1 ,081) 
Baseline values of the 
risk factors 
saturated fat 14.6 14.8 14.9 14.2 14.9 15.1 15.2 14.1 
(percent of energy) 
1.9 1.9 trans fatty acids 1.9 1.8 2.0 1.9 
(percent of energy) 
34 29 28 smoking (%) 39 30 39 36 26 
Reference scenario 5.1 10.8 17.2 23.4 1.4 4.8 9.0 11.5 
Population strategies 
saluraled fat to 12 4.7 10.1 16.4 22.5 1.2 4.3 8.4 10.8 
percent of energy 
saturaled fat 10 10 4.6 9.9 16.1 22.1 1.1 4.2 8.2 10.5 
percent of energy 
trans fatty acids to 0.5 4.5 9.7 15.9 21.9 1.2 4.3 8.2 10.5 
percent of energy 
15% quil smoking 4.9 10.4 16.9 23.1 1.3 4.6 8.8 11.4 
25% quit smoking 4.8 10.3 16.7 22.9 1.3 4.5 8.7 11.3 
High-risk strategy 5.1 10.6 16.6 22.8 1.4 4.8 8.9 11.4 
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The 1 O-year absolute risks of coronary heart disease for the different strategies in 
men and women in 10-year age groups are given in table 2. In the reference 
scenario, the average 10-year absolute risk of coronary heart disease was 5.1 % in 
men and 1.4% in women aged 35-44 years and increased to 23.4% in men and 
11.5% in women aged 65-74 years. The decline in absolute risk of coronary heart 
disease was highest for the intervention on trans fatty acids (1.5% in men and 1.0% 
in women aged 65-74 years), followed by the intervention on saturated fat and 
smoking. The interventions on smoking showed the same decline in absolute risk of 
coronary heart disease in every age category between 45 and 75 years in both men 
and women, while the interventions on diet showed a greater decline in absolute risk 
with increasing age. 
Table 3 Number of events of coronary heart disease in the next 10 years for the reference 
scenario, the different population strategies and the high-risk strategy in men and women 
aged 35-74 years in the total population ofThe Netherlands (N=6,933,000 in 1994). 
men women 
Total number of events of coronary heart disease 394,037 186,408 
reference scenario 
Number of events of coronary heart disease 
prevented*: 
population strategies 
saturated fat to 12 percent of energy 19,993 (5%) 15,220 (8%) 
saturated fat to 10 percent of energy 28,743 (7%) 19,641 (11%) 
trans fatty acids to 0.5 percent of energy 32,859 (8%) 18,635 (10%) 
15% quit smoking 8,375 (2%) 4,539 (2%) 
25% quit smoking 13,960 (4%) 7,566 (4%) 
combination of population strategies 
saturated fat to 12 percent of energy, trans fatty acids 49,967 (13%) 22,629 (12%) 
to 0.5 percent of energy and 15% quit smoking 
saturated fat to 10 percent of energy, trans fatty acids 62,133 (16%) 28,104 (15%) 
to 0.5 percent of energy and 25% quit smoking 
high-risk strategy 8,252 (2%) 1,751 (1%) 
number of events in reference scenario - number of events in population or high-risk strategy 
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The total number of events of coronary heart disease in the next ten years for the 
reference scenario and the population and high-risk strategies in men and women in 
The Netherlands are given in table 3. In the combination of the realistic population 
intervention strategies (reducing saturated fat from on average 15 percent of energy 
to 12 percent of energy, trans fatty acids from on average 1.9 percent of energy to 
0.5 percent of energy and the number of smokers with 15%) 49,967 (13%) events in 
men and 22,629 (12%) events in women would be prevented. For the high-risk 
strategy, 8,252 (2%) and 1,751 (1%) events in men and women respectively would 
be prevented. 
The gain in life expectancy for the population and high-risk strategies in men and 
women is given in figure 1. The gain in life expectancy was highest for the .optimistic 
intervention on smoking in both men (mean gain 7.3 months) and women (mean 
gain 2.6 months) aged 35-74 years. The gain in life expectancy for the optimistic 
intervention on saturated fat was 1.7 months in both men and women aged 35-74 
years. For the intervention on trans fatty acids the mean gain in life expectancy was 
1.3 months for men and 0.7 month for women aged 35-74 years. For the 
combination of the realistic population interventions (reducing saturated fat from on 
average 15 percent of energy to 12 percent of energy, trans fatty acids from on 
average 1.9 percent of energy to 0.5 percent of energy and the number of smokers 
by 15%) the gain in life expectancy varied from 7.7 months in men and 3.8 months in 
women aged 35-44 years to 4.8 months in men and 2.3 months in women aged 65-
74 years. The gain in life expectancy for the high-risk strategy was 0.3 month in men 
aged 65-74 years and 0.08 month in women of the same age. In those aged 35-64 
years the gain in life expectancy for the high-risk strategy was almost zero. 
The number of people needing cholesterol lowering medication, according to the 
Dutch consensus guidelines for cholesterol lowering therapy, for the reference 
scenario and the different population strategies in men and women is given in figure 
2. The number of people needing cholesterol lowering medication was about four 
times higher in men compared to women. For the population strategies, the number 
of people needing cholesterol lowering medication was lowest after the intervention 
on trans fatty acids, followed by the interventions on smoking and saturated fat. In 
men aged 55-64 years for example, the total number of people needing treatment 
was around 55 per 1000 for the reference scenario and 37 per 1000 for the 
intervention on trans fatty acids. In women, these figures were only 11 per 1000 and 
8 per 1000 respectively. 
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Table 4 Gain in life expectancy (in months) for the population strategies and the high-risk strategy compared with the reference scenario in 
men and women aged 35-74 years in 10-year age groups. 
men women 
35-44 yrs 45-54 yrs 55-64 yrs 65-74 yrs 35-44 yrs 45-54 yrs 55-64 yrs 65-74 yrs 
-~,-,--"'."'--
Population strategies 
saturated fat to 12 0.98 0.92 0.81 0.64 0.97 0.91 0.83 0.70 
percent of energy 
saturated fat to i 0 1.96 1.83 1.62 1.28 1.94 1.83 1.65 1.41 
percent of energy 
trans fatty acids to 0.5 1.50 1.40 1.23 0.98 0.82 0.78 0.70 0.60 
percent of energy 
15% quit smoking 5.21 4.80 4.10 3.14 2.02 1.76 1.39 0.97 
25% quit smoking 8.83 8.15 6.96 5.34 3.39 2.94 2.33 1.62 
High-risk strategy 0 0 0.064 0.27 0 0 0.0094 0.076 
Table 5 Total number of people needing cholesterol lowering medication (per 1,000) for the reference scenario and the population strategies 
in men and women aged 35-74 years in 1 O-year age groups. 
men women 
35-44 yrs 45-54 yrs 55-64 yrs 65-74 yrs 35-44 yrs 45-54 yrs 55-64 yrs 65-74 yrs 
Reference scenario 0.3 18.5 54.9 42.6 0 2.1 10.6 15.1 
Population strategies 
saturated fat to 12 0 14.1 43.2 31.9 0 1.6 9.5 10.6 
percent of energy 
saturated fat to 10 0.2 16.1 45.3 36.0 0 1.7 10.2 12.1 
percent of energy 
trans fatty acids to 0.5 0.2 10.8 36.6 27.2 0 1.2 7.5 11.4 
percent of energy 
15% quit smoking 0.3 14.7 44.9 36.1 0 1.8 9.4 12.8 
25% quit smoking 0.3 16.2 48.9 38.7 0 1.9 9.9 13.7 
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Discussion 
The results of the present study indicate that in both men and women the 
population strategies showed a larger effect on the primary prevention of coronary 
heart disease than the high-risk strategy. Of the population strategies, the trans fatty 
acids strategy had the largest effect on the decline in 10-year absolute risk of 
coronary heart disease, the number of events of coronary heart disease in the next 
ten years and the number of people needing cholesterol lowering medication across 
all age groups. The smoking strategies had the largest effect on the gain in life 
expectancy in both men and women. 
We modeled two different kind of diet interventions, of which the intervention on 
trans fatty acids showed a slightly stronger effect on most parameters studied. The 
reason for this is that a decline in trans fatty acids has not only an effect on total 
cholesterol but also on HDL cholesterol while saturated fat has only an impact on 
total cholesterol. It can be estimated, using the equation of Keys et al.20 what change 
in serum chOlesterol can be expected for both strategies of intervention. The mean 
intake of saturated fat in this study was 15 percent of energy. A decline in the 
saturated fat intake by 5 percent of energy (optimistic saturated fat scenario) results 
in a decline in serum total cholesterol by about 0.30 mmolll. The mean intake of 
trans fatty acids in this study was 1.9 percent of energy. A decline in the intake of 
trans fatty acids by 1.4 percent of energy (trans fatty acids scenario) results in a 
decline in serum total cholesterol by 0.04 mmol/L and an increase in HDL cholesterol 
by 0.02 mmol/L6 
Changes in the intake of trans fatty acids and saturated fat do not only have an 
impact on the serum cholesterol level, but also on other factors which are important 
in atherogenesis, like LDL-oxidation, coagulation factors, lipoprotein(a) and the 
quality of the vessel wal1.26 This means that the impact of the diet interventions could 
be larger than expected on the basis of the cholesterol level only, and therefore 
possibly underestimated. 
The intervention on trans fatty acids in the population could be achieved through 
advances in food technology, needing no behavioral change from the public.27 
Artificial trans fatty acids in food products, derived from the partial hydrogenation of 
oils, can be eliminated, leaving an intake level of approximately 0.5 percent of energy 
from natural sources (meat and dairy products).22 In contrast, a decline in the intake 
of saturated fat can only be achieved through changes in dietary habits of the 
population. Dietary intervention trials have shown that serum total cholesterol was 
reduced with 3.0% (95% CI 1.8% to 4.1%) after a diet with 8-10% saturated fat (step 
1 diet of the American Heart Association).28 
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The impact of the different intervention strategies depends on the prevalence of 
the risk factor in the population studied and the relative risk associated with it. The 
effect of the different strategies of intervention on the decline in absolute risk of 
coronary heart disease seems to be larger in the older age groups, due to their 
higher absolute risk. However, the effect of the interventions in the older age groups 
could be overestimated because the relative risks tend to decrease with increasing 
age. For the smoking strategies there was no larger decline in absolute risk in the 
older age groups due to the lower prevalence of smoking at older age. The effect of 
the population strategies on the gain in life expectancy was different across the age 
groups. The gain in life expectancy decreased with increasing age in especially the 
smoking strategies. This was also due to declining prevalence of smoking with age. 
For the diet strategies there was no large decline in the gain in life expectancy with 
increasing age. However, especially in the older age groups the life expectancy 
could be overestimated. We have used the same relative risks across all age groups 
for the calculation of the life expectancy, whereas there is evidence that relative risks 
tend to decrease with age. The gain in life expectancy was higher in men after the 
smoking strategy, because of the higher relative risk used for men and the higher 
smoking prevalence in men compared to women. The effect of the high-risk strategy 
on the decline in absolute risk of coronary heart disease and the gain in life 
expectancy in the whole population was low, due to the relatively small number of 
people eligible for drug treatment. However, the effect of the high-risk strategy on the 
individual level would be large and still 10,000 coronary heart disease events could 
be prevented in the next ten years in both men and women aged 35-74 years. The 
number of people needing cholesterol lowering medication was higher in those aged 
55-64 years compared with men and women aged 65-74 years, because the cut-off 
point of the absolute risk of coronary heart disease indicating medication use is 
higher in men and women aged 65-74 years. The number of events of coronary 
heart disease and the number of people needing treatment was higher in men 
compared with women for all strategies because of the higher absolute risks in men. 
There are several limitations of this study that should be mentioned. First, the 
estimation of the 10-year absolute risk of coronary heart disease in this study was 
based on the Framingham risk function. The question is whether this risk function 
can be generalized to the Dutch population. A recent study showed that the 
Framingham risk function is accurate for northern European populations.29 Second, 
ECG-Ieft ventricular hypertrophy, a variable included in the Framingham risk function 
for 10-year coronary heart disease risk, was not used in this study because of lack of 
Dutch prevalence data. We assumed that nobody had ECG-Ieft ventricular 
hypertrophy in the study population. This means that especially in the elderly (> 60 
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years) the risk of coronary heart disease could be underestimated, because ECG-Ieft 
ventricular hypertrophy is more common in this age group. Third, two different 
datasets were used in this study, data from the MORGEN-project and the Rotterdam 
Study. The measurement protocols of most variables were comparable, but diabetes 
was measured differently. In the MORGEN-project the use of antidiabetic medication 
was not known and therefore not included in the definition of diabetes. Therefore, the 
prevalence of diabetes could be somewhat underestimated in the MORGEN-project 
(persons aged 35-64 years). Fourth, we have not included the effect of lag-time in 
our model. However, we expect that the effect of lag-time on the coronary heart 
disease mortality would be approximately the same for the different interventions. 
A decline in serum total cholesterol has a significant impact on coronary heart 
disease mortality. We estimated that in total 10,003 (2%) coronary heart disease 
cases in Dutch men and women aged 35-74 years would be prevented in the next 10 
years if persons were treated according to the Dutch consensus guidelines for 
cholesterol lowering therapy. However, if all people aged 35-74 years in The 
Netherlands reduce their saturated fat intake to 12 percent of energy or less (instead 
of an average of. 15 percent of energy), their trans fatty acid intake to 0.5 percent of 
energy or less (instead of an average of 1.9 percent of energy) and if 15% of the 
smokers stop smoking, in total 72,596 (13%) cases of coronary heart disease would 
be prevented in the next 10 years. This means that a combination of the three 
population strategies would have a larger impact on the primary prevention of 
coronary heart disease compared to the high-risk strategy. 
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The aim of this thesis was to study the public health impact of serum total and 
HDL cholesterol levels in The Netherlands. In this chapter the results of the studies 
described in this thesis are integrated and discussed. After a summary of the main 
findings, the impact of the long-term trends in cholesterol levels on public health in 
The Netherlands is described. Subsequently, the question whether serum total and 
HDL cholesterol are still risk factors in the elderly is discussed. Therefore, the 
studies described in this thesis on the relation between total and HDL cholesterol 
and coronary heart disease carried out in the elderly are compared and some 
methodological aspects of studies in the elderly are considered. Also the public 
health effect of cholesterol treatment in the elderly is described. Risk functions 
developed for the elderly are described and discussed. Prevention of coronary heart 
disease through cholesterol lowering can be achieved by several types of 
interventions, of which the effect of dietary interventions and the use of cholesterol 
lowering medication is described in the third part of this chapter. Finally, the main 
conclusions are formulated. 
Main findings 
Recent levels and trends in total and HDL cholesterol levels in The Netherlands 
were studied (chapter 2). The total cholesterol level decreased significantly by 0.19 
mmol/L in men and by 0.27 mmol/L in women between 1993 and 1997, while the 
level of HDL cholesterol remained stable in both men and women. The observed 
trend in total cholesterol could only for a small part be explained by changes in the 
intake of saturated fatty acids, trans fatty acids, dietary cholesterol, use of 
cholesterol lowering medication and for women oral contraceptives and estrogen 
replacement. 
Results from a large 20-year follow-up study in middle-aged men and women 
showed that, given a low cholesterol level « 5.2 mmoI/L), the additional effect of 
smoking on coronary heart disease, cardiovascular diseases and all-cause mortality 
was larger compared to that of elevated blood pressure (systolic" 140 mmHg) 
(chapter 3). Despite low cholesterol levels, a Significantly higher risk of coronary 
heart disease, cardiovascular diseases and all-cause mortality was found in smoking 
men and women with elevated blood pressure. These mortality risks increased 
further in persons with intermediate cholesterol levels (5.2-6.5 mmoI/L). When the 
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total cholesterol level in smoking men and women with elevated blood pressure was 
elevated to " 6.5 mmollL, the risk of coronary heart disease mortality was almost 10 
times higher in men and 16 times higher in women compared to those with a low risk 
factor profile. 
Because it is still unclear whether the relation between serum cholesterol and 
coronary heart disease still holds in the elderly, more evidence on the impact of total 
and HDL cholesterol on coronary heart disease in the elderly is needed (chapter 4 
and 5). Results from two large prospective studies showed that serum total 
cholesterol remains an important predictor of coronary heart disease in elderly men 
and women. The effect of HDL cholesterol was less consistent in the elderly. HDL 
cholesterol was related to coronary heart disease in men and women aged 55 years 
and older, but lost its predictive power in men at older age (> 70 years). In women 
aged 70 years and older, HDL cholesterol was still a risk factor. 
Furthermore, a 10-year follow-up study carried out in the elderly in different 
European countries showed that it is essential to have separate risk functions 
developed in the elderly to predict their absolute risk for coronary heart disease and 
cardiovascular diseases mortality (chapter 6). Most classical risk factors for coronary 
heart disease and cardiovascular diseases mortality remain predictive in the elderty, 
of which total cholesterol and smoking were the most important ones for coronary 
heart disease mortality and HDL cholesterol, systolic blood pressure and smoking for 
cardiovascular diseases mortality. Left ventricular hypertrophy, being a prevalent 
case of coronary heart disease or cardiovascular diseases in Finland and The 
Netherlands and use of anti-hypertensive medication in Italy were also important risk 
factors. For estimating absolute risks in the elderly, it was necessary to take country 
into account. 
Finally, the impact of different preventive population strategies and a high-risk 
strategy on the primary prevention of coronary heart disease was statistically 
modelled (chapter 7). The results showed that in total 13% of the coronary heart 
disease events can be prevented in the next ten years in men and women aged 35-
74 years through lowering the intake of saturated fatty acids from on average 15 
percent of energy to 12 percent of energy, trans fatty acids from on average 1.9 
percent of energy to 0.5 percent of energy and reducing the number of smokers by 
15%. Of the population interventions separately, lowering the intake of trans fatty 
acids had the largest effect on the number of coronary heart disease events that 
could be prevented. 
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Trends in total and HDL cholesterol 
From a public health point of view it is important to study trends in total and HDL 
cholesterol. A decline in total cholesterol could have a large impact on incidence of 
and mortality from coronary heart disease. Besides this, monitoring studies can· be 
used for evaluation of public health campaigns that are focused on reducing 
cholesterol levels in the general population. The long-term trend in total and HDL 
cholesterol in The Netherlands could be studied using data from two large monitoring 
studies carried out between 1987 and 1997 in men and women aged 20-59 years. 
The results of both studies can be analysed together because the same study 
protocol was used and the same standardised measurements of cholesterol were 
carried out in the same reference laboratory. 
The trend in total and HDL cholesterol between 1987 and 1992 has previously 
been described by Verschuren et aL' In men, a decline in total cholesterol of 0.1 
mmol/L and a decline in HDL cholesterol of 0.07 mmol/L was observed between 
1987 and 1992. In women, no statistically significant changes in total and HDL 
cholesterol levels were observed. 
The trend in total and HDL cholesterol between 1993 and 1997 was described 
in chapter 2. In figure 1, the age-standardised long-term trends in total and HDL 
cholesterol levels are given. Between 1987 and 1997, total cholesterol declined 
significantly by 6.1 % in men from 5.41 mmol/L to 5.08 mmol/L and by 6.6% in 
women from 5.34 mmol/L to 4.99 mmollL. In both men and women, the largest 
decline was observed between 1994 and 1995. HDL cholesterol declined from 1.22 
mmol/L in 1987 to 1.19 mmol/L in 1997 in men and increased from 1.47 mmol/L in 
1987 to 1.52 mmol/L in 1997 in women. This means that between 1987 and 1997 a 
substantial decline in the level of total cholesterol has taken place in The 
Netherlands in men and women aged 20-59 years. Small, non-significant, changes 
in HDL cholesterol levels were observed. Results from the Zutphen Elderly Study 
showed also a decline in total cholesterol of similar magnitude in Dutch men aged 70 
years and older in the early nineteen nineties. Also in these elderly men, no change 
in HDL cholesterol levels was observed2 Therefore, it can be concluded that a 
decline in total cholesterol has taken place in the total Dutch population. 
The decline in total cholesterol levels observed between 1987 and 1997 in The 
Netherlands is of great public health importance. Most cases of coronary heart 
disease occur in persons aged 60 years and older. It is known from a meta-analysis 
of longitudinal studies that on average a total cholesterol reduction of 1 % results in a 
decrease of coronary heart disease mortality by 2-3% in men and women aged 60 
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Figure 1: Mean total and HDL cholesterol level per year in men and women, 
standardised to the age distribution of the Dutch population aged 20-59 years in 
1995. (Note: HOL cholesterol levels measured in the period January 1987 to November 1994 
were corrected for laboratory drift as described in chapter 3 of this thesis) 
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and by 6.6% in women was generalizable to the elderly, this would lead to a decline 
in mortality from coronary heart disease in the future by at least 12%. Applying these 
figures to a yearly mortality of coronary heart disease of 20,000 persons in The 
Netherlands aged mainly 60 years and older, this corresponds to a decline in the 
absolute number of coronary heart disease deaths per year of 2,400. 
It is interesting to relate the recent trend in total cholesterol levels to mortality from 
coronary heart disease. In Finland, it was estimated to what extent changes in total 
cholesterol levels explained the decline in coronary heart disease mortality.9 In men, 
the observed 13% decline in total cholesterol level was associated with a 26% 
decline in coronary heart disease mortality. In women, the observed 18% decline in 
total cholesterol level was associated with a 35% decline in coronary heart disease 
mortality. This means that a 1 % decrease in cholesterol concentration leads to an 
approximately 2% decline in coronary heart disease risk in Finland. 
In The Netherlands, it took until the early nineteen nineties before the total 
cholesterol level started to decline. This is in contrast with for example Finland where 
total cholesterol levels have decreased substantially since the nineteen seventies.' 
Mean total cholesterol declined by about 1.2 mmol/L in both men and women aged 
30-59 years between 1972 and 1997.' In 1997, the mean cholesterol level for men 
was 5.61 mmol/L and 5.45 mmol/L for women. Despite the large decline in 
cholesterol levels over the last decades in Finland, total cholesterol levels are still 
higher compared to those in The Netherlands. 
The large decline in cholesterol levels in Finland can mainly be attributed to 
intensive nutritional education and health promotion activities for preventing 
cardiovascular diseases. In Finland the North Karelia Project, a community-based 
cardiovascular prevention programme, was started in the early 1970s. The aim of 
this project was to give health education to the public on lifestyle, diet and coronary 
heart disease. Based on the provided health information people started to change 
their dietary habits and food and agricultural industries developed new low-fat 
products, like soft margarines and low-fat milk. The use of butter on bread declined 
for example from almost 90% to 10%. As a result, the intake of polyunsaturated fatty 
acids increased by 3 percent of energy, the intake of saturated fatty acids decreased 
by 6 percent of energy and dietary cholesterol decreased by about 25 mg/1000 kcal 
in Finland between 1972 and 1997.3 Based on these dietary changes, the expected 
decline in total cholesterol would be more than 0.6 mmol/L. A change from boiled to 
filtered coffee could have lowered the cholesterol levels by another 0.3 mmol/L4 
Since 1995 margarine fortified with plant stanols was introduced in Finland. It was 
estimated that using three servings of plant stanol ester margarine a day could 
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reduce serum total cholesterol with 10%. Approximately 140,000 (3%) individuals in 
Finland use this margarine daily.s In Finland, changes in dietary and other life-style 
factors could explain the decline in serum cholesterol. 
In The Netherlands however, the decline in total cholesterol levels between 1993 
and 1997 could only for a small part be explained by changes in dietary and life-style 
factors (chapter 2). The changes in these factors in The Netherlands were too small 
to explain the trend. The change in the intake of saturated fatty acids, 
polyunsaturated fatty acids, dietary cholesterol and trans fatty acids between 1993 
and 1997 in The Netherlands could only explain 20% of the observed decline in total 
cholesterol in men and about 30% of the observed decline in women. In the United 
States, mean total cholesterol declined by 0.2 mmolfL between 1976 and 1991 in 
men and women aged 20-74 years· This decline is comparable with that observed 
in The Netherlands. However, in the United States the decline in serum cholesterol 
could be fully explained by changes in dietary factors'" 
The decline in mean total cholesterol level in The Netherlands resulted in a 
decline of the prevalence of hypercholesterolemia (total cholesterol ~ 6.5 mmolfL). 
The prevalence of hypercholesterolemia declined by 8 percentage points in men 
(from 18% to 10%) and by 6 percentage pOints in women (from 14% to 8%) aged 20-
59 years between 1987 and 1997. This means that the decline of mean levels by 
about 6% led to a decrease in the number of people with hypercholesterolemia by 
more than 40% during this period. For public health it is important that the 
cholesterol distribution in a population moves to a lower level, because every person 
in the population would then have a lower risk of coronary heart disease. The impact 
of a population approach is larger than that of a high risk approach in which only 
persons with very high cholesterol levels are treated. This is illustrated by the results 
of chapter 7 in which the impact of different population prevention strategies and a 
high-risk strategy on primary prevention of coronary heart disease was statistically 
modelled. It could be calculated that for example lowering the intake of trans fatty 
acids from on average 1.9 percent of energy to 0.5 percent of energy (resulting in a 
decline in total cholesterol by 0.04 mmolfL and an increase in HDL cholesterol by 
0.02 mmolfL) will lead to a reduction in the number of coronary heart disease events 
in men and women aged 35-74 years in the next 10 years of 32,878. If all persons 
with a high absolute risk for coronary heart disease were treated with cholesterol 
lowering medication about 10,000 coronary heart disease events would be 
prevented in the next 10 years. These results suggest that a substantial number of 
coronary heart disease events in The Netherlands can be prevented through a 
combination of a population and a high-risk approach. 
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The health effects of a low risk factor profile (cholesterol < 5.2 mmol/L, systolic 
blood pressure < 120 mmHg and no smoking) in the general population are rarely 
studied because very large prospective studies are needed to study the health 
effects of a low risk factor profile. Since it is not realistic to expect a population in 
which everyone has a low risk factor profile, it is for public health action interesting to 
know for example the additional effect of smoking and elevated blood pressure at 
different cholesterol levels. The results in chapter 3 indicate that, given a low 
cholesterol level, the additional effect of smoking on coronary heart disease, 
cardiovascular diseases and all-cause mortality is more harmful than the effect of 
elevated blood pressure. However, having a low cholesterol level in combination with 
elevated blood pressure and smoking showed higher relative risks. This means that 
having low cholesterol levels only, in the presence of elevated blood pressure and 
smoking, is not a sufficient condition to prevent coronary heart disease, 
cardiovascular diseases and all-cause mortality. Extra health gain can therefore be 
achieved in smoking men and women with low cholesterol levels and elevated blood 
pressure through smoking cessation and treatment of elevated blood pressure. As 
expected, the highest relative risks were found in men and women with elevated 
cholesterol levels, elevated blood pressure and who smoked. Adjusted for regression 
dilution bias, the risk of coronary heart disease mortality was 30 times higher in men 
and 63 times higher in women with high risk factor levels compared to those with low 
risk factor levels. This clearly indicates that substantial health gain can be achieved 
in a population through a combined approach to lower cholesterol levels, blood 
pressure and smoking cessation. 
Although it is more effective to shift the population distribution of serum 
cholesterol to a lower level, adequate cholesterol lowering treatment for individuals 
with a high absolute risk for coronary heart disease remains required. Results from 
the large statin trials showed that using cholesterol lowering medication reduces not 
only coronary heart disease and total mortality, but also other manifestations of 
cardiovascular diseases. 'o These results prompted to revise the Dutch consensus 
guidelines for cholesterol lowering therapy. Nowadays, treatment with cholesterol 
lowering medication is recommended for cardiac patients and for persons with an 
increased risk of developing coronary heart disease taking the total risk profile of a 
person into account. 'O Risk factors included in this risk profile are gender, age, 
serum total and HDL cholesterol, hypertension, diabetes mellitus, smoking and 
family history of premature coronary heart disease « 60 years). 
In The Netherlands, cholesterol lowering medication in secondary prevention is 
indicated in men aged younger than 70 years and women aged younger than 75 
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years with a serum cholesterol level> 5.0 mmol/L. Cholesterol lowering in primary 
prevention is indicated if the absolute risk of coronary heart disease over the next 10 
years is > 25% at ages < 60 years and> 30% at age 60-69 years. In persons aged 
70 years and over, cholesterol lowering medication is indicated if the absolute risk 
exceeds 40% in men and 35% in women. For persons with a family history of 
premature coronary heart disease and for patients with diabetes mellitus the cut-off 
pOint was lowered with 5%, because of their increased risk of coronary heart disease 
due to factors that are not taken into account in the risk function. 'o 
Cholesterol and coronary heart disease in the elderly 
When serum cholesterol is still a risk factor for coronary heart disease in the 
elderly, substantial health gain can be achieved in this age group because the 
number of elderly people will increase in the years to come and most cases of 
coronary heart disease occur in this age group. Relative risks for coronary heart 
disease decrease with increasing age, but the absolute risk increases. This means 
that a decline in cholesterol level could also in the elderly lead to a decline in the 
number of coronary heart disease events. 
The evidence that serum total cholesterol is positively associated and HDL 
cholesterol inversely associated with coronary heart disease mortality in middle-aged 
men and women is very strong. Whether these relations hold in the elderly is less 
clear. Results of epidemiological studies on serum total and HDL cholesterol and 
coronary heart disease in the elderly are inconsistent. Most studies have found that 
serum total cholesterol is still an important risk factor for coronary heart disease in 




In both the Rotterdam Study and the FINE Study a statistically significant 
association was found between serum total cholesterol and coronary heart disease 
in the elderly (chapter 4 and 5). This is consistent with the results found in other 
studies. However, comparing the Rotterdam Study and the FINE Study, differences 
in population characteristics and endpoints studied have to be taken into account. In 
the Rotterdam Study, both men and women were included in contrast to the FINE 
study in which only men were included. For elderly men, the relative risks for 
coronary heart disease found in both studies were comparable, namely a relative risk 
of 1.20 (95% CI 1.03-1.41) per 1.00 mmol/L increase in total cholesterol in the 
Rotterdam Study and a relative risk of 1.29 (95% CI 1.07-1.56) per 1.00 mmol/L 
increase in total cholesterol in the Dutch cohort of the FINE Study. Also in women 
that participated in the Rotterdam Study, a statistically significant association was 
found between total cholesterol and coronary heart disease (RR 1.40; 95% CI 1.20-
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1.65). Besides this, the age range of the elderly in both studies was different. In the 
Rotterdam Study, the age of the men and women included varied from 55 years to 
over 95 years with a mean age of 69 years and in the FINE Study the age range was 
65-84 years, with a mean age of the elderly men of 72 years. It is well known that the 
relative risk for coronary heart disease declines with increasing age. However, in 
subgroup analyses carried out in the Rotterdam Study, the relative risk for coronary 
heart disease in men aged 70 years and older was higher compared to that in the 
total group of men aged 55 years and older. In women these relative risks were 
comparable between both age groups. It can be concluded that serum total 
cholesterol is still an important risk factor for coronary heart disease in the elderly. 
Declining relative risks with increasing age were observed for the relation between 
HDL cholesterol and coronary heart disease. The relation between HDL cholesterol 
and coronary heart disease was less consistent in both studies, as was seen in other 
studies. In the Rotterdam Study, there was a significant inverse association between 
HDL cholesterol and coronary heart disease in men and women aged 55 years and 
older. However, in elderly men aged 70 years and older (mean age 76.7 years) the 
risk weakened and was no longer statistically significant. Also in the Dutch cohort of 
the FINE Study, no significant inverse association between HDL cholesterol and 
coronary heart disease was found in elderly men. Women aged 70 years and older 
included in the Rotterdam Study still showed a significant relation between HDL 
cholesterol and coronary heart disease. It can be concluded that HDL cholesterol is 
a risk factor for coronary heart disease in both men and women aged 55-70 years, 
but after the age of 70 HDL cholesterol remained a risk factor in women only. 
When interpreting the results of epidemiological studies in the elderly, some 
methodological aspects have to be taken into account. First, co-morbidity and co-
mortality are highly prevalent in older people. The presence of more than one 
underlying disease or cause of death can modify the association between cholesterol 
and coronary heart disease. It is difficult to allow for co-morbidity in the analysis, 
because exclusion of all people with underlying diseases at baseline would lead to a 
select elderly population. This group would no longer be representative of the 
general elderly population. Therefore, prevalent cases of coronary heart disease 
were included, but adjusted for, in the analyses of the studies described in chapter 4 
and 5, although excluding prevalent cases of coronary heart disease did not alter the 
results. Cox's proportional hazards analYSis was used for estimating relative risks in 
the elderly in chapter 4 and 5 because this method partly takes co-mortality into 
account. In this method individuals remain at risk for coronary heart disease until 
they die of other causes than coronary heart disease.18,19 However, using logistic 
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regression also showed that total cholesterol is still a risk factor for coronary heart 
disease in the elderly (chapter 6). 
Second, the cholesterol level of a person at older age may not represent the 
lifetime exposure of that person. Due to underlying diseases andlor increased 
medication use in the elderly, cholesterol levels could be lower compared to the prior 
exposure level. Misclassification of elderly according to their cholesterol level could 
lead to an attenuation of the relation between cholesterol and coronary heart disease 
at older age. 'S 
Third, at older age selective survival has taken place. Persons with high 
cholesterol levels, especially those who also smoke or who are susceptible for 
coronary heart disease because of e.g. family history, are more likely to die with 
increasing age. Those with high cholesterol levels who are still alive at older age are 
possibly less susceptible to coronary heart disease. ,s.'9 This can partly explain the 
lower relative risks generally found in the elderly for the relation between cholesterol 
and coronary heart disease. 
To estimate the absolute risk of coronary heart disease in middle-aged men and 
women the Framingham risk function is widely us~d.2o Because this risk function 
does not apply to the elderly, a separate risk function for elderly men was presented 
in chapter 6. This risk function can be used in men aged 65 years and older to 
estimate absolute risks for coronary heart disease and cardiovascular diseases 
mortality. The risk functions developed for the elderly in the FINE Study showed that 
most classical risk factors for coronary heart disease and cardiovascular diseases 
mortality remain predictive in the elderly. Total cholesterol and smoking were the 
most important ones for coronary heart disease mortality and HDL cholesterol, 
systolic blood pressure and smoking for cardiovascular diseases mortality. 
Comparing the risks estimated from the coefficients of the classical risk factors 
included in the risk function for the elderly with the risks observed in middle-aged 
men, indeed lower, but for most risk factors still significant risks, were observed in 
the elderly. Left ventricular hypertrophy, being a prevalent case of coronary heart 
disease or cardiovascular diseases in Finland and The Netherlands and use of anti-
hypertensive medication in Italy were also important risk factors for coronary heart 
disease and cardiovascular diseases mortality included in the risk functions for 
elderly men. This means that not only risk factors related to diet and lifestyle (like 
cholesterol, blood pressure and smoking) are important in the elderly, but also 
variables related to disease (like left ventricular hypertrophy and being a prevalent 
case) have an important predictive value in the elderly. 
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These findings have major implications for prevention and treatment of coronary 
heart disease in the elderly. Lowering cholesterol levels and blood pressure through 
dietary and lifestyle changes, smoking cessation and proper treatment of risk factors 
and diseases will also in the elderly lead to a substantial reduction of the absolute 
risk. 
When calculating absolute risks for coronary heart disease in the elderly it is 
necessary to take country into account (chapter 6). Absolute risks in southern 
European populations are lower than absolute risks in northern European 
populations (chapter 5). This is probably due to differences in dietary habits, lifestyle 
factors and unknown genetic factors between the different populations. In the 
European Atherosclerosis Research Study, designed to assess the influence of 
genetic and environmental factors on predisposition for coronary heart disease, 
differences in distributions of apoE4 were found between different European 
countries. 21 There was a clear decreasing gradient in apoE4 from the northern to the 
southern regions of Europe that followed the gradient of coronary heart disease 
mortality rates. Therefore, both genetic and environmental factors are important in 
influencing the level of absolute risk. 
To take into account the differences in absolute risk between countries, a variable 
for country was added to the risk functions for the elderly. Also for middle-aged 
persons it is important to develop a European risk function in which a variable for 
country is included, because absolute risks for coronary heart disease estimated at 
the same cholesterol and blood pressure level in middle-aged men were also 
different between countries.22.23 In the European guidelines for prevention of 
coronary heart disease, based on absolute risks estimated with the Framingham risk 
function2., a variable for country was not included. However, this is necessary 
because it was estimated that the Framingham risk function overestimates the 
absolute risk of coronary heart disease in Italy.25 Using the European coronary risk 
chart in Italy will consequently lead to overtreatment. Therefore, the SCORE 
(Systematic Coronary Risk Evaluation) project was started to develop and compare 
risk functions derived from prospective population-based studies carried out in 
different European countries. The goal of the project is to create a uniform coronary 
risk chart that can be used in all European countries.26 Based on the results 
presented in chapter 6 it is very important to include a variable for country in this 
European risk function to take into account the differences in absolute risks between 
different European countries. 
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The fact that there is still an association between total cholesterol and coronary 
heart disease in the elderly and the high absolute risks of coronary heart disease in 
the elderly means that modifying cholesterol levels in this age group could have a 
large impact on public health. However, observational studies alone are insufficient 
to decide whether elderly have to be treated for elevated cholesterol levels or not. It 
is therefore important to perform randomised controlled clinical trials to establish if 
cholesterol lowering treatment is efficacious in preventing coronary heart disease in 
the elderly. A meta-analysis of the most important statin trials showed that reduction 
of coronary events was similar above (32%; 95% CI 23%-39%) and below the age of 
65 years (31%; 95% CI 23%-39%),>7 However, there are insufficient data yet to 
conclude definitively that treatment with cholesterol lowering medication is as 
effective in middle-aged persons as it is in the 'oldest elderly'. Persons older than 75 
years were not included in the statin trials used in the meta-analysis. Therefore, 
several ongoing trials investigate the effect of cholesterol lowering by statins in the 
elderly. 
Both secondary and primary prevention in the elderly are important, because the 
prevalence of coronary heart disease in the elderly is high and most coronary events 
occur in people aged 65 years and over. The question in the elderly is: who should 
be treated? It is important to take the overall health status and life expectancy into 
account. In the Dutch cholesterol consensus, starting cholesterol lowering 
medication is indicated in men and women with a life expectancy of at least about 5 
years in order to be able to profit from the benefit of statin treatment. This means that 
it is recommended that most newly diagnosed patients are not treated with 
cholesterol lowering medication if they are older than 70 years (men) or older than 
75 years (women). This cut-off point was chosen since there are no specific data 
available on the effect of treatment in elderly aged 75 years and older. 
Prevention through cholesterol lowering 
Primary and secondary prevention of coronary heart disease through cholesterol 
lowering can be achieved by means of several types of interventions, of which 
dietary interventions such as reducing the intake of saturated and trans fatty acids, 
and use of cholesterol lowering medication, mainly statins, are the most important 
ones. 
Dietary interventions can lower serum cholesterol concentrations, which would 
subsequently lead to a decline in coronary heart disease mortality and morbidity. The 
eX1ent to which cholesterol declines depends on the intensity of the dietary change. 
Reducing saturated and trans fatty acids, increasing polyunsaturated fatty acids and 
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reducing dietary cholesterol can have a substantial effect on serum total cholesterol 
lowering. In a review of 17 randomised controlled dietary intervention studies 
Truswe1l28 showed that a 10% reduction in total cholesterol levels resulted in a 
significantly lower number of coronary events in the intervention group compared to 
the control group (OR=0.87; 95% Cl 0.83-0.91). Besides this, the pooled odds ratio 
for total mortality was also significantly lower in the intervention group compared to 
the control group (OR=0.94; 95% Cl 0.89-0.99). But in the seven trials with most 
effective cholesterol lowering (about 13%) the number of coronary events decreased 
with 30% and the number of total deaths with 11 %. This suggests a dose-response 
relation between degree of cholesterol lowering in relation to coronary events and 
all-cause mortality. 
The effect of different dietary interventions on cholesterol lowering has been 
extensively studied in different settings. A meta-analysis of metabolic ward studies 
showed that replacement of 60% of saturated fatty acids by unsaturated fatty acids 
and a reduction of the intake of dietary cholesterol by 60%, reduces serum total 
cholesterol by 10-15% (about 0.8 mmoI/L).29 Metabolic ward studies, in which the 
adherence to diets is likely to be high, showed what could be achieved with dietary 
interventions under ideal conditions. It is also important to look at the more realistic 
effects of dietary interventions that can be achieved in free living subjects. The 
effects of a lipid lowering diet in the general population would be smaller than that in 
volunteers living in a metabolic ward, due to the lower compliance with the 
prescribed diet. Dietary advice given to free living subjects reduce serum total 
cholesterol by 3-6% depending on the type and intensity of the diet.3o In people 
going on a step 1 diet of the American Heart Association « 30% of total energy 
intake as fat, with 8-10% as saturated fatty acids and cholesterol intake < 300 
mg/day) for at least six months, total cholesterol levels were reduced by 3%. These 
results are in line with other reviews that found a decline in serum total cholesterol of 
about 4-5% in free living persons receiving different types of dietary advice.31 .32 
The effect of dietary advice on coronary heart disease and all-cause mortality is 
not only effective through lowering cholesterol levels. Changes in the intake of 
saturated fatty acids can also have an impact on other factors that are important in 
the atherogenesis, like LDL-oxidation, coagulation factors, lipoprotein(a) and the 
quality of the vessel wall. 33 Besides this, the DART trial showed a reduction in 
coronary heart disease mortality and all-cause mortality by about 30% due to the use 
of fatty fish at least twice a week.34 An even larger reduction in coronary heart 
disease and all-cause mortality of respectively 65% and 56% was observed in the 
Lyon Diet Heart Study after 46 months of folloW_up.3s The intervention in this study 
consisted of an a-linolenic acid enriched Mediterranean type of diet. These trials 
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showed that changes in the diet are an important tool for reducing coronary heart 
disease and all-cause mortality risk. 
The number of coronary heart disease events that can be prevented in The 
Netherlands through dietary and lifestyle interventions was statistically modelled in 
chapter 7. Lowering the intake of trans fatty acids from on average 1.9 percent of 
energy to 0.5 percent of energy had the largest impact, preventing more than 50,000 
(9%) coronary heart disease events in the next ten years in men and women aged 
35-74 years. The effect of a decline in trans fatty acids was modelled through a 
decline in serum cholesterol levels. However, the effect of a change in trans fatty 
acids on coronary heart disease seems to be larger than the effect on cholesterol 
levels alone36 , so our estimate probably even underestimates the effect. The 
intervention on trans fatty acids could be achieved through advances in food 
technology.37 Since 1985, the amount of trans fatty acids in fats for use in 
households has decreased substantially through changes in the production process. 
In commonly used products like hard margarines the trans fatty acid content 
decreased from a maximum of 50% in the nineteen eighties to on average 1-2% 
nowadays.38 Further elimination of manufactured trans fatty acids that are nowadays 
mainly present in bakery products and fast foods, may reduce the intake to 
approximately 0.5 percent of energy from natural sources (meat and dairy products). 
It was estimated that lowering the intake of trans fatty acids from on average 1.9 to 
0.5 percent of energy would lead to a reduction in the number of coronary events by 
8% (almost 33,000) in men and by 10% (almost 19,000) in women aged 35-74 years 
in the next ten years. Lowering the intake of saturated fatty acids from on average 15 
to 12 percent of energy, almost 20,000 (5%) coronary heart disease events in men 
and more than 15,000 (8%) coronary heart disease events in women aged 35-74 
years could be prevented in the next ten years. This means that the number of 
coronary heart disease events prevented was 30% lower for the saturated fatty acid 
intervention compared to the trans fatty acid intervention. However, reducing the 
saturated fatty acid intake from on average 15 to 10 percent of energy reduced the 
number of coronary events by 7% in men and by 11 % in women aged 35-74 years in 
the next ten years. This means that the magnitude of the reduction in coronary 
events depends on the target of the intervention. However, as shown in chapter 7 
the number of coronary events prevented was largest for a combination of the 
dietary interventions. 
Larger reductions in cholesterol levels through 'manufactured' dietary 
interventions can be obtained by using margarines with added plant sterols or 
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stanols. Plant sterols and stanols lower serum cholesterol levels through reducing 
the absorption of cholesterol from the gut. The daily intake of plant sterols occurring 
naturally in the diet, is about 0.25 grams. Adding 2 grams of plant sterols or stanols 
to the daily diet, which corresponds to putting sterol or stanol enriched margarine on 
4 slices of bread, reduces the level of LDL cholesterol by 0.33-0.54 mmollL, 
depending on age. The reduction in LDL cholesterol was significantly higher in older 
persons compared to younger persons. A daily dose of more than 2 grams of plant 
sterols or stanols per day does not further reduce LDL cholesterol levels. However, 
the use of margarines fortified with plant sterols or stanols may be limited due to the 
high costs of approximately 115 euros per person per year.39 
Changes in diet, like lowering the intake of saturated and trans fatty acids, can 
substantially change the serum cholesterol levels. It can be estimated that if the 
saturated fatty acid intake of a person is lowered from 15 to 10 percent of energy, 
the trans fatty acid intake from 1.9 to 0.5 percent of energy and margarine enriched 
with plant sterols or stanols was put on 4 slices of bread, LDL cholesterol levels 
would be reduced by about 0.8 mmollL (=20% decline in a person with an average 
LDL cholesterol level of 4.0 mmoIIL). This means that the decline in cholesterol that 
can be achieved with these dietary interventions is somewhat lower than that 
obtained by using statins, but if there are also changes in other dietary and lifestyle 
factors like an increase in the intake of soluble fibre, a decrease in body weight, stop 
smoking and an increase in physical activity, the effects could be comparable. 
Besides this, dietary interventions are much cheaper compared to statin treatment 
and can be advised to the whole population while statin treatment is restricted to 
persons with high absolute risks. 
For cholesterol lowering by drugs nowadays mostly statins (HMG-CoA reductase 
inhibitors) are used because of their efficacy in reducing LDL cholesterol and their 
tolerability and safety. Statins also raise HDL cholesterol and lower triglyceride 
levels.40 Five large statin trials have been carried out during the past years, of which 
three secondary prevention trials (4S, CARE and LIPID) and two primary prevention 
trials (WOSCOPS and AFCAPSlTexCAPS). Recently, a meta-analysis of these trials 
was published.27 Pooling the results of the five trials, statin treatment was associated 
with a 20% reduction in total cholesterol, 28% reduction in LDL cholesterol and 13% 
reduction in triglycerides and 5% increase in HDL cholesterol. Overall, statin 
treatment reduced the number of coronary events by 31% (95% CI 26%-36%), the 
number of fatal coronary events by 29% (95% CI 20%-36%) and total mortality by 
21% (95% CI 14%-28%). These trials showed that non-cardiovascular mortality was 
not increased. This was an important finding, because the first-generation trials 
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found an increase in non-cardiovascular mortality and no effect on all-cause 
mortality. Besides this, the reduction in cholesterol levels was comparable between 
primary and secondary prevention trials. Therefore it now seems effective to use 
statins in both primary and secondary prevention of coronary heart disease. 
Statins do not only have an effect on coronary heart disease mortality and all-
cause mortality. Despite the fact that there is no clear relationship between serum 
cholesterol levels and the risk of stroke in observational studies, two meta-analyses 
found that using statins lowered the risk of stroke41 .42 Patients assigned to statins 
had a 24-29% lower risk of stroke. This suggests that the effect of statins on 
cerebrovascular diseases is probably independent of cholesterol. A recently 
published case-control study found a substantially lowered risk of dementia in 
persons aged 50 years and older using statins43 This effect was independent of the 
presence or absence of untreated hyperlipidemia, or the use of other lipid lowering 
drugs. This means that statins can be used also for reducing the risk of other 
diseases than coronary heart disease. 
The relative effect of statin treatment is large, preventing 31 % of the coronary 
events and 21 % of the total mortality, but the absolute effects are rather small 
especially in middle-aged persons. The absolute risk reduction in coronary events 
was 32 per 1000 treated patients younger than 65 years and 44 per 1000 patients 
aged 65 years and older after about 5 years of treatment?7 This means that a large 
number of persons has to be treated with statins to prevent a few cases of coronary 
heart disease. Because the costs of statins are high, about 500 euros per treated 
person per year, it is important to consider these costs when treatment decisions are 
made. The annual costs of statins in The Netherlands went up from more than 50 
million euros in 1994 to almost 160 million euros in 1998. This means an average 
increase in costs of statins of 32% yearly.44 The Dutch consensus guidelines for 
cholesterol lowering therapy in primary prevention takes into account the cost-
effectiveness. Statin treatment is indicated if the cost-effectiveness ratio is 18,180 
euros per life year gained. This corresponds to a 10-year absolute risk of coronary 
heart disease ranging from 25% at 40 years of age to 35-40% at 70 years of age. 
Recently, a report about cholesterol-lowering therapy was published by the 
Cholesterol Committee of the Health Council in The Netherlands45 The committee 
recommended to use cholesterol lowering therapy in: 1) patients with familial 
hyperlipidemia, 2) patients with manifest cardiovascular disease and a total 
cholesterol level above 5 mmollL, and 3) patients with diabetes mellitus and a total 
cholesterol level above 5 mmol/L and one of the following criteria: CHD risk score of 
at least 8, microalbuminuria or left ventricular hypertrophy. The CHD risk score is 
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defined as: n + total/HDL cholesterol ratio, where n equals the number of risk factors 
(diabetes mellitus, hypertension, smoking and the occurrence of coronary heart 
disease before the age of 60 in first-degree relatives). The committee could not 
reach agreement about the indications for cholesterol lowering therapy in primary 
prevention. The majority of the committee advises to use cholesterol lowering 
therapy when it is medically worthwhile, without considering the .costs of statins. 
They recommend to use cholesterol lowering therapy in persons aged 40 years and 
over with a total cholesterol level above 5 mmol/L and when there is either a CHD 
risk score of at least 8, or left ventricular hypertrophy. The minority of the committee 
takes the costs of statins into account in advising on the use of cholesterol lowering 
therapy. They stated that persons free of cardiovascular diseases, diabetes or 
severe lipid disorders, with the exception of a small group of middle-aged male 
smokers with multiple risk factors, have a high absolute risk for coronary heart 
disease comparable with patients who have to be treated with cholesterol lowering 
therapy. In those patients to stop smoking is much more cost-effective in relation to 
health gain than prescription of statins. This point of view of the minority of the 
committee was recently (February 2001) supported by the Dutch Minister of Health, 
Welfare and Sport. Applying the recommendations of the majority of the committee 
would have a large impact on the costs of health care in The Netherlands, due to the 
high costs of statins. Because of the high prevalence of people at high risk in The 
Netherlands, especially at older ages, an integrated approach of lifestyle changes 
and treatment with cholesterol lowering medication is important to limit the costs of 
health care. 
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Despite the declining trend in age-adjusted coronary heart disease mortality since 
1972, it is still the most important cause of death in The Netherlands. Due to better 
treatment and the increasing number of elderly in the Dutch population in the future, 
the prevalence of coronary heart disease will increase. This means that coronary 
heart disease remains one of the largest public health problems in The Netherlands. 
Serum cholesterol is a major risk factor for coronary heart disease. To quantify the 
amount of health gain that can be achieved through cholesterol lowering, it is 
important to have information on recent levels and trends in total and HDL 
cholesterol levels in the general population. Also more evidence on the impact of 
total and HDL cholesterol on coronary heart disease in the elderly is needed. 
Furthermore, for treatment purposes it is necessary to develop risk functions for the 
elderly to predict their absolute risk of coronary heart disease. Finally information on 
the effect of different cholesterol lowering interventions on incidence of coronary 
heart disease in The Netherlands is needed. 
Trends in plasma total and HDL cholesterol in The Netherlands between 1993 and 
1997 were studied using data from the Monitoring Project on Risk Factors for 
Chronic Diseases (MORGEN-project). It was also examined whether the observed 
trend in total chOlesterol could be explained by changes in body mass index 
(weight/height"), smoking, use of cholesterol lowering medication, intake of saturated 
fatty acids, cholesterol and trans fatty acids (chapter 2). The MORGEN-project was 
carried out in three towns: Amsterdam, Doetinchem and Maastricht. In total more 
than 21,000 men and women aged 20-59 years were examined. The total 
cholesterol level decreased significantly by 0.19 mmol/L in men and 0.27 mmol/L in 
women between 1993 and 1997. The prevalence of hypercholesterolemia (total 
cholesterol" 6.5 mmol/L) decreased in men from 12.3% in 1993 to 9.8% in 1997 and 
in women from 12.4% in 1993 to 7.6% in 1997. The level of HDL cholesterol 
remained stable between 1993 and 1997 in both men and women. 
Between 1993 and 1997 the intake of trans fatty acids decreased significantly by 
0.4 percent of energy in both men and women. The intake of saturated fatty acids 
decreased significantly by 0.4 percent of energy in men and 0.5 percent of energy in 
women. The intake of cholesterol decreased significantly by 0.6 mg/MJ in men and 
1.9 mg/MJ in women. The use of cholesterol lowering medication increased 
significantly by 1.5% in men and 0.4% in women. The use of oral contraceptives 
increased significantly by 3.0% and the prescription of estrogens increased 
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significantly by 1.3%. However, changes in these determinants could only for a small 
part explain the observed trend in total cholesterol. 
The effect of low, medium and high serum cholesterol levels in combination with 
elevated blood pressure and smoking on cause-specific and all-cause mortality in 
middle-aged men and women was studied in the CB Heart project (chapter 3). The 
CB Heart Project is a large population based cohort study carried out in The 
Netherlands between 1974 and 1980 in about 49,000 men and women aged 30-54 
years. The mean follow-up period was 20 years. Several risk factor profiles were 
defined according to levels of total cholesterol, systolic blood pressure and smoking. 
Having a low risk factor profile was associated with low mortality rates and, 
surprisingly, to similar mortality rates in men and women. Given a low cholesterol 
level « 5.2 mmoI/L), the impact of smoking on coronary heart disease, 
cardiovascular diseases and all-cause mortality was larger than that of elevated 
blood pressure (systolic" 140 mmHg). A low cholesterol level in combination with 
both elevated blood pressure and smoking was associated with relative risks for 
CHD, CVD and all-cause mortality of 3.0 (95% CI 1.1-8.8), 6.0 (95% CI 2.4-14.9) and 
4.1 (95% CI2.7-6.3) respectively in men and 2.3 (95% CI 0.6-8.6), 3.6 (95% CI1.8-
7.1) and 2.6 (95% CI 2.0-3.5) respectively in women. When elevated blood pressure 
and smoking were accompanied by intermediate cholesterol levels (5.2-6.5 mmoI/L), 
these relative risks increased further. An elevated cholesterol level (" 6.50 mmol/L) 
in combination with elevated blood pressure and smoking was associated with 
relative risks for CHD, CVD and all-cause mortality of respectively 9.7 (95% CI 3.6-
26.7),13.9 (95% CI 5.7-34.0) and 5.7 (95% CI 3.7-8.6) respectively in men and 15.9 
(95% CI 5.6-44.8), 9.3 (95% CI 4.8-17.8) and 4.3 (95% CI 3.1-5.8) respectively in 
women. 
The association between serum total and HDL cholesterol and the risk of 
myocardial infarction in men and women aged 55 years and over was studied in the 
Rotterdam Study (chapter 4). The relation between serum total and HDL cholesterol 
and coronary heart disease mortality in elderly men in different European countries 
was studied in the Finland, Italy and The Netherlands Elderly (FINE) Study (chapter 
5). The Rotterdam Study is a population-based prospective cohort study carried out 
in 2.453 men and 3,553 women aged 55 years and older. During 4 years of follow-
up, 117 men and 76 women had a first or recurrent myocardial infarction. The FINE 
Study is a prospective follow-up study carried out in 2,132 men aged 65-84 years in 
Finland, The Netherlands and Italy. During 10 years of follow-up, 140 Finnish men, 
88 Dutch men and 48 Italian men died from coronary heart disease. 
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In the Rotterdam Study, the relative risk of myocardial infarction in subjects aged 
55 years and older was 1.9 (95% CI 1.1-3.3) in men and 3.2 (95% CI 1.5-6.4) in 
women in the highest compared to the lowest serum total cholesterol quartile. In a 
subcohort of men and women aged 70 years and older, total cholesterol remained 
an important risk factor for myocardial infarction, the relative risk was about three 
times higher in the highest compared to the lowest total cholesterol quartile. In men 
aged 65-84 years living in The Netherlands and Italy, the relative risk of coronary 
heart disease mortality in the highest total cholesterol terti Ie was about two times that 
in the lowest tertile. In Finland, there was a small but not significantly higher risk in 
the highest tertile. The combined relative risk for the total population of the FINE 
Study was 1.17 (95% CI 1.06-1.29) for each 1.00 mmol/L increase in total 
cholesterol. 
For HDL cholesterol, the relative risk of myocardial infarction in the highest 
compared to the lowest quartile was 0.5 (95% CI 0.3-0.9) in men and 0.4 (95% CI 
0.2-0.9) in women aged 55 years and older participating in the Rotterdam Study. 
Subgroup analyses in men and women aged 70 years and older showed that HDL 
cholesterol was a weaker predictor of myocardial infarction in the elderly men but not 
in women. In the FINE Study, HDL cholesterol was inversely related to coronary 
heart disease mortality in Finland, but not in The Netherlands and Italy. In Italy, an 
interaction between HDL cholesterol, body mass index and alcohol intake was found. 
There was an inverse association between HDL cholesterol and coronary heart 
disease mortality in lean men (body mass index < 25 kg/m2) with no or moderate 
alcohol intake « 40 g/day) (RR=0.76; 95% CI 0.59-0.97) and a positive association 
in overweight men (body mass index;, 25 kg/m2) with a high alcohol intake (;' 40 
g/day) (RR=1.25; 95% CI 1.07-1.46). 
The non-HDUHDL cholesterol ratio is also an important predictor of myocardial 
infarction in men and women aged 55 years and older. The relative risk of 
myocardial infarction observed in the Rotterdam Study in the highest compared to 
the lowest quartile was more than three times higher in both men and women. 
Data of the FINE Study were used to develop risk functions for coronary heart 
disease and cardiovascular diseases mortality for elderly men in different European 
countries (chapter 6). Of the 2,170 elderly men 289 died from coronary heart disease 
and 545 from cardiovascular diseases during 10 years of follow-up. Most classical 
risk factors for coronary heart disease and cardiovascular diseases mortality remain 
predictive in the elderly, of which total cholesterol (OR=1.24; 95% CI 1.11-1.38) and 
smoking (OR=1.24; 95% CI 0.91-1.69) were the most important ones for coronary 
heart disease mortality and HDL cholesterol (OR=0.69; 95% CI 0.49-0.96), systolic 
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blood pressure (OR=1.05; 95% CI 1.01-1.11 per 10 mmHg increase) and smoking 
(OR=1.28; 95% CI 1.01-1.63) for cardiovascular diseases mortality. Left ventricular 
hypertrophy, being a prevalent case of coronary heart disease or cardiovascular 
diseases in Finland and The Netherlands and use of anti-hypertensive medication in 
Italy were also important risk factors. For estimating the absolute risk of coronary 
heart disease and cardiovascular diseases mortality in the elderly it is necessary to 
take country into account. The absolute risk of coronary heart disease and 
cardiovascular diseases was higher in Northern Europe compared with Southern 
Europe at similar levels of the risk factors. 
The impact of different population prevention strategies and a high-riSk strategy 
on the primary prevention of coronary heart disease was modelled in men and 
women aged 35-74 years (chapter 7). Several population strategies were simulated: 
lowering the intake of saturated and trans fatty acids and smoking cessation. In the 
high-risk strategy, all persons with a high absolute risk of coronary heart disease 
were treated with cholesterol lowering medication. Through lowering the intake of 
saturated fatty acids from on average 15 percent of energy to 12 percent of energy, 
trans fatty acids from on average 1.9 percent of energy to 0.5 percent of energy and 
reducing the number of smokers by 15%, 49,967 (13%) coronary heart disease 
events can be prevented in men and 22,629 (12%) events in women aged 35-74 
years in the next 10 years. Using the high-risk strategy, 8,252 (2%) and 1,751 (1%) 
events in men and women respectively would be prevented. The gain in life 
expectancy for the combination of the population interventions varied from 7.7 
months in men and 3.8 months in women aged 35-44 years to 4.8 months in men 
and 2.3 months in women aged 65-74 years. The gain in life expectancy for the high-
risk strategy was 0.3 month in men and 0.08 month in women aged 65-74 years. In 
those aged 35-64 years the gain in life expectancy for the high-risk strategy was 
almost nil. Of the population interventions simulated, lowering the intake of trans fatty 
acids, attainable through advances in food technology, had the largest effect on the 
number of events of coronary heart disease that could be prevented in the years to 
come. 
In conclusion, total cholesterol levels declined in The Netherlands between 1987 
and 1997. This decline is of great public health importance because it could lead to a 
decline in mortality from coronary heart disease in the future. For public health 
purposes it is important to know that the cholesterol distribution in a population 
moves to a lower level. A population approach together with a high risk approach is 
the best way to prevent coronary heart disease. Because it was shown that serum 
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total cholesterol is also an important risk factor for coronary heart disease in the 
elderly, modifying cholesterol levels in the elderly could have a major impact on the 
health of this age group. Cholesterol reduction in the whole population can be 
achieved by dietary interventions. Apart from lowering the intake of saturated fatty 
acids, a further elimination of trans fatty acids and the use of margarines enriched 
with plant sterols or stanols can lower the total cholesterol levels. Besides this, 





De sterfte aan coronaire hartziekten is nog steeds de belangrijkste doodsoorzaak 
in Nederland, ondanks een daling hierin sinds 1972. Door verbeteringen van de 
medische technologie en de vergrijzing van de Nederlandse bevolking zal de 
prevalentie van coronaire hartziekten de komende jaren toenemen. Dit betekent dat 
het voorkomen van coronaire hartziekten een van de belangrijkste 
volksgezondheidsproblemen blijft in Nederland. Het cholesterolgehalte in het bloed 
is een belangrijke risicofactor voor coronaire hartziekten. Voor het kwantificeren van 
de gezondheidswinst, die behaald kan worden door het cholesterolgehalte te 
verlagen, is het van be lang om over gegevens te beschikken over het totaal en HDL 
cholesterolgehalte in de algemene bevolking en veranderingen die daarin 
plaatsvinden. Ook kennis over de relatie tussen totaal en HDL cholesterol en de 
sterfte aan coronaire hartziekten bij ouderen is in dit kader van belang. Daarnaast is 
het met het oog op behandeling van de ouderen belangrijk om risicofuncties te 
ontwikkelen voor deze groep om hun absolute risico op coronaire hartziekten te 
voorspellen. Tenslotte is het noodzakelijk om te weten wat het effect is van 
verschillende cholesterolverlagende interventies op de incidentie van coronaire 
hartziekten in Nederland. 
Veranderingen in het totaal en HDL cholesterolgehalte in Nederland tussen 1993 
en 1997 zijn bestudeerd door gebruik te maken van gegevens uit het project 
Monitoring van Risicofactoren en Gezondheid in Nederland (MORGEN). Daarnaast 
is onderzocht of veranderingen in Quetelet index (gewichtllengte2), roken, gebruik 
van cholesterolverlagende medicatie, inname van verzadigde vetzuren, cholesterol 
en transvetzuren de gevonden verandering in het totaal cholesterolgehalte konden 
verklaren (hoofdstuk 2). Het MORGEN-project werd uitgevoerd in drie steden: 
Amsterdam, Doetinchem en Maastricht. Ruim 21.000 mannen en vrouwen in de 
leeftijd van 20 to 59 jaar werden onderzocht. Tussen 1993 en 1997 werd een 
significante daling in het totaal cholesterolgehalte gevonden van 0,19 mmol/l bij 
mannen en 0,27 mmolfl bij vrouwen. De prevalentie van hypercholesterolemie (totaal 
cholesterol" 6,5 mmolfl) daalde van 12,3% in 1993 tot 9,8% in 1997 bij mannen en 
van 12,4% in 1993 naar 7,6% in 1997 bij vrouwen. Het HDL cholesterolgehalte 
veranderde niet tussen 1993 en 1997 bij de mannen en de vrouwen. 
Tussen 1993 en 1997 was er bij zowel mannen als vrouwen een significante 
daling in de in name van transvetzuren met 0,4 energieprocent. De in name van 
verzadigde vetzuren daalde significant met 0,4 energieprocent bij mannen en 0,5 
energieprocent bij vrouwen. De in name van cholesterol daalde significant met 0,6 
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mg/MJ bij mannen en 1,9 mg/MJ bij vrouwen. Het gebruik van cholesterolverlagende 
medicatie steeg significant met 1,5% bij mannen en 0,4% bij vrouwen. Het gebruik 
van de anti-conceptiepil steeg significant met 3,0% en het gebruik van post-
menopauzale oestrogenen steeg significant met 1,3%. Veranderingen in 
bovengenoemde determinanten konden echter maar een klein deel van de 
gevonden verandering in het totaal cholesterolgehalte verklaren. 
In het CB-project is het effect onderzocht van een laag, middelmatig en hoog 
cholesterolgehalte in combinatie met een verhoogde bioedddruk en roken op de 
oorzaak-specifieke en totale sterfte bij mannen en vrouwen van middelbare leeftijd 
(hoofdstuk 3). Het CB-project is een groot bevolkingsonderzoek dat uitgevoerd is in 
Nederland tussen 1974 en 1980 bij ruim 49.000 mannen en vrouwen in de leeftijd 
van 30 to 54 jaar. De gemiddelde follow-up periode bedroeg 20 jaar. Aan de hand 
van verschillende categorieen voor totaal cholesterol, systolische bloeddruk en roken 
zijn verschillende risicofactor profielen gedefinieerd. Mannen en vrouwen met een 
laag risicoprofiel hadden verrassend genoeg gelijke, zeer lage sterftecijfers. Bij 
mannen en vrouwen met een laag cholesterolgehalte « 5,2 mmolll) was het effect 
van roken op de totale sterfte en de sterfte aan coronaire hartziekten en 
cardiovasculaire ziekten groter dan het effect van een verhoogde bloeddruk (systole 
~ 140 mmHg). De relatieve risico's voor de relatie tussen een laag cholesterolgehalte 
in combinatie met een verhoogde bloeddruk en roken en de sterfte aan coronaire 
hartziekten, cardiovasculaire ziekten en de totale sterfte waren respectievelijk 3,0 
(95% BI1,1-8,8), 6,0 (95% BI2,4-14,9) en 4,1 (95% BI 2,7-6,3) voor mannen en 2,3 
(95% BI 0,6-8,6), 3,6 (95% BI 1,8-7,1) en 2,6 (95% BI 2,0-3,5) voor vrouwen. Deze 
relatieve risico's waren hoger bij personen met een matig verhoogd 
cholesterolgehalte (5,2-6,5 mmolll), een verhoogde bloeddruk en die rookten. De 
relatieve risico's voor de relatie tussen een verhoogd cholesterolgehalte (~ 6,5 
mmolll) in combinatie met een verhoogde bloeddruk en roken en de sterfte aan 
coronaire hartziekten en cardiovasculaire ziekten en de totale sterfte waren 
respectievelijk 9,7 (95% BI 3,6-26,7), 13,9 (95% BI 5,7-34,0) en 5,7 (95% BI 3,7-8,6) 
voor mannen en 15,9 (95% BI 5,6-44,8),9,3 (95% BI 4,8-17,8) en 4,3 (95% BI 3,1-
5,8) voor vrouwen. 
De relatie tussen het totaal en HDL cholesterolgehalte en het risico op een 
myocard infarct bij mannen en vrouwen van 55 jaar en ouder werd onderzocht in het 
Erasmus Rotterdam Gezondheid en Ouderen (ERGO) onderzoek (hoofdstuk 4). Het 
verband tussen het totaal en HDL cholesterolgehalte en de sterfte aan coronaire 
hartziekten bij oudere mannen is onderzocht in een studie uitgevoerd in Finland, 
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Nederland en Italie (FINE studie) (hoofdstuk 5). Het ERGO onderzoek is een 
prospectief bevolkingsonderzoek uitgevoerd bij 2.453 mannen en 3.553 vrouwen van 
55 jaar en ouder. Na gemiddeld 4 jaar follow-up kregen 117 mannen en 76 vrouwen 
een myocard infarct. De FINE studie is een prospectieve follow-up studie uitgevoerd 
bij 2.132 mannen van 65-84 jaar wonend in Finland, Nederland en Italie. Gedurende 
een follow-up periode van 10 jaar stierven 140 Finse mannen, 88 Nederlandse 
mannen en 48 Italiaanse mannen aan een coronaire hartziekten. 
In het ERGO onderzoek was het risico op een myocard infarct bij personen van 
55 jaar en ouder 1,9 (95% BI 1,1-3,3) voor mannen en 3,2 (95% BI 1,5-6,4) voor 
vrouwen in het hoogste totaal cholesterol kwartiel vergeleken met het laagste 
kwartiel. Voor mannen en vrouwen van 70 jaar en ouder was het totaal 
cholesterolgehalte nog steeds een belangrijke risicofactor voor het ontstaan van een 
myocard infarct. Het relatieve risico was ongeveer drie keer hoger in het hoogste 
totaal cholesterol kwartiel vergeleken met het laagste kwartiel. Het relatieve risico 
voor sterfte aan coronaire hartziekten voor Nederlandse en Italiaanse mannen van 
65-84 jaar was !wee keer hoger in het hoogste totaal cholesterol tertiel vergeleken 
met het laagste tertiel. Voor de Finse mannen was er een klein, niet-significant, 
hoger risico in het hoogste tertiel. Het gecombineerde relatieve risico v~~r de gehele 
populatie in de FINE studie was 1,17 (95% BI 1,06-1,29) v~~r elke toename in totaal 
cholesterol met 1,00 mmoi/i. 
V~~r het HDL cholesterolgehalte was het risco op een myocard infarct bij 
deelnemers aan het ERGO onderzoek van 55 jaar en ouder 0,5 (95% BI 0,3-0,9) 
voor mannen en 0,4 (95% BI 0,2-0,9) voor vrouwen in het hoogste vergeleken met 
het laagste kwartiel. V~~r mannen van 70 jaar en ouder was HDL cholesterol een 
slechtere voorpeller van het risico op een myocard infarct, maar dat was niet het 
geval voor vrouwen van 70 jaar en ouder. HDL cholesterol was invers gerelateerd 
aan sterfte aan coronaire hartziekten in Finland, maar niet in Nederland en Italie. In 
Italie was er een interactie tussen HDL cholesterol, Quetelet index en alcohol 
consumptie. Er was een invers verband tussen HDL cholesterol en sterfte aan 
coronaire hartziekten in slanke mann en (Quetelet index < 25 kg/m2) die niet of matig 
alcohol dronken « 40 g/dag) (RR=0,76; 95% BI 0,59-0,97) en een positief verband 
in dikke mannen (Quetelet index;;: 25 kg/m2 ) die veel alcohol dronken (;;: 40 g/dag) 
(RR=1 ,25; 95% BI1 ,07-1 ,46). 
De non-HDUHDL cholesterol ratio is een belangrijke voorspeller van het risico op 
een myocard infarct voor mannen en vrouwen van 55 jaar en ouder. In het ERGO 
onderzoek was het risico op een myocard infarct bij zowel mannen als vrouwen ruim 
drie keer hoger in het hoogste vergeleken met het laagste kwartiel. 
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Voor het ontwikkelen van risicofuncties voor sterfte aan coronaire hartziekten en 
cardiovasculaire ziekten voor oudere mannen in verschillende Europese landen is 
gebruik gemaakt van gegevens uit de FINE studie (hoofstuk 6). Van de in totaal 
2.170 oudere mannen waren na 10 jaar follow-up 289 mannen overleden aan 
coronaire hartziekten en 545 aan cardiovasculaire ziekten. De meeste klassieke 
risicofactoren voor sterfte aan coronaire hartziekten en cardiovasculaire ziekten 
behielden hun voorspellende waarde bij de ouderen, waarbij totaal cholesterol 
(OR=1,24; 95% BI 1,11-1,38) en roken (OR=1,24; 95% BI 0,91-1,69) de 
belangrijkste risicofactoren waren voor sterfte aan coronaire hartziekten en HDL 
cholesterol (OR=0,69; 95% BI 0,49-0,96), systolische bloeddruk (OR=1,05; 95% BI 
1,01-1,11 per 10 mmHg toename) en roken (OR=1,28; 95% BI 1,01,1,63) de 
belangrijkste risicofactoren waren voor sterfte aan cardiovasculaire ziekten. 
Daarnaast waren in Finland en Nederland ook linker ventrikel hypertrofie en het 
eerder hebben doorgemaakt van een coronaire hartziekte of cardiovasculaire ziekte 
en in Italie het gebruik van anti-hypertensiva belangrijke risicofactoren. Voor het 
berekenen van he! absolute risico voor sterfte aan coronaire hartziekten en 
cardiovasculaire ziekten bij ouderen is het eveneens belangrijk om rekening te 
houden met het land waarin de personen leven. Bij vergelijkbare niveau's van 
risicofactoren is het absolute risico op coronaire hartziekten en cardiovasculaire 
ziekten hoger in Noord-Europa vergeleken met Zuid-Europa. 
Het effect van verschillende preventie strategieen gericht op de totale populatie en 
een hoog-risico strategie in het kader van primaire preventie van coronaire 
hartziekten is bestudeerd bij mannen en vrouwen van 35-74 jaar (hoofdstuk 7). Er 
werd gebruik gemaakt van verschillende populatie strategieen, te weten het verlagen 
van de inname van verzadigde- en transvetzuren en stoppen met roken. In de hoog-
risico strategie werd verondersteld dat alle personen met een hoog absoluut risico 
voor coronaire hartziekten werden behandeld met cholesterolverlagende medicatie. 
Op grond van de populatie strategieen zouden in de komende 10 jaar49.967 (13%) 
gevallen van coronaire hartziekten bij mannen en 22.629 (12%) gevallen van 
coronaire hartziekten bij vrouwen van 35-74 jaar voorkomen kunnen worden als de 
inname van verzadigde vetzuren verlaagd wordt van gemiddeld 15 naar 12 
energieprocenten, de inname van transvetzuren verlaagd wordt van gemiddeld 1,9 
naar 0,5 energieprocenten en het aantal rokers wordt verlaagd met 15%. In de hoog-
risico strategie zouden bij mannen 8.252 (2%) en bij vrouwen 1.751 (1%) gevallen 
van coronaire hartziekten voorkomen kunnen worden. De winst in levensverwachting 
voor de combinatie van de populatie interventies varieerde van 7,7 maanden voor 
mannen en 3,8 maanden voor vrouwen van 35-44 jaar tot 4,8 maanden voor 
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mannen en 2,3 maanden voor vrouwen van 65-74 jaar. De winst in 
levensverwachting voor de hoog-risico strategie was 0,3 maanden voor mannen en 
0,08 maand voor vrouwen van 65-74 jaar. De winst in levensverwachting voor de 
hoog-risico stratgie v~~r personen van 35-64 jaar was nihil. Van de onderzochte 
scenario's resulteert de verlaging van de in name van transvetzuren, die bereikt kan 
worden door technologische verbeteringen in de samensteliing van 
voedingsmiddelen, in het grootste effect op het aantal gevalien van coronaire 
hartziekten die voorkomen zouden kunnen worden in de komende jaren. 
Geconcludeerd werd dat het totaal cholesterolgehalte in Nederland is gedaald 
tussen 1987 en 1997. Deze daling is van groot be lang voor de volksgezondheid, 
omdat die in de toekomst kan lei den tot een daling in de sterfte aan coronaire 
hartziekten. Voor de volksgezondheid is het van groot belang dat de 
cholesterolverdeling van de bevolking opschuift naar een lager niveau. Deze 
populatie benadering, samen met een hoog-risico benadering, is de beste manier 
om coronaire hartziekten te voorkomen. Omdat aangetoond is dat het totaal 
cholesterolgehalte ook een belangrijke risicofactor is v~~r coronaire hartziekten bij 
ouderen, kan een verlaging van het cholesterolgehalte bij ouderen een behoorlijk 
effect hebben op de gezondheid in deze leeftijdsgroep. Een verlaging van het 
cholesterolgehalte in de gehele bevolking kan bereikt worden door 
voedingsinterventies. Naast de verlaging van de in name van verzadigde vetzuren 
zouden een verdere eliminatie van transvetzuren en het gebruik van margarines 
verrijkt met planten sterolen of stanolen verder kunnen bijdragen aan een verlaging 
van het cholesterolgehalte. Daarnaast is adequate behandeling van personen met 
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